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General summary and aim of the thesis 
The complement system is a key component of the innate immune system (1). It consists of 
several plasma and cell-associated proteins and acts as an enzymatic-driven protein cascade. 
The complement system can be activated via at least 3 different pathways: the classical 
pathway (CP), the lectin pathway (LP), and the alternative pathway (AP) (1, 2). C1q, the 
recognition and starter molecule of the CP of complement, is considered to be involved in the 
pathogenesis of systemic lupus erythematosus (SLE). This observation is based on the fact 
that homozygous C1q deficiency is the strongest known genetic disease susceptibility for the 
development of SLE in humans (3, 4). In addition, C1q-deficient mice develop a SLE-like 
disease (5). However, most SLE patients do not suffer from primary C1q deficiency, 
moreover, aberrant complement activation is accounted for secondary hypocomplementemia 
(6). Another reason for low C1q levels are autoantibodies directed against C1q (anti-C1q) 
which are present in 20-50% of SLE patients. The occurrence of anti-C1q not only correlates 
with hypocomplementemia, but additionally, also with the occurrence of severe lupus nephritis 
(7-9). The association of anti-C1q with lupus nephritis suggests a pathogenic role of these 
autoantibodies in this inflammatory kidney disease. Even though, anti-C1q correlate with renal 
involvement, the direct evidence how these autoantibodies contribute to the pathogenesis of 
lupus nephritis is not yet available. Animal studies demonstrated that anti-C1q were only 
pathogenic in combination with predeposited glomerular C1q-containing immune complexes. 
Trouw et al. proposed that extensive anti-C1q-mediated complement activation might damage 
the kidney and lead to the infiltration of immune cells resulting in glomerular injury by 
Fcgamma receptor (FcγR)-mediated mechanisms suggesting a role for both, the complement 
system as well as phagocytes, in lupus nephritis (10). Nevertheless, little knowledge is 
available on the pathogenic properties of these autoantibodies and their biological function is 
not well defined. 
 
The aim of my thesis was to analyze the interaction of anti-C1q with the complement system 
and the down-stream effects of anti-C1q on macrophages. The following questions have been 
addressed during my thesis: 
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Part 1: Do anti-C1q trigger the activation of the complement system?  
So far, it was not known if anti-C1q influence the activation of the complement system. In 
nephritic kidneys of SLE patients co-localization of complement components (C1q, MBL, C4, 
C3) and immunoglobulins (Ig; IgG, IgA, IgM) occurs (11, 12), suggesting that the complement 
system is involved in the pathogenesis of lupus nephritis (13). Anti-C1q can be of the IgG-, 
IgA-, and IgM-class (14-16). The anti-C1q Ig-class repertoire might indicate that anti-C1q 
bound to immobilized C1q (imC1q) could activate the complement system via its different 
pathways. Indeed, when evaluating the relative contribution of each complement pathway in 
the complement-activating potential of anti-C1q using an ELISA-based assay, we found that 
SLE patient-derived anti-C1q amplify complement activation in vitro via the CP and the LP 
dependent on the anti-C1q Ig-class repertoire present in the lupus patient’s serum with IgG 
anti-C1q primarily activating the CP, IgA the LP, and IgM both the CP and the LP. In addition, 
bound anti-C1q resulted in the activation of the CP as reflected by C4b deposition in the 
presence of purified C1 and C4 in a dose-dependent manner. The extent of C4b deposition 
correlated with IgG anti-C1q levels of SLE patients but not of healthy controls. These findings 
are of importance for the understanding of the role of anti-C1q in SLE suggesting a direct link 
to hypocomplementemia. 
 
Part 2: Do anti-C1q induce a proinflammatory phenotype in macrophages? 
Functional defects in myeloid cells obtained from SLE patients are well known, although the 
underlying molecular mechanism is not fully understood. Macrophages and monocytes 
obtained from SLE patients exhibit a defect in the phagocytosis of apoptotic cell material (17-
19), which contributes to the accumulation of a large number of apoptotic cells in various 
tissues (20, 21). Furthermore, C1q facilitates the uptake of apoptotic cell material by 
monocytes, macrophages, and dendritic cells (DCs) (22-24). During the phagocytosis of 
apoptotic cells, C1q exerted a potent inhibitory capacity in macrophage-mediated 
inflammation (25). These data suggest that C1q is crucial in limiting inflammation during the 
uptake of apoptotic cells. In this context, it has been hypothesized that the binding of anti-C1q 
to C1q might interfere in the immune-regulatory functions of this molecule. However, the direct 
downstream effect of anti-C1q on professional phagocytes is not well understood. Therefore, 
we developed an in vitro model to study the effect of SLE patient-derived anti-C1q bound to 
imC1q on human monocyte-derived macrophages (HMDMs) obtained from healthy donors 
and SLE patients. Morphologically, bound anti-C1q induced the formation of cell aggregates of 
HMDMs when compared to imC1q or IgG alone. In addition, anti-C1q reversed the effect of 
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imC1q alone shifting the lipopolysaccharide (LPS)-induced cytokine release towards a 
proinflammatory response. By FcγR-blocking experiments, the secretion of proinflammatory 
cytokines was found to be mediated via FcγRII. The anti-C1q-induced inflammatory cytokine 
profile was accompanied by a downregulation of CD163 and an upregulation of LPS-induced 
CD80, CD274, and MHC class II. Finally, HMDMs primed on bound anti-C1q versus imC1q 
alone displayed a significantly lower phagocytosis rate of early and late apoptotic cells 
accompanied by a reduced Mer tyrosine kinase expression. Interestingly, anti-C1q-dependent 
secretion of proinflammatory cytokines was similar in SLE patient-derived cells with the 
exception of IL-10 being slightly increased. In conclusion, anti-C1q induced a proinflammatory 
phenotype in HMDMs reversing the effects of imC1q alone. This effect might exacerbate 
underlying pathogenic mechanisms in lupus nephritis.   
 
Part 3: Do anti-C1q influence C1q secretion by macrophages? 
As opposed to most other complement proteins, C1q has a non-hepatic origin and is 
predominantly produced by myeloid cells, i.e., DCs and macrophages (26). In tissues, C1q is 
accumulated during inflammatory processes due to local production by infiltrating DCs and 
macrophages (27, 28). In the glomeruli of patients with proliferative nephritis, deposited C1q 
as well as anti-C1q can be found (11, 12). In addition, anti-C1q strongly correlate with the 
occurrence of lupus nephritis (7-10). In parallel, anti-C1q seem to influence C1q levels, as 
anti-C1q negatively correlate with C1q levels (29, 30). In this context, anti-C1q might be able 
to directly alter C1q secretion by HMDMs. Therefore, we investigated the C1q secretion profile 
of HMDMs obtained from healthy donors and SLE patients in vitro. In contrast to our 
expectations, we observed that bound anti-C1q induced significantly higher C1q secretion 
levels as compared to imC1q alone or healthy donor IgG. The extent of C1q secretion by 
HMDMs correlated with IgG anti-C1q levels of SLE patients but not of healthy controls. 
Furthermore, bound autoantibodies and imC1q induced continuous and de novo C1q 
synthesis as evident by the stored intracellular C1q content which correlated with C1q 
secretion levels. In addition, secreted C1q was able to activate the CP as reflected by C4b 
deposition in a dose-dependent manner. Interestingly, anti-C1q-dependent C1q secretion was 
similar in SLE patient-derived cells. In conclusion, our data indicate that imC1q-bound anti-
C1q strongly stimulate C1q production by HMDMs. Thus, bound anti-C1q can induce a potent 
C1q-producing phenotype in macrophages. This enhanced C1q secretion might potentiate 
anti-C1q induced complement activation and the binding of additional anti-C1q molecules 
leading to a local vicious circle. 
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Taken together, I can demonstrate that anti-C1q activate the complement system via the CP 
and the LP but not via the AP dependent of the anti-C1q Ig-class present in the patient’s sera 
(see part 1, p. 29). Furthermore, I show that anti-C1q induce a proinflammatory phenotype in 
HMDMs via an FcγRII-dependent pathway (see part 2, p. 46). In addition, I can also 
demonstrate that anti-C1q trigger C1q secretion by HMDMs (see part 3, p. 73). Moreover, I 
can show that the inhibition of Cathepsin S can suppress the anti-C1q-triggered induction of a 
proinflammatory phenotype in HMDMs (data not shown).  
 
The thesis is divided into a general introduction summarizing the current knowledge on topics 
relevant for this thesis followed by 3 main parts summarizing manuscripts. The results of the 
first study (part 1) are published in Clinical Immunology. The manuscript of part 2 is currently 
under revision and the manuscript of part 3 was recently submitted for publication. 
The thesis is completed by my conclusions and an outlook of ongoing and future projects. 
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General introduction 
The complement system 
The complement system is part of the innate immune system. Its biological functions include 
host defense by opsonization of invading pathogens followed by complement-mediated cell 
lysis, clearance of immune complexes (ICs) and apoptotic cell material, as well as bridging 
adaptive with innate immunity (1, 31). The complement system consists of several plasma and 
cell-associated proteins, which either participate in the complement cascade itself or are 
regulators of complement activation. The complement system acts as an enzymatic protein 
cascade and its activation can occur via at least 3 different pathways: the classical pathway 
(CP), the lectin pathway (LP), and the alternative pathway (AP) followed by a terminal 
pathway common to all (Figure 1). Each of these pathways has its own activating recognition 
mechanism, i.e., is activated by its own specific ligand (1, 2).  
 
 
Figure 1: Overview of the complement system. 
The complement system can be activated via the CP, the LP, or the AP depending on the activating 
ligand. Upon activation, all 3 pathways converge at the level of the C3 convertase. Downstream 
activation of terminal complement proteins (C5 to C9) leads to the formation of the membrane-attack 
complex which is inserted into the target cell wall causing cell lysis (modified according to (32)). 
Classical pathway
(CP)
Lectin pathway
(LP)
Alternative pathway
(AP)
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The CP (Figure 2) is activated upon binding of C1q, the recognition molecule of C1 (a 
complex consisting of C1q and 2 serine proteases C1r and C1s), to Fc regions of 
immunoglobulins (Ig; IgM- and certain IgG-classes (IgG1, IgG2, and IgG3 in humans)) which 
are bound to antigens (Ags). Upon binding of C1q to its ligands, C1q changes its conformation 
resulting in subsequent activation of C1r which then activates C1s. C1s further cleaves C4 
into its 2 fragments, C4a and C4b. The latter is deposited onto the cell membrane. Further 
activation of the complement cascade leads to the generation of the CP-C3 convertase 
(C4b2a) (1, 33).   
 
 
Figure 2: Activation of the CP by IgM binding to Ags on the surface of a pathogen.  
The CP is triggered by an activated C1 complex which is composed of the recognition molecule C1q 
and its 2 serine proteases C1r and C1s. Binding of C1q to the Fc region of certain Ig (IgM and certain 
IgG-classes) in ICs leads to the activation of the C1 complex. Upon binding of C1q to a ligand, C1q 
activates C1r which in turn activates C1s that cleaves C4 into C4a and C4b. C4b binds covalently to the 
surface of a pathogen. Then, C4b binds C2 which is cleaved by C1s into C2a and C2b. C2a forms 
together with C4b the CP-C3 convertase (C4b2a). Downstream activation of terminal complement 
proteins (C5 to C9) leads to the formation of the MAC which is inserted into the cell wall of the pathogen 
causing its lysis (obtained from (34)). 
 
The AP is initiated by spontaneous C3(H2O) binding and activation/turn-over, or by direct 
binding to microbial structures (e.g., lipopolysaccharide (LPS)) leading to the cleavage of C3 
into C3a and C3b or as an amplification loop by C3b deposition on cell surfaces after initial 
activation of the CP or the LP (1, 33).  
The recently described LP is usually not activated by antibodies but by binding of mannose-
binding lectin (MBL) or ficolins to, e.g., mannose residues exposed on the surface of certain 
pathogens (1, 33).  
Independent of the pathway which has been initially activated, all 3 pathways converge in the 
formation of the C3 convertase which cleaves C3 into C3a and C3b. Finally, downstream 
activation of terminal complement components (C5 to C9) leads to the assembly of the C5b-
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C9 complex (termed membrane-attack complex (MAC)) which is inserted into the target cell 
wall causing cell lysis (33, 35). 
During the activation of the complement system, complement fragments are generated by 
cleavage, such as anaphylatoxins (namely C3a and C5a) as well as opsonins (inactivated 
C3b (iC3b)) (36). Anaphylatoxins act as potent chemotactants for several immune cells, such 
as neutrophils, mast cells, or macrophages, and take part in inflammatory processes (37). 
Additionally, many cell types express receptors for intact or cleaved complement proteins, 
e.g., complement receptor 1 (CR1, CD35) and complement receptor 2 (CR2, CD21) or 
receptors for C1q (C1qRs) (data not shown) (38). 
Regulation of the complement system 
To prevent self from complement-mediated damage, the complement system is tightly 
regulated (Figure 1). For this purpose, most mammalian cells express regulatory proteins on 
their surface to control complement activation, e.g., CR1, membrane cofactor protein (MCP, 
CD46), decay accelerating factor (DAF, CD55), and MAC-inhibitory protein (MAC-IP, CD59). 
Additionally, the complement system is regulated by several plasma proteins at different 
stages of the complement cascade, e.g., C1-inhibitor, C4b-binding protein, factor I, factor H, 
and Properidin (38, 39). 
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Systemic lupus erythematosus 
In Northern Europe, about 40/100’000 people are affected by this incurable chronic 
autoimmune disease. However, the incidence varies between geographic regions, ethnical 
groups, genders, and age. Systemic lupus erythematosus (SLE) is most common in women 
during their childbearing years and in black Americans as well as Hispanics (40, 41). It is 
characterized by a wide range of clinical and immunological manifestations and the potential 
involvement of multiple organs, including joints, central nervous system, skin, heart, blood 
vessel, and kidneys, leading to a variety of symptoms. The disease course often follows 
phases of relapses and remissions (42). The etiology of this autoimmune disease is mostly 
unknown and seems to involve genetical, hormonal, and environmental factors (43).  
SLE is characterized by B cell hyperactivity, antibodies specific for various auto-Ags such as 
intra-cellular components (e.g., anti-double-stranded DNA autoantibodies (anti-dsDNA)) or 
plasma proteins (e.g., anti-C1q autoantibodies (anti-C1q)), the formation of ICs, and the 
aberrant activation of the complement system resulting in complement deposition and 
hypocomplementemia (44, 45). 
The complement system and SLE 
The complement system has an important role in the pathogenesis of SLE. In particular, 
deficiencies of the early complement proteins of the CP (C1q, C4, C2) have been associated 
with an increased risk to develop SLE (3). Nevertheless, the highest known susceptibility in 
humans to develop SLE has been described in individuals suffering from homozygous C1q 
deficiency (46, 47). However, most SLE patients do not suffer from primary deficiency in 
complement proteins (3). In general, low circulating complement levels are considered to 
reflect aberrant complement activation, i.e., so-called secondary hypocomplementemia.  
The clearance of apoptotic cell material and SLE 
Furthermore, the strong link between C1q deficiency, the development of SLE, and the 
clearance of apoptotic cells led to the formulation of the so-called “waste disposal hypothesis”: 
Next to its involvement in host defense, the complement system has multiple other functions, 
including the clearance of apoptotic cell material (1). The efficient and fast clearance of early 
apoptotic cell material is crucial to avoid inflammatory and autoimmune processes (48-50). 
More importantly, dying cells and inefficiently cleared apoptotic cells might serve as an 
accessible source of intracellular Ags (such as dsDNA) and trigger autoantibody production in 
susceptible individuals (51, 52). Experiments in mice support this hypothesis. Mice having an 
inefficient removal of apoptotic cells develop severe autoimmunity characterized by the 
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occurrence of autoantibodies directed against nuclear components and resembling human 
SLE (53). Vice versa, lupus-prone mice have an impaired clearance of apoptotic cell material 
(54). Injection of an excess of apoptotic thymocytes into healthy mice induced the production 
of autoantibodies, including anti-nuclear antibodies (ANA) and anti-dsDNA (55). Therefore, a 
defective clearance of apoptotic material by macrophages has been proposed as the 
pathogenic mechanism underlying SLE, causing an accumulation of dead cell material 
resulting in inflammation and autoimmunity (20, 50). Indeed, it is well established that SLE 
patient-derived macrophages exhibit a defect in the clearance of apoptotic cell material 
correlating with low complement levels (17, 18). Moreover, many targets for lupus patient-
derived autoantibodies are concentrated on the surface of apoptotic cells (56). 
Based on the observations reported above, a defective clearance of apoptotic cells has been 
suggested to break peripheral tolerance, provide a reservoir of self-Ags inducing autoantibody 
production, and finally lead to the development of SLE (57-60).  
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The complement protein C1q   
C1q (Figure 3) is a 460kDa collagen-like, hexametric glycoprotein which belongs to the family 
of the so-called collectins. The intact C1q molecule consists of 3 distinct polypeptide chains 
(C1qA, C1qB, and C1qC chains). Each of these chains occurs 6 times in the protein adding 
up to a total of 18 chains. The 3 different polypeptide chains are translated from 3 distinct C1q 
genes (C1qA/B/C genes), which are all located on chromosome 1. Furthermore, each chain 
consists of an amino-terminal collagen-like region (cC1q) and a carboxyl-rich terminal globular 
head region (gC1q). One C1qA and one C1qB chains are covalently linked together to form 
an A-B dimer and 2 C1qC chains to form a C-C dimer, respectively. Additionally, one A-B 
dimer is non-covalently linked to one C1qC chain of a C-C dimer forming one triple helical 
strand. In total, 6 triple helical strands form the C1q molecule. A doublet is then assembled by 
2 of these strands through a disulfide bond of 2 C1qC chains. 3 of these doublets build up the 
intact C1q molecule that due to its organization resembles a bouquet of tulips (61-64). 
 
 
Figure 3: Overview of the structural organization and subunit assembly of intact C1q. 
One C1qA chain is covalently linked to one C1qB chain through a disulfide bond (A-B dimer). A triple 
helix is formed by an A-B dimer non-covalently linked to a C1qC chain of a C-C dimer. 6 of these triple 
helices are formed by the 18 polypeptide chains forming the intact C1q molecule. Each chain consists 
of a collagen-like region and a globular head region (modified according to (64)).  
 
In the blood circulation, C1q is mostly associated with its 2 serine proteases C1s2-C1r2, in a 
calcium-dependent manner, to form the C1 complex, the starter molecule of the CP (61, 63, 
65, 66). The concentration of C1q (complexed) in sera of healthy individuals varies from 80-
180µg/ml (67). However, under physiological conditions in healthy individuals the occurrence 
of free C1q is mostly limited to tissues due to local C1q production by myeloid cells, i.e., 
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macrophages and dendritic cells (DCs) (26, 68-70). The secretion and functions of C1q in 
immune cell modulation will be discussed later (see p. 12/16).  
Functions of C1q 
Beyond its function as the recognition molecule in the C1 complex, initiating the activation of 
the CP upon binding to ICs, C1q has many other functions (Figure 4).  
 
 
Figure 4: Classical and non-
classical functions of C1q.  
C1q has many other functions in 
the human body which are not 
directly related to complement 
activation. Some are listed in the 
figure (modified according to 
(71)). 
 
 
C1q is involved in many pathological conditions, including autoimmune diseases (e.g., SLE), 
cancer, atherosclerosis, and preeclampsia (72-75).   
For example, C1q is involved in the clearance of apoptotic cell material. It has been 
demonstrated that C1q binds to the surface of apoptotic cells and facilitates their uptake by 
phagocytes (22, 76-78). As outlined before, C1q-deficient (C1q-/-) mice develop an 
autoimmune phenotype resembling human lupus characterized by an accumulation of 
apoptotic cells in the kidneys (5), underlining the importance of C1q in the clearance of 
apoptotic cell material.  
Furthermore, C1q serves as a pattern recognition molecule binding to numerous ligands, 
including DNA, annexins A2 and A5, phosphatidylserine (PS), and LPS (79-81), thereby 
recognizing pathogens and apoptotic cells and modulating biological and cellular responses 
(reviewed in (82, 83)). C1q also regulates cell differentiation, adhesion, chemotaxis, migration, 
activation, and survival (84-87). C1q’s function in immune cell modulation will be discussed 
later (see p. 16).  
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C1q production and secretion 
Most complement proteins have a hepatic-origin and are produced and regulated as acute 
phase proteins. Nevertheless, many complement components have next to the liver also other 
production sites (88, 89). Indeed, many immune cells are able to produce functional 
complement proteins. For example, several studies reported that DCs and macrophages 
produce a variety of different complement proteins, including C1s, C4, C2, C3, C5, and C9 
(68, 90-92). This synthesis is differently regulated in response to inflammatory stimuli, such as 
LPS or cytokines (26, 90). 
As opposed to most complement proteins, C1q has mainly a non-hepatic origin (88). Studies 
of liver-derived cells, isolated from guinea pigs (93) and rats (mainly Kupffer cells (KCs)) (94), 
confirmed that C1q may also have a hepatic-origin, however, C1q mRNA levels in liver-
derived cells from guinea pigs were at considerably lower expression levels as compared to 
those of recruited peritoneal macrophages (pMac) (93). In addition, it has been reported that 
in mouse organs (liver, lung, and small intestine) only trace amounts of C1q-specific mRNA 
can be detected (95), suggesting that liver cells are not the main source of serum C1q. So far, 
many different cell types have been described to produce and secrete C1q, including epithelial 
cells and fibroblasts (96, 97). An overview of cell types producing C1q is listed in Table 1.  
 
Table 1: Overview of C1q-producing cells in humans, guinea pigs, mice, and rats. 
Species C1q-producing cell type Ref 
human 
monocytes 
→ no C1q secretion but positive for C1q mRNA (donor-specific) 
(98, 99) 
DCs: iDCs>>mDCs 
→ independent of the maturation stimuli used (LPS, IFNα, …) 
(100-102) 
macrophages (HMDMs, pMac) (69, 70, 103, 104) 
osteoclasts       (105) 
fibroblasts    (96, 106-108) 
endothelial cells (109) 
epithelial cells (97) 
mesenchymal cells (97) 
microglial cells (110, 111) 
trophoblasts  (109, 112) 
guinea pig pMac (103) hepatocytes (hepatocyte primary cell culture) (93) 
mouse 
bone marrow stromal cells (macrophages, DCs) (113) 
macrophages  (114) 
pMac (95) 
rat C1q-expressing spleen cells (macrophages, DCs) (115) 
liver-derived mononuclear phagocytes (KCs) (94) 
Legend: HMDMs: human monocyte-derived macrophages; iDCs: immature dendritic cells; mDCs: 
mature dendritic cells 
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Nevertheless, it is believed that C1q is predominantly produced by myeloid cells (26, 68-70). 
This hypothesis is based on the fact that C1q-/- mice, lacking detectable serum C1q levels, 
were able to restore normal C1q serum levels upon receiving a bone marrow transplant from 
wild type mice, and vice versa (116). Interestingly, monocytes fail to synthesize C1q, even 
though, some cells have been tested positive for C1q mRNA (98, 99). However, monocytes 
gain the ability to produce C1q during their differentiation into macrophages or DCs (26, 68-
70). C1q is expressed by bone marrow stromal DCs and macrophages (113). In particular, 
iDCs are an important source of functional C1q, but upon maturation they downregulate this 
capability (26, 100). Besides DCs, macrophages as well produce C1q, although their secreted 
C1q levels are lower as compared to those of DCs (unpublished data; (26)). Interestingly, 
subsets of macrophages (see p. 25/unpublished data) differ in their C1q producing capacity. 
Even though, resident macrophages produce constantly low C1q levels, their proinflammatory 
counterparts are able to produce much higher C1q levels (117, 118). It is hypothesized that 
the modulation of C1q secretion by macrophages in response to different stimuli is dependent 
on the developmental stage of these cells. HMDMs kept in culture for several weeks 
constantly secreted C1q (69) and secreted C1q was found to share similarities to serum C1q 
(68, 70). In addition, C1q secreted by iDCs and macrophages was functionally active in the 
activation of the CP and in binding to apoptotic cells (S. Thanei et al. (submitted); see part 3, 
p. 73, (26, 70)). Therefore, C1q secreted and produced by immune cells is considered to have 
an important role in the local environment of immune cells, at sites of inflammation where 
macrophages and DCs are present and freshly synthesized C1q might accumulate.  
In vitro, C1q synthesis and expression can be influenced by different agents, including LPS, 
steroids, cytokines (IFN-γ, IL-6), C3b-opsonized zymosan, and ICs (27, 69, 104, 119). 
Notably, immobilized C1q (imC1q) was shown to trigger its own production in DCs but not in 
HMDMs (120). In contrast, Galvan et al. reported that imC1q also upregulates C1q mRNA in 
murine macrophages (121). These reports suggest that imC1q itself can lead to an elevated 
C1q production consistent with our findings (S. Thanei et al. (submitted); see part 3, p. 73). 
Studies addressing how C1q secretion and production can be influenced in different cell types 
by different agents are summarized in Table 2. 
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Table 2: Regulation of C1q expression and secretion in different cell types. 
Only papers analyzing isolated mononuclear cells or cell lines have been included. 
C1q expression: Refers to the expression of C1q mRNA 
C1q secretion: Refers to the secretion of C1q into supernatants (SN) of cell cultures 
 
Table 2.1: Upregulation of C1q expression and secretion. 
Stimulatory 
agent used 
Mechanism of regulation 
C1q-producing cells/species 
Ref 
TLR ligands 
(LPS, LTA, PGN) 
-  Induction of C1q secretion by human iDCs (122) 
LPS - Upregulation of C1q expression and secretion by human and 
murine macrophages  
- Induction of C1q expression by THP-1 cells 
(26-28, 
123) 
IL-6 - Upregulation of C1q expression and secretion by murine pMac 
and THP-1 cells 
(119, 123) 
 
IFNα/β - Upregulation of C1q expression and secretion by murine 
macrophages  
(28, 114) 
IFNγ - Induction of C1q production by THP-1 cells and murine microglia 
cells 
- Induction of C1q expression and secretion by murine 
macrophages  
(27, 28, 
114, 123-
125) 
Steroids  
(Hydrocortisone, 
Pred, Dexa) 
- Upregulation of C1q gene expression and/or secretion by KCs 
and human pMac 
- Induction of C1q production but not C1q secretion by murine 
(resident) pMac 
- Stimulation of C1q production by THP-1 cells 
(94, 104, 
118, 123) 
NSAIDs - Induction of C1q production but not C1q secretion by murine 
(resident) pMac  
(118, 119) 
imC1q - Upregulation of C1q mRNA expression by murine macrophages 
- Induction of C1q secretion by HMDMs (study dependent) and 
DCs 
(120, 121) 
(S. Thanei 
(sub.)) 
C3b-opsonized 
zymosan 
- Induction of C1q expression and secretion by murine 
macrophages upon C3bR triggering 
(27) 
anti-C1q bound 
to imC1q  
-  Induction of C1q secretion and de novo synthesis by HMDMs (S. Thanei 
(sub.)) 
ICs - Induction of C1q expression and secretion by murine 
macrophages upon FcγR triggering 
(27) 
SIV - Upregulation of C1q expression by rhesus macaques-derived 
microglia cells 
(126) 
tumor cells - Upregulation C1q expression by murine TAMs (127) 
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Table 2.2: Inhibition of C1q expression and secretion. 
Inhibitory agent 
used 
Mechanism of regulation 
C1q-producing cells/species 
Ref 
NSAIDs - Inhibition of C1q production by murine pMac  
- ASA: decreased C1q secretion by human pMac 
(104, 118) 
IFN-γ - Downregulation of C1q gene expression by rat-derived KCs and 
murine microglia cells 
- Suppression of C1q expression and secretion by murine pMac 
(94, 119, 
128, 129) 
IL-1 - Inhibition of C1q expression by murine pMac (119, 128) 
PMA - Suppression of C1q production by THP-1 cells (123) 
Tacrine - Inhibition of C1q secretion in IFNγ-treated THP-1 cells by Tacrine, 
but not by Indomethacin, Cimetidine, or Propentofylline 
(123) 
LPS - Downregulation of C1q gene expression by rat-derived KCs 
- Downregulation of C1q secretion during maturation process of 
human iDCs 
(26, 94) 
 
IFN-α - Inhibition of C1q secretion by human iDCs (26) 
 
Table 2.3: No effect on C1q expression and secretion. 
Stimulatory or 
inhibitory agent 
used 
Mechanism of regulation 
C1q-producing cells/species 
Ref 
yeast   - No effect on C1q production by HMDMs (69) 
IgG-opsonized 
SRBCs 
- No effect on C1q production by HMDMs (69) 
 
Legend: ASA: Acetylsalicylacid; Dexa: Dexamethasone; FcyR: Fcgamma receptor; LTA: lipoteichoic 
acid; NSAIDs: non-steroidal anti-inflammatory drugs; PGN: peptidoglycan; PMA: phorbol 12-myristate; 
Pred: Prednisone; SIV: simian immunodeficiency virus; SRBCs: sheep red blood cells; TAMs: tumor-
associated macrophages 
 
So far, the pathway and the mechanism leading to up- or downregulation of C1q synthesis 
and the regulation of the genes encoding C1q are not well understood. Locally secreted C1q 
probably acts in an auto-/paracrine manner maintaining tissue homeostasis by suppressing 
cell-mediated inflammation. Recently, we observed that HMDMs on imC1q and bound-anti-
C1q continuously secreted high C1q levels and produced an accumulation of iC1q suggesting 
continued de novo synthesis. This observation indicates that high levels of secreted C1q are 
unlikely to act as a negative feedback mechanism thereby inhibiting the synthesis of fresh C1q 
(S. Thanei et al. (submitted); see part 3, p. 73). Furthermore, addition of exogenous C1q 
(20µg/ml) to cultured murine macrophages led to an increase in C1q mRNA levels (28). These 
reports suggest that C1q secretion might act as a positive feedback loop reflecting a temporal 
requirement of an increased amount of C1q in an inflamed tissue (130, 131). Local synthesis 
of C1q in tissues by myeloid cells is believed to play an important role in the clearance of 
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apoptotic cell material and in the recruitment of immune cells to sites of inflammation or injury 
in situ. Indeed, upregulated C1q production has been demonstrated in the brains of mice 
suffering from infections or Alzheimer’s disease (130, 131), underlining the importance of local 
C1q production in the regulation of tissue homeostasis during inflammation. However, in the 
circulation of healthy individuals C1q is mostly associated with its proteases C1s and C1r to 
form the C1 complex (61, 63, 65, 66).  
Notably, patients with active lupus having low serum C1q levels often display a serological 
abnormality: high levels of a non-functional form of C1q (so-called low-molecular-weight C1q 
(LMW-C1q)), which is unable to participate in the activation of the CP. This form of C1q was 
predominantly detected in SLE patients suffering from homozygous C1q deficiency (132). 
Nevertheless, LMW-C1q also occurred in SLE patients and healthy donors but not in 
rheumatoid arthritis (RA) patients or in patients suffering from acute poststreptococcal 
glomerulonephritis (132, 133). In addition, it has been demonstrated that SLE patient-derived 
macrophages produce elevated levels of LMW-C1q but the secretion of normal C1q was not 
impaired, indicating that LMW-C1q could be considered as a by-product of regular C1q 
synthesis (134). Furthermore, monocytes obtained from SLE patients without inherited C1q 
deficiency have a significantly impaired ability to upregulate C1q synthesis, both at the mRNA 
and protein levels, upon stimulation by Dexa and IFNγ, as compared to cells obtained from 
healthy donors or RA patients, underscoring the importance of C1q in autoimmunity and in 
particular in SLE (99).   
C1q in immune cell modulation  
The function of C1q is not only restricted to serve as the recognition molecule of the C1 
complex and thus as the activator of the CP. The C1q molecule itself has an important 
function in immune cell modulation (summarized in Table 3). 
As mentioned above, C1q serves as a regulatory protein during inflammatory processes 
including autoimmunity. Moreover, C1q participates in the clearance of apoptotic cell material. 
C1q can directly bind to the surface of apoptotic cells via its globular heads (76, 78). The 
collagen-like region (CLR) then interact with phagocytes via C1qRs (22) thereby facilitating 
the ingestion of apoptotic cells (23, 120). Additionally, studies from different research groups 
demonstrated that C1q not only enhances the uptake of apoptotic cell material but also 
modifies the cytokine profile released by phagocytic cells towards a less inflammatory 
response during phagocytosis, as evident by suppressed secretion of proinflammatory 
cytokines, including IL-1α/β, IL-6, and TNFα (23, 120, 135, 136). During the uptake of early 
and late apoptotic cells, C1q exerts a potent inhibitory capacity in macrophage-mediated 
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inflammation (24, 25). Furthermore, macrophages and DCs which ingested C1q bound to 
apoptotic cells significantly suppress the proliferation of Th17 and Th1 subsets (137). These 
data suggest that C1q is crucial in limiting inflammation during the uptake of apoptotic cells 
and proliferation of T cell subsets. Furthermore, C1q-polarization of macrophages induces an 
anti-inflammatory (M2-like) phenotype in macrophages (S. Thanei et al. (submitted); see part 
2, p. 46). 
 
Table 3: Summary of C1q- and bound anti-C1q-mediated effects on human immune cells. 
Only papers focusing on isolated human-derived cells for in vitro experiments have been included. 
imC1q: Refers to cells cultured on C1q immobilized/bound to a plastic surface  
sC1q: Refers to cells incubated with fluid-phase C1q 
 
Table 3.1: Papers analyzing the effect of sC1q. 
Cell 
type  
C1q-mediated effect Ref 
M
on
oc
yt
es
 - Binding of sC1q to monocytes in a dose-dependent manner 
- Binding of sC1q to monocytes is partially mediated by LAIR-1: 
→ binding of C1q triggers phosphorylation of LAIR-1 
- Suppression of IFN type I production by CpG-challenged monocytes by C1q trough 
activating LAIR-1 
(87, 
138, 
139) 
H
M
D
M
s 
- Binding of sC1q to HMDMs in a dose-dependent manner 
- Migration of M2-like HMDMs (IL-4) towards C1q  
→ C1q induced migration: untreated macrophages<M1<M2a 
 
 
(84, 
138)  
D
C
s 
- Binding of sC1q to iDCs and mDCs in a dose-dependent manner 
- Chemotaxis of iDCs, but not of mDCs, in a dose-dependent manner  
→ Migration mediated through ligation of both cC1qR and gC1qR 
- Differentiation of DCs in the presence of sC1q (tolerogenic DCs): 
→ Enhanced phagocytic capacity 
→ Impaired capacity to secrete cytokines (IL-6, TNFα, IL-10, IL-12p70) 
→ Impaired upregulation of costimulatory molecules (CD80, CD83, CD86) upon LPS 
stimulation 
→ Impaired ability to stimulate alloreactive T cells, including reduced production of IFNγ 
- Inhibition of the differentiation of monocytes to DCs by the interaction of C1q with 
LAIR-1 
- Inhibition of INFα secretion by pDCs by the interaction of C1q with LAIR-1 
(85-87, 
140) 
 
 
Ly
m
ph
oc
yt
es
  - Binding of sC1q to B and T cells in a dose-dependent manner 
- Inhibition of mitogen-induced T cell proliferation 
- Stimulation of Ig production in B cells (S. aureus activated) derived from healthy 
donors and 2 SLE patients in a dose-dependent manner 
 
(138, 
141, 
142) 
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N
eu
tr
op
hi
ls
 - Upregulation of CR3 expression and adherence to albumin-coated surfaces by 
stimulated neutrophils 
- Stimulation of migration (mainly chemotaxis and not chemokinesis) in a dose-
dependent manner 
→ mediated by the CLR of C1q  
(143, 
144) 
Fi
br
ob
la
st
s 
- Activation of C1qRs leads to Ca2+-influx and stimulation of Ca2+-activated K+ 
channels and initiation of chemotaxis of human skin fibroblasts 
- Response of proliferating fibroblast to sC1q: 
→ Increased phosphorylation of p38 MAPK in proliferating fibroblasts partially mediated by 
the binding of CLR to CRT 
→ Induction of apoptosis by CLR in fibroblasts 
(145, 
146) 
 
Table 3.2: Papers analyzing the effect of imC1q. 
Cell 
type  
C1q-mediated effect Ref 
M
on
oc
yt
es
 - Upregulation of phagocytosis of SRBCs by imC1q-primed monocytes  
- Modulation of LPS-induced cytokine production at the mRNA and protein levels 
towards a less inflammatory response: 
→ suppression of proinflammatory cytokines: IL-1α/β, TNFα 
→ upregulation of IL-10, IL-1RA, MCP-1, IL-6 
(24, 
135, 
147) 
H
M
D
M
s - Modulation of LPS-induced cytokine release towards a less inflammatory response - Upregulation of FcγR- and CR-mediated phagocytosis of apoptotic cells 
- Upregulation of C3 secretion 
- Enhanced phagocytosis of SRBCs by imC1q-primed HMDMs 
(24, 
138, 
147) 
D
C
s 
- Modulation of LPS-induced cytokine release towards a less inflammatory response 
- Induction of maturation of iDCs: 
→ Upregulation of MHC class II, CD80, CD83, CD86, and CCR7 expression 
→ Elevated secretion of IL-12, IL-10, and TNFα 
→ Increased T cell stimulating capacity (increased production of IFN-γ consistent with the 
generation of a Th1 response) 
→ Induces NF-κB translocation to the nucleus 
(24, 
86) 
N
eu
tr
op
hi
ls
  - C1q-stimulated superoxide production:  
→ Stimulation of O2- release via a Ca2+-dependent pathway 
→ Costimulatory signal by CD18 (beta2 integrins) binding to ICAM-1 essential for C1q-
triggered superoxide production 
→ Inhibition of C1q-triggered superoxide production by blocking CD59  
 
(148-
150) 
 
T 
ce
lls
 - Regulation of IFN-γ, IL-4, and IL-10 production by CD3-positive T cells (83) 
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Table 3.3: Papers analyzing the effect of anti-C1q bound to imC1q. 
Cell 
type  
C1q-mediated effect Ref 
M
on
oc
yt
es
 - Induction of proinflammatory cytokine response  
(IL-1β, IL-6, TNFα: ↑; IL-10: ↓) 
 
 
 
(unpub
. data) 
H
M
D
M
s 
- Induction of a proinflammatory phenotype in macrophages: 
→ Induction of proinflammatory cytokine response (IL-1β, IL-6, TNFα: ↑; IL-10: ↓) 
→ Upregulation of MHC class II, CD14, CD80, and CD274 expression 
→ Downregulation of CD163 and MerTK 
→ Downregulation of FITC-dextran uptake as compared to imC1q 
→ Downregulation of phagocytosis rate of apoptotic cells 
- Elevated C1q secretion 
(S. 
Thanei 
et al. 
(sub.)) 
D
C
s 
- Elevated C1q secretion (iDCs>>mDCs) (unpub
. data) 
 
Table 3.4: Papers analyzing the effect of C1q bound to the surface of apoptotic cells (imC1q on 
apoptotic cells). 
Cell 
type  
C1q-mediated effect Ref 
M
on
oc
yt
es
 - Modulation of LPS-induced cytokine release towards a less inflammatory response 
during the ingestion of apoptotic cells 
 
 
 
(24) 
H
M
D
M
s 
- Opsonization of apoptotic cells by C1q and facilitation of apoptotic cells uptake 
- Modulation of LPS-induced cytokine release towards a less inflammatory response 
during ingestion of apoptotic cells 
- Stimulation of the phagocytosis of apoptotic cells by ligation of CRT (cC1qR)/CD91 
→ involvement of macropinocytosis 
- Opsonization of apoptotic cells by C1q induces ERK signaling 
- C1q binding to CRP-opsonized apoptotic cells: 
→ Activation of early (only CP) but not late complement components and  promoting 
phagocytosis 
→ Ingestion of apoptotic cells by macrophages stimulated TGF-β secretion (non-
inflammatory clearance of apoptotic cells) 
- Directing of macrophage polarization during the uptake of apoptotic cells: 
→ Modulation of gene expression in LPS-stimulated macrophages associated with: 
JAK/STAT signaling, chemotaxis, immuno-regulation, and NLRP3 inflammasome activation 
→ Upregulation of LPS-induced cytokine release (type I IFN, IL-27, IL-10) 
→ Inhibition inflammasome activation: down-regulation of procaspase-1 cleavage and 
caspase-1-dependent cleavage of IL-1β 
- Regulation of T cell proliferation: 
→ Upregulation of PD-L1/2 and CD40 expression 
→ Reduction of allogenic and autologous Th17 and Th1 subset proliferation 
→ Increased Treg proliferation 
(22-25, 
137, 
151, 
152) 
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D
C
s 
- Increased phagocytosis rate of apoptotic cells by iDCs 
→ Increased secretion of IL-12 in the presence of LPS (Inhibition by PTX3) 
- Opsonization of apoptotic cells by C1q and facilitation/enhancing of apoptotic cells 
uptake  
→ in a C1q dose-dependent manner 
→ stimulation of IL-6, IL-10, TNFα but no effect on IL-12p70 secretion 
- Modulation of LPS-induced cytokine release towards a less inflammatory 
environment during ingestion of apoptotic cells 
- Regulation of T cell proliferation: 
→ Upregulation of PD-L2 and CD86 expression 
→ Reduction of autologous Th17 and Th1 subset proliferation 
(23, 
24, 
122, 
137) 
 
Table 3.5: Papers analyzing the effect of anti-C1q bound to imC1q on apoptotic cells. 
Cell 
type  
C1q-mediated effect Ref 
TH
P-
1 
ce
lls
 
- Anti-C1q target C1q deposited on the surface of early apoptotic cells 
→ suppression of the uptake of apoptotic cells by THP-1 cells  
 
(153, 
154) 
 
Table 3.6: Papers analyzing the effect of C1q bound to other surfaces. 
Cell 
type  
C1q-mediated effect Ref 
M
on
oc
yt
es
 - Interaction of C1q with LDL:  
→ C1q binding to modified LDL but not to native LDL 
→ Enhanced ingestion of LDL upon C1q binding to LDL 
→ Upregulation of CD80 and CD31 expressions 
→ Upregulation of CCL2 chemokine expression 
 
(155) 
H
M
D
M
s 
- C1q binding to modified LDL but not to native LDL: 
→ Upon C1q binding to LDL enhanced ingestion  
- Engulfment of NETs by HMDMs in a cytochalasin D-dependent manner 
→ active, endocytic process 
- C1q binding and opsonization of NETs facilitates their uptake by HMDMs  
→ silent process 
(155, 
156) 
 
Table 3.7: Papers analyzing the effect of C1q-bearing ICs (C1q-ICs). 
Cell 
type  
C1q-mediated effect Ref 
M
on
oc
yt
es
 - Incubation of monocytes with C1q-ICs derived from SLE patients: 
→ Reduction of the expression of IFN-response genes 
→ No detectable upregulation of CD40 and CD86 expression 
- C1q promotes the binding of SLE ICs to monocytes 
→ Altering the trafficking of ICs within monocytes: ICs persisted in early endosomes 
→ Inhibition of IFNα secretion by C1q-ICs 
(157, 
158) 
D
C
s 
- C1q slightly promotes the binding of SLE ICs to pDCs 
 
 
(157) 
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T 
ce
lls
 - Effect of C1q-ICs: 
→ Stimulation of TNFα and IFNγ secretion in a dose-dependent manner 
→ Upregulation of CD25 (low expression levels) 
(159) 
 
Legend: CRP: C-reactive protein; CRT: Calreticulin; ERK: extracellular signal-regulated kinase; IL-1RA: 
IL-1 receptor antagonist; JAK: Janus kinases; LAIR-1: leucocyte-associated Ig-like receptor 1; LDL: 
lipoproteins; M1: proinflammatory macrophages; M2: anti-inflammatory macrophages; MAPK: mitogen-
activated protein kinase; MCP-1: monocyte chemoattractant protein-1; MerTK: Mer tyrosine kinase; NF-
κB: nuclear factor- κB; pDCs: plasmacytoid DCs; PD-L1/2: programmed cell death ligand-1/2; PTX3: 
pentraxin 3; STAT: signal transducers and activators of transcription 
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Anti-C1q 
Hypocomplementemia, that most SLE patients display during a disease flare, is believed to be 
rather due to an accelerated consumption rate of complement proteins by aberrant 
complement activation and not the consequence of a primary deficiency of complement 
components (6). A rational reason for low C1q levels are anti-C1q. These autoantibodies were 
first detected in 1971 (160) and finally identified in 1988 by Antes et al. and Uwatoko et al. 
(161, 162). Anti-C1q have been observed in patients suffering from different autoimmune 
diseases but also in patients with renal or infectious diseases as well as in healthy individuals 
(Table 4). The incidence of anti-C1q varies highly between these different diseases. In a 
healthy population, anti-C1q positive individuals varied between 4-10% depending on the age 
of the population analyzed (163-165). In unselected SLE patients, anti-C1q positivity has been 
found to range from 20-50% (7-9). Nevertheless, the highest anti-C1q levels were found in 
patients suffering from hypocomplementemic urticarial vasculitis syndrome (HUVS) with a 
penetrance of 100% (166). No differences in the binding characteristics of anti-C1q between 
SLE or HUVS patients could be identified (167).  
 
Table 4: List of selected pathological conditions associated with the occurrence of anti-C1q. 
  Disease  Anti-C1q occurrence 
[%] 
Ref 
autoimmune  
diseases 
HUVS 100% (166) 
SLE 
- without lupus nephritis 
- with lupus nephritis 
20-50% 
- 14-32% 
- 60-100% 
(7-9, 29, 
163, 166, 
168) 
Sjörgen’s syndrome 13% (169) 
renal diseases membranoproliferative glomerulonephritis 54-88% (14, 170) 
IgA nephropathy 0-31% (14, 171) 
infectious 
diseases 
HIV 13% (172) 
hepatitis C 26% (164) 
- healthy individuals 4-10% (163-165) 
 
The strong association of anti-C1q with lupus nephritis suggests that these autoantibodies 
have a major role in the pathogenesis of lupus nephritis (7-9). Even though, anti-C1q are 
associated with renal involvement, direct evidence how these autoantibodies contribute to 
renal damage is not yet available. A study in a lupus-prone mouse model suggests that renal 
inflammation is only induced by anti-C1q in combination with preformed glomerular C1q-
containing ICs (10). The authors suggested that anti-C1q triggered complement activation is 
determined by the amount of deposited ICs and C1q in the kidneys. They hypothesized that, if 
complement activation passes beyond a certain threshold level, complement activation and 
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the infiltrating inflammatory cells lead to cell damage in the kidneys with consecutive overt 
renal disease and loss of renal function (10).  
Figure 5 illustrates the proposed mechanism of disease: ICs deposition occurs along the 
glomerular basal membrane in the kidneys of patients suffering from a pre-existing ICs-
glomerular nephritis (Figure 5A). C1q from the circulation or locally produced by infiltrating 
myeloid cells can then be fixed by these ICs (C1q-ICs) (Figure 5B). Due to the tight regulation 
of the complement activation by complement regulators, it is believed that this construct has 
not yet the ability to efficiently activate the complement cascade. Nevertheless, C1q-ICs can 
then be targeted by anti-C1q (Figure 5C). If sufficient C1q-ICs are deposited in the kidneys, 
bound anti-C1q can trigger further complement activation which is not sufficiently inhibited by 
complement regulators anymore. This will induce full-blown complement activation and 
secondary infiltration and activation of inflammatory immune cells, which ultimately lead to 
kidney damage (Figure 5D). With regard to downstream mechanisms, anti-C1q are believed 
to involve both, activation of the complement system as well as recruitment of FcγRs upon 
binding to, e.g., C1q-ICs deposited in the kidneys, with consecutive amplification of the 
inflammatory process during flares (10). 
 
 
Figure 5: The pathogenic effect of anti-C1q in nephritic kidneys of SLE patients. 
ICs deposit along the glomerular basement membrane in the kidneys of SLE patients (A). C1q is fixed 
onto these deposited ICs (B). Upon binding of C1q to deposited ICs, C1q exposes a cryptic epitope to 
which anti-C1q can bind to (C). Activation of the complement system and infiltration and activation of 
inflammatory immune cells leads to inflammation and tissue damage (D). The pathogenic mechanism 
of anti-C1q is thought to require both activation of the complement system as well as the recruitment of 
FcγRs for their pathogenicity (modified according to (10)). 
 
Importantly, the mechanism which renders C1q antigenic and leads to the production of anti-
C1q has not yet been identified. However, the occurrence of anti-C1q was demonstrated to be 
Ag-driven using phage display technology (173). Anti-C1q bind with high-affinity via their 
F(ab’)2 fragments to the CLR of C1q but not to the globular heads (161, 174). Furthermore, 
anti-C1q bind to a cryptic epitope exposed on surface-bound C1q, but hidden on fluid-phase 
  General introduction  
24 
C1q (175, 176). Recently, a specific linear epitope (termed A08), located on the C1qA chain, 
could be identified as a major target of anti-C1q (177). Nevertheless, this does not exclude the 
existence of additional epitopes. Anti-C1q are specifically directed against C1q since no cross-
reactivity with structural similar collectins, such as MBL or lung surfactant protein A, could be 
detected (178, 179). In vitro experiments evaluating the binding characteristics of anti-C1q 
demonstrated that anti-C1q do not recognize C1q when it is bound to different IgG-classes or 
ICs, suggesting that none of these constructs are able to present C1q and, more importantly, 
the cryptic epitope that is required for the binding of anti-C1q (153). Therefore, alternatively to 
the mechanism proposed in Figure 5, it has been hypothesized that these autoantibodies 
might rise due to a decreased or aberrant clearance of dying cell material which has been 
shown to occur in SLE patients (reviewed in (50)). Indeed, anti-C1q target C1q bound to the 
surface of early apoptotic cells (153, 154). This might induce autoantibody formation due to 
the prolonged exposure of C1q epitopes which are normally hidden in fluid-phase C1q. In this 
context, it has been hypothesized that the binding of anti-C1q to C1q might interfere with the 
process of phagocytosis. Indeed, Pang et al. demonstrated that anti-C1q of lupus nephritis 
patients bind to C1q deposited on the surface of early apoptotic cells and thereby suppressed 
their removal by THP-1 cells (154). 
Anti-C1q can be of the IgG-, IgA-, or IgM-class (14). However, the IgG-class distribution is 
discussed controversially. Whereas Coremans et al. and others mainly found IgG2 and IgG3 
(15, 167), other groups found IgG1 and IgG2 (180-182). Depending on the anti-C1q subclass, 
these autoantibodies might differ in their pathogenic properties, based on their interaction with 
bound C1q, concerning complement activation and FcγR activation on phagocytes. Indeed, 
we found that SLE patient-derived anti-C1q amplify complement activation in vitro via the CP 
and the LP dependent on the anti-C1q subclass repertoire present in the lupus patient’s 
serum (183) (see part 1, p. 29). In addition, we can show that imC1q-bound anti-C1q alter the 
C1q-dependent suppression of macrophage-mediated inflammation by inducing a 
proinflammatory phenotype via an FcγRII-dependent pathway and induce C1q secretion by 
HMDMs (S. Thanei et al. (both manuscripts submitted); see parts 2/3, p. 46/73). 
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Macrophages  
The classification of macrophage subsets 
Macrophages are key players of the innate immune system. They participate in host defense, 
clearance of dying and dead cells, tissue remodeling and homeostasis, inflammatory 
processes, and in immune diseases by contributing to tissue damage and pathology (184). 
The functional profile of macrophages is determined by their activation and exposure to 
environmental factors, such as cytokines and growth factors, during their differentiation from 
monocytes into macrophages (185). In analogy to the Th cell nomenclature, Mantovani et al. 
proposed a concept for dividing macrophages in a continuum between 2 functionally polarized 
states based on the cytokines used for in vitro polarization (Table 5) (184). In vitro, monocytes 
can be polarized into different macrophage subsets by specific cytokines, the most prominent 
being GM-CSF, IFN-γ, or LPS to induce mainly proinflammatory macrophages (termed M1), 
or M-CSF or IL-10 to induce mainly anti-inflammatory macrophages, also called alternatively 
activated or anti-inflammatory macrophages (M2). M2 can be further divided in M2a, M2b, and 
M2c subsets, which are induced by IL-4 or IL-13, ICs in combination with toll-like receptor 
(TLR) ligands such as LPS, and IL-10, TGFβ, or Glucocorticoids (particularly Dexa), 
respectively. Interestingly, the stimuli used for M2 polarization are very heterogeneous. 
However, polarized macrophages exhibit functional differences evident by their phenotypic 
profiles such as cytokine release and surface markers (185-187). M1 macrophages mainly 
produce proinflammatory cytokines, phagocyte microorganisms and are often linked to tissue 
injury and inflammation, whereas M2 macrophages display in general a low Ag-presenting 
capacity, inhibit and prevent T cell activation, and are associated with tissue repair and 
fibrosis (188, 189).  
 
  
  General introduction  
26 
Table 5: Overview of different macrophage subsets.  
 M1 (classically activated 
macrophages) 
M2 (alternatively activated 
macrophages) 
Polarizing cytokines used 
in in vitro experiments 
GM-CSF 
IFNγ, LPS, TNFα,  
M-CSF 
M2a: IL-4, IL-13 
M2b: ICs + IL-1β/LPS 
M2c: IL-10, TGFβ, Glucocorticoids 
Cytokine secretion profile  Proinflammatory cytokines 
(IL-1β, IL-6, IL-12, IL-15, IL-18, 
TNFα, …) 
Anti-inflammatory cytokines 
(IL-10) 
Proinflammatory cytokines 
Induction of T cell 
response 
Th1 response Th2 effector response/functions 
Expression 
of surface 
markers 
CD14 +++ + (↓) 
CD40 ++ +++ 
CD80 +++ ++ 
CD86 +++ (↑) + (M2b: (↑); M2a: (↑)) 
CD163 + ++++ (↑) 
CD206 + (↓) ++ (↑) 
CD273 + ++ 
CD274 +++ + 
MHC class II +++ (↑) + (M2b: (↑)) 
Functions Endocytosis 
Type I inflammation 
Killing of intracellular pathogens 
Tumor resistance 
Type II inflammation 
Allergy 
Killing and encapsulation of 
parasites 
Tissue repair and remodeling 
Clearance of apoptotic cell material 
Promoting angiogenesis 
Wound healing 
Metabolism characteristics High levels of nitric oxide 
synthase 
High levels of arginase 
C1q secretion High C1q secretion levels Low C1q secretion levels 
Summarized from: (190, 191) 
 
The model used to categorize macrophages originally only referred to M1 and M2 subsets 
which are associated with different functions as mentioned above (188, 189). However, 
translation of the macrophage phenotypes, as described before, into disease models has 
been recognized to be over simplified. The classification of macrophages into the different 
subsets should be regarded as a useful framework. In vivo, macrophages are constantly 
encountering various signals. Therefore, it might be possible that macrophages exhibit a 
phenotype showing both M1 and M2 characteristics and that multiple phenotypes coexist in 
tissues. Additionally, polarization of macrophages is thought to be not permanent but rather 
milieu-dependent and partially reversible, i.e., in response to their microenvironment 
macrophages can express constantly changing phenotypes, also termed plasticity (184, 188, 
192). In disease conditions, macrophages might play a dual role. Therefore, it is not surprising 
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that so far no characteristic macrophage phenotype could be defined in lupus nephritis. 
Different reports show that infiltrating macrophages/DCs in murine lupus nephritis are very 
heterogeneous (193, 194). Nevertheless, mononuclear cells play a role in the pathogenesis of 
organ related diseases, such as lupus nephritis, and are associated with chronic tissue 
damage and injury (195). 
Macrophages and DCs in SLE patients 
Functional defects and abnormalities in the cells of the monocyte-macrophage lineage 
obtained from SLE patients are well known, although the underlying molecular mechanism is 
not fully understood. Macrophages obtained from SLE patients exhibit a defect in 
phagocytosis of apoptotic cell material correlating with low complement levels (17, 18). 
Additionally, monocytes from SLE patients have an abnormal cytokine secretion profile in 
response to apoptotic cells independent of the monocyte’s phagocytic efficiency or the 
patient’s disease state (19). This contributes to the accumulation of a large number of 
apoptotic cells which can be found in various tissues (20, 21). Further functional alterations 
occurring in SLE patient-derived cells are listed in Table 6. 
 
Table 6: Functional alterations in monocytes, macrophages, and DCs from SLE patients. 
 Monocytes Macrophages DCs 
Phagocytosis 
capability 
↓ Phagocytosis rate  
↑ TNFα/↓TGFβ during 
uptake (19) 
↓ Phagocytosis rate (17, 
196) 
na 
Cytokine secretion ↑ TNFα (197) 
↑ IL-10 
↑ IL-10 (S. Thanei et al. 
(submitted)) 
↑ IL-8 (198) 
Chemotaxis ↑ (199) na  na 
Expression of 
surface markers 
↑ CD64 on circulating 
monocytes (199) 
↑ CD40 (200) 
↓ CD14 (197) 
na  Inability to mature 
(201) 
↑ CD80, CD86, HLA-
DR (198) 
T cell proliferation 
induction 
na na  ↑ Proliferation and 
activation of 
allogenic T cells 
(198) 
C1q 
secretion 
C1q 
mRNA 
Unstimulated: normal 
Stimulated: ↓C1q expression 
(99) 
nt  nt 
C1q 
secretion 
nt Normal (S. Thanei et al. 
(submitted)) 
↑ LMW-C1q (132-134) 
nt 
Apoptosis na ↑ (196) na 
Superoxide 
production 
↓ (202) na  na 
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Legend: na: not available; nt: not tested 
Based on the characteristic features of M1/M2 macrophages one would expect that SLE 
patients display a predominance of M1-like cells. Low phagocytosis ability of apoptotic cells 
and high secretion rates of proinflammatory cytokines (such as TNFα) would underline this 
assumption. Nevertheless, the M1 versus M2 paradigm may not be appropriate for the 
classification of lupus cells. M1 macrophages are unlikely to produce IL-10 which can be 
found at high levels in lupus patients. These high IL-10 levels are considered to be a hallmark 
of the disease and were found to correlate with disease activity (203, 204). Furthermore, the 
combination of ICs and TLR ligands favor the induction of M2b macrophages. Studies of lupus 
prone mice suggest that both macrophage subtypes, M1 as well as M2, are increased in lupus 
nephritis kidneys (193, 194, 205).  
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Part 1 
Anti-C1q autoantibodies from systemic lupus erythematosus patients activate 
the complement system via both the classical and lectin pathways 
Abstract 
Autoantibodies against complement C1q (anti-C1q) strongly correlate with the occurrence of 
lupus nephritis and hypocomplementemia in systemic lupus erythematosus (SLE).  Although a 
direct pathogenic role of anti-C1q has been suggested, the assumed complement-activating 
capacity remains to be elucidated. Using an ELISA-based assay, we found that anti-C1q 
activate the classical (CP) and lectin pathways (LP) depending on the anti-C1q 
immunoglobulin-class repertoire present in the patient’s serum. IgG anti-C1q resulted in the 
activation of the CP as reflected by C4b deposition in the presence of purified C1 and C4 in a 
dose-dependent manner. The extent of C4b deposition correlated with anti-C1q levels in SLE 
patients but not in healthy controls. Our data indicate that SLE patient-derived anti-C1q can 
activate the CP and the LP but not the alternative pathway of complement. These findings are 
of importance for the understanding of the role of anti-C1q in SLE suggesting a direct link to 
hypocomplementemia. 
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Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B cell 
hyperactivity, antibodies specific for various auto-antigens, the formation of immune 
complexes (ICs), the aberrant activation of the complement system resulting in complement 
deposition and hypocomplementemia (44, 45). 
The complement system is an integral part of the innate immune system, consisting of several 
plasma and cell-associated proteins, and acting upon triggering as a cascade resulting in the 
opsonization and lysis of targeted cells (e.g., pathogens), in the production of anaphylatoxins 
(C3a, C5a), and in the recruitment of immune cells to the site of local inflammation (1). The 
complement system can be activated by at least 3 different pathways: the classical pathway 
(CP), the lectin pathway (LP), and the alternative pathway (AP) (1, 2). Each of these pathways 
is initiated by a specific ligand. The CP is activated by binding of the C1 complex to ICs, the 
LP by binding of mannose-binding lectin (MBL) or ficolins to, e.g., mannose-containing groups 
on bacterial surfaces, and the AP by spontaneous C3(H2O) binding and activation/turn-over or 
by bacterial products (e.g., lipopolysaccharide (LPS)) (1, 2). All 3 pathways converge in the 
formation of the C3 convertase, the cleavage of C3 into C3a and C3b, further downstream 
activation of terminal complement components and finally in the assembly of the membrane-
attack complex (C5b-C9) (35).  
Primary deficiencies of early components of the CP (C1q, C4, C2) are strongly associated 
with SLE. In particular, homozygous C1q deficiency was shown to be the strongest genetic 
susceptibility to develop SLE (3, 4). This observation suggests that complement plays a major 
role in the pathogenesis of SLE. However, most SLE patients do not suffer from primary C1q 
deficiency, but aberrant complement activation is accounted for low complement levels (5). A 
rational reason for low C1q levels are autoantibodies against C1q (anti-C1q) that are present 
in 20-50% of unselected SLE patients. Anti-C1q levels in these patients not only correlate with 
hypocomplementemia but also with the occurrence of proliferative lupus nephritis (7-9). 
Limited evidence is available supporting a direct role of these autoantibodies in the 
pathogenesis of lupus nephritis. Animal models suggest that renal inflammation is not induced 
by anti-C1q deposited in the kidneys together with C1q alone. Anti-C1q were only found to be 
pathogenic in these models in combination with preformed glomerular C1q-containing ICs 
(10). Anti-C1q were shown to bind to a cryptic epitope only exposed when C1q is surface-
bound, but that is shielded on C1q in fluid-phase (161). Importantly, anti-C1q specifically 
target C1q bound to early apoptotic cells (153, 154), providing a link between SLE, C1q, and 
apoptosis.  
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Little is known about the complement-activating potential of anti-C1q bound to immobilized 
C1q (imC1q) or which activation pathways might be triggered by anti-C1q. In a recent study, 
Pang et al. demonstrated that affinity purified anti-C1q of lupus nephritis patients inhibited the 
activation of the CP using ICs as the initiating structure (154). In contrast, other studies 
showed that autoantibodies in general have rather complement-activating capacities (206). 
However, the complement pathway that is primarily triggered by autoantibodies seems not 
only to be dependent on the dominant immunoglobulin-class (Ig-class) but also on the target 
antigen. In an in vitro assay, anti-citrullinated protein antibodies from rheumatoid arthritis (RA) 
patients were found to activate both, the CP as well as the AP of complement (207), whereas 
anti-neutrophil cytoplasmic autoantibodies were described to primarily activate the AP without 
apparent signs of LP or CP activation (208). Others demonstrated that ICs consisting of 
collagen and anti-collagen autoantibodies could activate both the CP and the AP (209). Also, 
anti-phospholipid antibodies have been linked to complement activation whereby the CP was 
found to be the initiator and the AP the amplifier of complement activation (210). Finally, 
cryoglobulins were shown to activate all 3 pathways of complement, the CP, the LP, and the 
AP (211). 
The aim of this study was to elucidate the complement-activating potential of SLE patient-
derived high-affinity anti-C1q. Comprehension of the complement-activating potential of anti-
C1q will improve the understanding of the disease and support the development of 
complement-targeting treatments.  
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Patients and methods 
Anti-C1q source  
A cohort of 27 SLE patients (Table 7) and 25 healthy control donors were included in the 
study.  
 
Table 7: SLE patient characteristics. 
Sex (females/males) 22/5 
Age (mean range years) 47 (28-71) 
Hypocomplementemia (low C3 and C4) (yes/no) 1 14/13 
Lupus nephritis (yes/no) 1 16/11 
Positive for anti-C1q1: 
- Positive for IgG anti-C1q 
- Positive for IgG and IgM anti-C1q 
- Positive for IgG and IgA anti-C1q 
- Positive for IgG, IgM, and IgA anti-C1q 
20 
9 
3  
5 
3 
Negative for anti-C1q1 7 
1 Information at time point of blood sampling 
 
All SLE patients fulfilled at least 4/11 criteria of the American College of Rheumatology (212, 
213). Collection and use of serum samples were approved by the local Ethics Committee 
(EKZ-No.: 110/04; 130/05). Before serum samples were diluted to their final working 
concentration, each sample was heat-inactivated (56°C, 30min) and centrifuged at 14’000xg 
for 30min at 4°C. 
Complement-active/-deficient sera and dilution buffers 
As a source of complement, normal human sera (NHS) from healthy donors were aliquoted 
and stored at -80°C until used. These NHS had normal C1q and MBL levels and no detectable 
anti-C1q levels. In addition, we used MBL-deficient sera from healthy donors (undetectable 
MBL; but normal C1q levels) and C1q-depleted serum (C1qDS; Complement Technology: 
negative for C1q; but normal MBL levels). 
Purified complement proteins and sera used as a source of complement were diluted either 
using veronal buffered saline (VBS: 5mM barbituric acid/0.5mM MgCl2/2mM CaCl2/140mM 
NaCl/0.05% Tween, pH 7.5), Mg-EGTA buffer (modified VBS: 10mM EGTA/15mM 
MgCl2/140mM NaCl/0.05% Tween, pH 7.5), or PBS-EDTA (PBS/10mM EDTA/0.05% Tween, 
pH 7.5). The presence of 0.05% Tween did not impair the activation of any of the complement 
pathways (data not shown). 
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Detection of anti-C1q levels 
For the detection of anti-C1q levels, ELISA plates (MaxiSorp, Nalge Nunc International) were 
coated with purified C1q (5µg/ml; Complement Technology) in coating buffer (0.1M sodium 
carbonate buffer, pH 9.6) overnight at 4°C. After each incubation step, the plates were 
washed 3times with washing buffer (PBS-T: PBS/0.05% Tween 20). C1q-coated plates were 
incubated with serum samples from SLE patients or healthy donors diluted 1:50 in high-salt 
buffer (HS-PBS: PBS-T/1M NaCl) for 1h at 37°C. After washing, different anti-C1q classes 
(IgG, IgA, IgM) were detected with specific antibodies diluted in HS-PBS for 1h at room 
temperature (RT). Bound IgG was detected with alkaline phosphatase (AP)-conjugated rabbit 
anti-IgG (Promega), bound IgA with AP-conjugated goat anti-IgA, and bound IgM with AP-
conjugated donkey anti-IgM (both obtained from Jackson ImmunoResearch). The enzyme 
activity of AP was detected by incubating plates with AP substrate (Sigma-Aldrich) according 
to the manufacturer’s instructions. Absorbance was read at 405nm using a microplate 
biokinetics reader (BioTek instruments). For data analysis the results were standardized as 
follows: measurements were expressed in units relative to the O.D. values of a reference SLE 
serum having high anti-C1q levels and corresponding to 1’000 arbitrary units (AU). The 
reference serum was used as an internal control and included on each plate in each 
experiment. The cut-off was determined as the interquartile mean (IQM) of the AU obtained 
with NHS plus 3times the SD. Every sample was tested in duplicate within a single 
experiment, and experiments were performed 3times.  
Complement activation assays 
Detection of CP, LP, and AP activation  
Functional activity of the 3 complement activation pathways was analyzed by ELISA using 
coated IgM (2µg/ml) for the CP, coated mannan (100µg/ml; Saccharomyces cerevisiae; 
M7504) for the LP, and coated LPS (10µg/ml; Escherichia coli: 0127:B8, all obtained from 
Sigma-Aldrich) for the AP. Plates were coated over night at 4°C. Residual binding sites were 
blocked with blocking buffer (BSA-PBS: PBS/1% BSA) for 1h at RT. Then, the plates were 
washed and incubated for 1h at 37°C with NHS diluted at 1% (for the CP and the LP) or 10% 
(for the AP) in VBS, Mg-EGTA buffer, or PBS-EDTA buffer as a source of complement. After a 
wash step, deposited C3 was detected by goat anti-C3 (Quidel) and deposited C4b by goat 
anti-C4b (Complement Technology). For both a secondary HRP-labeled mouse anti-goat IgG 
(Sigma-Aldrich) was used. After a final washing step, HRP activity was quantified by using 
TMB substrate (BD Biosciences) according to the manufacturer’s instructions. The reaction 
was stopped by the addition of 4M H2SO4 and absorbance was read at 450nm. 
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Complement activation by anti-C1q  
To investigate the ability of anti-C1q in activating the complement system, ELISA plates were 
coated with C1q in coating buffer overnight at 4°C and free binding sites were blocked with 
PBS-BSA for 1h at RT. After a washing step, plates were incubated for 10min at 37°C with 
heat-inactivated sera from SLE patients or healthy donors diluted in HS-PBS. This short 
10min incubation time was found to be sufficient for anti-C1q binding to imC1q in preliminary 
kinetic experiments (data not shown). Then, plates were washed again. In case of using sera 
as a source of complement for the assay, plates were incubated for 1h at 37°C with 
complement-active NHS or complement-deficient sera (MBL-deficient serum/C1qDS) diluted 1 
or 10% in VBS or Mg-EGTA buffer respectively. For the CP-specific assay, plates were 
incubated for 1h with purified C1 (0.5µg/ml) diluted in VBS, followed by an incubation of 40min 
with purified C4 (2µg/ml; both obtained from Complement Technology) diluted in VBS. After a 
wash step, activation of complement was assessed by detecting deposited C4b or C3 
fragments using specific antibodies as described before.  
Statistical analysis 
Data are expressed as AU or as mean (O.D. values) ± SEM. The significance of differences 
between 2 groups was determined using the Mann-Whitney U test and correlations were 
calculated using the Spearman’s rank correlation coefficient. More than 2 groups were 
compared using one-way ANOVA followed by the Bonferroni post-test (GraphPad Prism). A 
p<0.05 was considered statistically significant. 
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Results 
Detection of in vitro complement activation 
To analyze the complement-activating capacity of patient-derived anti-C1q in vitro, an ELISA-
based assay was developed to specifically distinguish the activation of the CP, the LP, and 
the AP. Selective inhibition of specific complement pathways was obtained by using special 
buffers, lacking either magnesium and/or calcium, or by using complement-deficient sera. 
NHS diluted in VBS, a buffer containing both calcium and magnesium, allowed the activation 
of all 3 complement pathways evident by both C4b and C3 depositions. When NHS was 
diluted in Mg-EGTA buffer, containing only magnesium but no calcium, clear C3 deposition 
could be measured indicating AP activation, whereas only minor C4b deposition could be 
observed on LPS coating. Finally, using EDTA buffer, devoid of both calcium and magnesium, 
prevented the activation of all three pathways (Figure 6A+B). 
The specificity of this assay was confirmed by using C1qDS or MBL-deficient serum instead of 
NHS as a source of complement (Figure 6C+D). As expected, MBL-deficient serum showed 
normal CP activity but no LP activity. C1qDS showed no CP activity. However, C1qDS had in 
general lower complement activity than NHS potentially as a consequence of the C1q-
depleting manipulation.  
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Figure 6: Activation of the 3 pathways of complement in vitro.   
IgM-, mannan-, or LPS-coated plates were used for the activation of the CP, the LP, or the AP. Coated 
plates were incubated with NHS, as a source of complement, diluted in special buffers (VBS, Mg-
EGTA, or EDTA-PBS) and either C4b deposition (A) or C3 deposition (B) was detected. Under the 
same coating conditions, plates were also incubated with C1qDS or MBL-deficient serum and again 
C4b deposition (C) as well as C3 deposition (D) were measured. Data represent the mean ± SEM of 3 
independent experiments. One-way ANOVA incl. Bonferroni post-test (vs VBS control), p<0.05*, 
p<0.01**, p<0.001***.  
Legend: Mg2+: magnesium; Ca2+: calcium. 
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Anti-C1q activate the CP and the LP but not the AP  
In order to study the complement-activating capacity of anti-C1q, we used C1q immobilized 
(imC1q) to a polystyrene surface and serum from either SLE patients or healthy donors as a 
source of anti-C1q. All sera were diluted in high-salt buffer. By the use of a high-ionic strength 
buffer containing 1M NaCl, three advantageous effects were achieved: avoiding unspecific ICs 
binding to imC1q, allowing only binding of high-affinity anti-C1q to imC1q, and blocking 
activation of complement factors present in SLE serum (data not shown; (14, 174)). 
Complement activation was further inhibited by heat-inactivation of all sera which did not 
affect the binding of anti-C1q to imC1q (data not shown). 
To validate the assay, four different SLE patients and two healthy donors were selected based 
on the Ig-class of anti-C1q present in their sera. SLE(1) had IgG and IgA anti-C1q, SLE(2) IgG 
and IgM anti-C1q, and SLE(3) IgG, IgA, and IgM anti-C1q, whereas SLE(4) and both healthy 
donors (NHS(1+2)) were negative for anti-C1q. After incubation of the sera on C1q-coated 
plates, NHS was added as a source of complement and C4b and C3 depositions were 
quantified as described in patients and methods.  
Although, there was a low amount of C3 and C4b deposition on imC1q after exposure to NHS 
that was independent of anti-C1q (SLE(4)/NHS(1+2)), we observed a significant enhanced 
deposition following the binding of anti-C1q to imC1q (Figure 7A+D). In order to discriminate 
whether C4 deposition was caused by the CP, the LP, or by both pathways, we next used 
MBL-deficient serum or C1qDS instead of NHS. 
To evaluate the relative contribution of the CP, we used MBL-deficient serum diluted in VBS 
(Figure 7B). Yet, we could still detect C4b deposition, indicating that anti-C1q of the IgG- and 
IgM-class are able to activate the complement system via the CP. Anti-C1q-dependent CP 
activation was always higher in SLE patients having IgG and IgM anti-C1q (SLE(1–3)) as 
compared to anti-C1q negative individuals (SLE(4)/NHS(1+2)).  
When instead CP activation was prevented by using C1qDS diluted in VBS, we could still see 
enhanced C4b deposition, suggesting that in the presence of NHS both, the CP and the LP, 
contribute to anti-C1q-mediated C4b deposition (Figure 7C). C4b deposition was evident in 
the presence of anti-C1q derived from patients having IgA anti-C1q (SLE(1+3)). But, low 
levels of deposited C4b could be also detected with SLE(2), a patient having no IgA anti-C1q. 
Control sera, SLE(4) and both healthy donors (NHS(1+2)), who were screened negative for 
anti-C1q, led to only minor C4b deposition.  
Activation of all 3 complement pathways leads to the generation of deposited C3 fragments. 
Since anti-C1q from patients (SLE(1-3)) bound to imC1q induced levels of C3 deposition that 
were higher as compared to serum from anti-C1q negative patients or healthy donors 
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(SLE(4)/NHS(1+2) (Figure 7D)), we determined the relative contribution of the AP to this anti-
C1q induced complement activation. 
As seen in Figure 7E, C3 deposition was completely abolished when NHS was diluted in Mg-
EGTA instead of VBS, suggesting that anti-C1q derived from SLE patients do not directly 
activate the AP.  
 
 
Figure 7: Anti-C1q bound to imC1q trigger the activation of the CP and the LP but not of the AP. 
C1q-coated plates were incubated with sera of different SLE patients (3 anti-C1q positive, 1 anti-C1q 
negative) or sera of 2 different healthy donors (both anti-C1q negative). Subsequently, NHS diluted in 
VBS (A+D), MBL-deficient serum diluted in VBS (B), C1qDS diluted in VBS (C), or NHS diluted in Mg-
EGTA buffer (E) was added and either C4b (A-C) or C3 (D+E) deposition was detected. Anti-C1q 
classes present in the serum sample are indicated for each patient and healthy donor below the figure 
(-: 0-250AU; +: 250-500AU; ++: 500-750AU; +++: 750-1’000AU). Data are shown as the mean ± SEM 
of 3 independent experiments. 
 
Taken together, our data indicate that anti-C1q bound to imC1q activate the complement 
system via the CP and the LP depending on the anti-C1q class present in the patient’s serum 
leading to C4b and C3 depositions. However, anti-C1q do not directly activate the AP. 
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Anti-C1q activate the CP and the LP dependent on the anti-C1q class  
To further dissect the relative contribution of the CP and the LP in the complement activation 
mediated by anti-C1q, we screened a larger cohort of SLE patients and healthy donors. 
Occasionally healthy donor serum contains anti-C1q (29). Thus, we included 2 of such sera in 
the assay.  
We used either MBL-deficient serum or MBL-deficient serum reconstituted with 4µg/ml purified 
MBL in addition to C1qDS or NHS. No C4b deposition could be measured on a plate coated 
with mannan alone using MBL-deficient serum, whereas the reconstitution of MBL-deficient 
serum with purified MBL partially restored LP activity. Likewise, the incubation of an IgM-
coated plate with C1qDS did not lead to C4b deposition (Figure 8A).  
Anti-C1q bound to imC1q were further incubated with NHS, C1qDS, or MBL-deficient serum 
with or without exogenous MBL (Figure 8B-D). 
As shown in Figure 8B, C4b deposition triggered by anti-C1q bound to imC1q in the presence 
of NHS was higher in SLE patients and healthy donors being anti-C1q positive, independent 
of the anti-C1q class, as compared to anti-C1q negative individuals. However, as already 
observed in experiments outlined before, there was already significant C4b deposition, when 
C1q-coated plates were incubated with sera from anti-C1q negative SLE patients (SLE(4+10)) 
or healthy donors (NHS(1+2)).   
In a next step, bound anti-C1q from the same individuals were further incubated with C1qDS 
allowing only LP-mediated complement activation (Figure 8C). No or little C4b deposition was 
detectable in patients and healthy donors having no anti-C1q (SLE(2+10)/NHS(1+2)). 
Interestingly, an association could be seen between LP-mediated C4b deposition and the 
presence of IgA anti-C1q (SLE(1/3/7/9)). Decreased C4b deposition was most pronounced 
when in addition to the absence of IgA anti-C1q the sera only contained either IgG or IgM anti-
C1q (SLE(6+5)). Highest LP-mediated C4b deposition was observed with anti-C1q from 
patients (SLE(1/3/7)) or healthy donors (NHS(3+4)) consisting of mainly IgA or IgA combined 
with IgG/IgM anti-C1q. Together, these data suggest that IgA anti-C1q and to a lesser extend 
IgM anti-C1q are responsible for LP-mediated complement activation.  
In analogy, plates with anti-C1q bound to imC1q were incubated with MBL-deficient serum 
with or without exogenous MBL (Figure 8D). As expected, no restoration of C4b deposition 
was observed for sera being anti-C1q negative or having only IgG anti-C1q 
(SLE(4/5/10)/NHS(1/2)) when using MBL-deficient serum supplemented with exogenous MBL. 
In contrast, in SLE patients having IgA anti-C1q (SLE(1/3/7/9)), C4b deposition was higher, 
when we used MBL-deficient serum reconstituted with MBL as compared to MBL-deficient 
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serum alone. We also observed an increased MBL-dependent C4b deposition triggered by 
IgM anti-C1q in SLE patients (SLE(2/6/8)). 
 
 
Figure 8: Activation of the CP and the LP mediated by anti-C1q bound to imC1q. 
IgM- or mannan-coated plates were incubated with NHS or complement-deficient serum (C1qDS or 
MBL-deficient serum ± exogenous MBL) and C4b deposition was analyzed (A). As a source of anti-
C1q, C1q-coated plates were incubated with heat-inactivated sera of 10 SLE patients (8 anti-C1q 
positive, 2 anti-C1q negative) or sera of 4 different healthy donors (2 anti-C1q positive, 2 anti-C1q 
negative) (B-D). As a source of complement NHS (B), C1qDS (C), or MBL-deficient serum with/without 
4µg/ml exogenous MBL (D), diluted in VBS, was added to the plates. Finally, C4b deposition was 
detected. Anti-C1q classes present in the serum samples are indicated for each patient and healthy 
donor below the figure. Data represent the mean of duplicates ± SEM of one experiment being 
representative of 2 independent experiments.  
 
Taken together, anti-C1q-dependent complement activation involves both the CP and the LP. 
Our data indicate that IgG anti-C1q primarily activate the CP and IgA anti-C1q the LP, while 
IgM anti-C1q seem to be able to activate both, the CP and the LP. 
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CP activation by anti-C1q dependent on IgG anti-C1q levels  
To investigate the potency of anti-C1q to activate the CP of complement, we repeated the in 
vitro assay using purified complement proteins instead of NHS to exclude any contribution of 
the LP.  
As previously, C1q-coated plates were incubated with sera from SLE patients or healthy 
donors as a source of anti-C1q. Plates were then incubated with purified complement proteins 
and again C4b deposition was analyzed. Optimization experiments indicated that the 
complement proteins, C1 and C4, should be incubated one after another, that different 
incubation times were required for C1 (1h) and C4 (40min), and that at least a molar ratio of 
1:2 of C1:C4 was required for a successful anti-C1q-mediated activation (data not shown). 
Using serial dilutions of serum from a SLE patient being highly anti-C1q positive or from a 
healthy donor, we observed dose-dependent complement activation by anti-C1q showing 
complement activation in lower dilutions as compared to the assay performed with NHS (data 
not shown). 
This assay was repeated with cohorts of SLE and healthy donor sera all being diluted 1:1’000 
in high-salt buffer. Under these conditions, anti-C1q from different SLE patients bound to 
imC1q resulted in the activation of the CP as reflected by C4b deposition in the presence of 
purified C1 and C4 (Figure 9). C4b deposition triggered by anti-C1q of SLE patients was 
usually higher as compared to C4b deposition measured with unspecific IgG control coating 
but lower as compared to IgM control coating (data not shown).  
 
 
Figure 9: Activation of the CP of the complement system by 
anti-C1q derived from SLE patients. 
To C1q-coated plates, serum of SLE patients (●; n=27) or healthy 
donors (○; n=22) as a source of anti-C1q was added. After 
washing the plates, purified C1 (0.5µg/ml) and then C4 (2µg/ml; 
both diluted in VBS) were added and the activation of the CP was 
assessed by detecting C4b deposition. C4b deposition values are 
expressed relative to the same reference serum as described in 
patients and methods. Samples were tested in duplicates within a 
single experiment and data points represent the mean of 3 
independent experiments. Mann-Whitney U test, p<0.0005***. 
 
More importantly, we observed a correlation between IgG anti-C1q binding levels and CP-
mediated C4b deposition in SLE patients (Figure 10A). No such correlation was seen when 
serum of healthy donors was used as a source of anti-C1q (Figure 10B).  
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Figure 10: Correlation of IgG anti-C1q levels with the activation of the CP in SLE patients and 
healthy donors.  
The extent of C4b deposition correlated with IgG anti-C1q levels in SLE patients (n=27; (A)) but not in 
healthy donors (n=22; (B)). Both, IgG anti-C1q levels and C4b deposition values are expressed relative 
to the same reference serum as described in patients and methods. Crossed horizontal and vertical 
lines indicate the cut-off values for IgG anti-C1q levels and complement activation. Spearman’s rank 
correlation coefficient (R), p<0.005**. 
 
Taken together, the levels of complement activation by SLE anti-C1q correlates with IgG anti-
C1q levels, suggesting that anti-C1q exacerbate complement activation. 
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Discussion 
Although it is believed that anti-C1q play a pathogenic role in lupus nephritis, their biological 
and pathogenic functions are largely unknown. In this context, limited information is available 
on the complement-activating capacity of anti-C1q. We could now demonstrate that SLE 
patient-derived anti-C1q activate the complement system in vitro. Dependent on the anti-C1q 
class present in the patient’s sera, anti-C1q bound to imC1q activate the CP and the LP. IgG 
anti-C1q predominantly activate the CP and IgA anti-C1q the LP, whereas IgM anti-C1q seem 
to trigger both pathways. In the presence of purified complement proteins, we detected 
specific CP activation correlating with IgG anti-C1q levels of SLE patients. In contrast, anti-
C1q did not directly activate the AP. 
In principle, it is not surprising that anti-C1q classes activate the complement system by its 
different pathways given the fact that anti-C1q can be of the IgG-, IgA-, and IgM-class (14-16). 
It is well known that the different Ig-classes differ in their complement fixing and activating 
capacity. However, recent publications challenged the traditional view that immunoglobulins 
mainly activate the complement system via the CP (214, 215). Furthermore, autoantibodies 
even when belonging to the same Ig-class were shown to have strongly differing complement-
activating capacities (206-211). 
Our results are not in line with a previous study by Pang et al. (154) showing that affinity 
purified anti-C1q of lupus nephritis patients inhibit complement activation. The authors 
hypothesized that this observation could be due to the binding of anti-C1q to the binding site 
of C1s or C1r inhibiting C1 activation. Nevertheless, anti-C1q are not described to directly bind 
to C1 (unpublished data; (161, 174)). In addition, Siegert et al. demonstrated in vivo and in 
vitro that anti-C1q did not influence C4 consumption concluding that anti-C1q do not interfere 
with C1 activation by ICs in SLE patients (216). In contrast, we found that anti-C1q bound to 
imC1q amplify complement activation in vitro via the CP and the LP dependent on the anti-
C1q Ig-class distribution in the serum of SLE patients. Yet, we did not detect direct AP 
activation by anti-C1q leading to C3 deposition. Nevertheless, the activation and amplification 
of the AP have been shown to be of importance in the context of tissue damage in murine 
models (217). Although, our results do not fully exclude low level direct activation of the AP, 
we assume that AP activation is rather a secondary event playing an important role as 
amplifier after initial activation of the complement system via the CP and/or the LP. Indeed, 
the AP was shown to account for up to 80% of total complement activation, even after initial 
triggering of the CP or the LP (48).  
Our study primarily focused on the analysis of autoantibodies against intact C1q since these 
autoantibodies have been best described to correlate with SLE disease activity (218, 219). In 
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addition, using intact C1q maybe best reflect the situation occurring in vivo, allowed the 
analysis of high-affinity antibodies, and avoided manipulations of the molecule as well as the 
presence of non-physiological components such as peptide 2J (214) and Neutravidine (177). 
The main complement activation route in lupus nephritis is considered to be the CP (10, 220). 
Nevertheless, the LP and the AP seem to also play a role in the progression of this 
inflammatory kidney disease (221). Data from mouse studies suggest that complement 
activation in murine lupus nephritis occurs via the CP but also via the LP based on the fact 
that C3 co-localizes with both C1q and MBL in kidney biopsies (222). Likewise, in the kidneys 
of lupus nephritis patients immunoglobulins (IgG, IgA, IgM) are deposited close to 
complement proteins (C1q, MBL, C4, C3) (11, 12). In addition, concentrations of deposited 
anti-C1q in the glomeruli are up to 50times above those found in the sera of patients (223) 
leading to the conclusion that anti-C1q deposition and consecutive complement activation in 
kidneys occur and contribute to the pathogenesis of lupus nephritis. Finally, the link between 
the CP and anti-C1q is underlined by the negative correlation of anti-C1q titers with C1q 
serum levels and other complement components (29). Furthermore, deposition of C1q and 
nucleosomes to glomerular endothelial cells occurs in vitro and the subsequent binding of 
different autoantibodies, including anti-DNA and anti-C1q, leads to complement activation 
(224). 
With regard to downstream mechanisms, anti-C1q are believed to involve both, activation of 
the complement system as well as recruitment of Fc receptors upon binding to e.g., C1q-
containing ICs deposited in the kidneys with consecutive amplification of the inflammatory 
process during flares (10). Anti-C1q were described to bind to C1q-containing ICs deposited in 
mouse glomeruli (225) leading to the hypothesis that C1q bound to ICs deposited in the 
kidneys serves as a target for anti-C1q.  
Next to its involvement in host defense, the complement system has multiple other functions 
such as bridging innate with adaptive immunity and clearing apoptotic cell material. The 
efficient and fast clearance of early apoptotic cell material is essential to avoid inflammatory 
and autoimmune processes (48, 226). The structurally similar molecules, C1q and MBL, both 
bind to the surface of apoptotic cells, facilitate their uptake by phagocytes (23, 24), and trigger 
the activation of the CP and the LP which then in turn can activate the AP (22, 77, 227). 
During a flare even more cells in the kidneys might render apoptotic, as occurring in the 
glomeruli of C1q-deficient mice and highlighting the importance of C1q in the removal of 
apoptotic cell material (5). In this context, the binding of anti-C1q to C1q might interfere with 
biological functions of C1q beyond complement activation, e.g., the clearance of apoptotic cell 
material. As has been shown previously, C1q bound to the surface of apoptotic cells is 
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targeted by anti-C1q (7), which thereby decreases phagocytosis of apoptotic cells by THP-1 
cells (154). Whether anti-C1q bound to C1q on apoptotic cells also amplify complement 
activation and as a consequence alter the interaction with immune cells, needs to be further 
studied.  
Anti-C1q have not only been described in SLE patients, but also occur in other autoimmune 
and renal diseases such as RA, hypocomplementemic urticarial vasculitis, acute post-
streptococcal glomerulonephritis, and IgA nephropathy (14, 228). Whereas anti-C1q seem to 
have a pathogenic role in severe lupus nephritis, in RA patients the occurrence of anti-C1q is 
not more frequent than in healthy individuals. Nevertheless, the prevalence of anti-C1q is 
increased in patients having severe RA accompanied by rheumatoid vasculitis, with IgA anti-
C1q being the predominant Ig-class (14). Although the pathogenic role of IgA anti-C1q in RA 
needs to be investigated, our data suggest that IgA anti-C1q might contribute to the 
pathogenesis and tissue injury in severe RA by triggering complement activation via the LP.  
In conclusion, we can show that both the CP and the LP play a critical role in complement 
activation triggered by anti-C1q. Our results provide new insights into the pathogenic 
mechanisms of anti-C1q and their role in lupus nephritis. These new insights eventually might 
help in the development of complement-specific treatments (229). 
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Part 2  
Anti-C1q autoantibodies from systemic lupus erythematosus patients induce a 
proinflammatory phenotype in macrophages 
Abstract 
Autoantibodies against C1q (anti-C1q) are frequently found in patients with systemic lupus 
erythematosus (SLE) and correlate with the occurrence of proliferative lupus nephritis. A 
previous study of anti-C1q in experimental lupus nephritis demonstrated an important role of 
Fcgamma receptors (FcγR) in the pathogenesis of lupus nephritis suggesting a direct effect 
on phagocytes. Therefore, we developed an in vitro model to study the effect of SLE patient-
derived anti-C1q bound to immobilized C1q (imC1q) on human monocyte-derived 
macrophages (HMDMs) obtained from healthy donors and SLE patients. HMDMs were 
investigated by analyzing the cell morphology, LPS-induced cytokine profile, surface marker 
expression, and the phagocytosis rate of apoptotic Jurkat cells. Morphologically, bound anti-
C1q induced cell aggregations of HMDMs when compared to imC1q or IgG alone. In addition, 
anti-C1q reversed the effect of imC1q alone shifting the LPS-induced cytokine release 
towards a proinflammatory response. By FcγR-blocking experiments, the secretion of 
proinflammatory cytokines was found to be mediated via FcγRII. The anti-C1q-induced 
inflammatory cytokine profile was accompanied by a downregulation of CD163 and an 
upregulation of LPS-induced CD80, CD274, and MHC class II. Finally, HMDMs primed on 
bound anti-C1q versus imC1q alone displayed a significantly lower phagocytosis rate of early 
and late apoptotic cells accompanied by a reduced MerTK expression. Interestingly, anti-C1q-
dependent secretion of proinflammatory cytokines was similar in SLE patient-derived cells 
with the exception of IL-10 being slightly increased. In conclusion, anti-C1q induced a 
proinflammatory phenotype in HMDMs reversing the effects of imC1q alone. This effect might 
exacerbate underlying pathogenic mechanisms in lupus nephritis.   
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Introduction 
Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity, a variety of 
antibodies directed against autoantigens, such as intra-cellular components or plasma 
proteins, the formation of immune complexes (ICs), and aberrant complement activation (44, 
45).  
Inherited as well as acquired complement deficiencies have been associated with the 
development and pathogenesis of SLE. Particularly, primary deficiencies of early components 
of the classical pathway (CP) (C1q, C4, C2) are strongly linked to SLE. The strongest 
genetical susceptibility to develop SLE is homozygous C1q deficiency, underlining that 
complement plays a major role in the pathogenesis of SLE (3). However, most SLE patients 
do not suffer from primary C1q deficiency, but in general, ongoing complement activation is 
accounted for low or undetectable complement levels. A rational reason for low C1q levels are 
autoantibodies against C1q (anti-C1q) which are present in 20 to 50% of unselected SLE 
patients and their occurrence correlates with both, low complement levels as well as lupus 
nephritis (7-9). Even though, these autoantibodies are linked to renal involvement, the direct 
evidence how these autoantibodies contribute to the pathogenesis of lupus nephritis is not yet 
available. Animal models suggested that renal inflammation is only induced by anti-C1q in 
combination with preformed glomerular C1q-containing ICs, requiring both complement 
activation as well as Fcgamma receptor (FcγR) triggering (10). Recently, Pang et al. 
demonstrated that affinity purified anti-C1q from lupus patients bind to C1q on early apoptotic 
cells and thereby decrease the uptake of apoptotic cells by THP-1 cells (154). However, the 
direct downstream effect of anti-C1q on professional phagocytes is not well understood.  
C1q, the recognition molecule of the C1 complex, acts as the initiator of the CP of the 
complement system (1). Beyond complement activation, C1q serves as a regulatory protein 
during inflammatory processes including autoimmunity. The regulatory functions also affect 
cell differentiation, chemotaxis, migration, and survival (84-87). Moreover, C1q participates in 
the clearance of apoptotic cell material. C1q can directly bind to the surface of apoptotic cells 
via its globular heads (76, 78). The collagen-like tails then interact with phagocytes via C1q 
receptors (22), thereby facilitating the engulfment of apoptotic cells (23, 120). Additionally, 
studies from different research groups demonstrated that C1q not only enhances the uptake 
of apoptotic cell material, but also modifies the cytokines profile released by phagocytic cells 
towards a less inflammatory response during phagocytosis (23, 120, 135, 136). During the 
uptake of early and late apoptotic cells, C1q exerted a potent inhibitory capacity in 
macrophage-mediated inflammation (25). These data suggest that C1q is crucial in limiting 
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inflammation during the uptake of apoptotic cells. Furthermore, C1q-polarization of 
macrophages might induce an anti-inflammatory (M2-like) phenotype. 
Macrophages play an important role in host defense, inflammatory processes, tissue 
remodeling and homeostasis. The functional profile of macrophages is determined by their 
activation and exposure to environmental factors such as cytokines and growth factors during 
their differentiation from monocytes into macrophages (185). In vitro, monocytes can be 
polarized into different macrophage subtypes by specific cytokines. Based on the stimuli 
providing an activation signal, macrophages have been divided in a continuum between 2 
functionally polarized states: proinflammatory macrophages (termed M1) and anti-
inflammatory macrophages (termed M2). The polarized macrophages exhibit functional 
differences as evident by their phenotypic profiles such as cytokine release and surface 
markers (185-187). M1 macrophages mainly produce proinflammatory cytokines, phagocyte 
microorganisms, and are often linked to tissue injury and inflammation, whereas M2 
macrophages display in general a low antigen-presenting capacity, inhibit and prevent T cell 
activation, and are associated with tissue repair and fibrosis (188, 189). However, polarization 
of macrophages is not permanent, but rather milieu dependent and reversible (192).  
Functional defects in the cells of the monocyte-macrophage lineage from SLE patients are 
well known, although the underlying molecular mechanism is not fully understood. SLE 
patient-derived macrophages exhibit a defect in the phagocytosis of apoptotic cell material 
correlating with low complement levels (17, 18). Additionally, monocytes from SLE patients 
have an abnormal cytokine secretion profile in response to apoptotic cells independent of the 
monocyte’s phagocytic efficiency or the patient’s disease state (19). These reports underline 
that phagocytes and complement play a key role in the pathogenesis of lupus. 
The aim of the study was to determine the simultaneous interaction of human monocyte-
derived macrophages (HMDMs) with bound autoantibodies, on the one hand, and the 
immuno-regulatory C1q molecule, on the other hand, using SLE patient-derived high-affinity 
anti-C1q which have been found to correlate with disease activity. 
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Patients and methods 
Anti-C1q source/IgG source 
A cohort of 17 SLE patients (Table 8) and 15 healthy control donors was included in the study.  
 
Table 8: Characterization of SLE patients used as a source for anti-C1q. 
Pat ID  
(sex (f/m)) 
Age 
(y)  
LN  
(yes/no) 
1,2 
Anti-C1q 
levels 
[AU] 
(cut-off: 
98AU) 
C1q 
levels 
[µg/ml] 
Hypocomple-
mentemia  
(low C3 and C4)  
(yes/no) 1 
CP 
activation 
(yes/no) 
ANA/ 
Anti-
dsDNA 
(yes/no) 
Medication 
SLE(1)  
(f) 
28 yes (IV) 1’000 0 yes yes yes AZA, CTX, 
Pred, RIT 
SLE(2)  
(f) 
36 yes (III) 625 0 yes yes yes AZA, CTX, 
Pred 
SLE(3)  
(f) 
25 yes (IV) 533 0 yes yes yes AZA, Pred 
SLE(4)  
(f) 
27 yes (IV) 782 15.7 yes yes yes MMF 
SLE(5)  
(f) 
31 yes (IV) 494 95.9 yes yes only 
ANA 
none 
SLE(6) 
(m) 
45 yes (IV) 233 13.8 yes yes yes none 
SLE(7) 
(m) 
56 yes (II) 396 54.8 yes yes yes Pred 
SLE(8)  
(f) 
50 yes (III) 543 0 yes yes yes HCQ, Pred 
SLE(9)  
(f) 
29 yes (IV) 584 19.9 yes yes yes MTX, Pred 
SLE(10) 
(m) 
45 yes (III) 268 122 yes yes yes Pred 
SLE(11) 
(f) 
50 yes (II) 131 74.7 no (borderline) no yes none 
SLE(12) 
(f) 
53 yes (II) 180 82.6 only low C4 yes yes none 
SLE(13) 
(f) 
57 R 16 79.9 no no yes none 
SLE(14) 
(f) 
55 R 49 98.4 no no only 
ANA 
none 
SLE(15) 
(m) 
40 R 72 73.0 no no yes AZA, HCQ, 
Pred 
SLE(16) 
(f) 
34 R 14 105.3 no no only 
ANA 
MMF 
SLE(17) 
(f) 
37 R 57 86.6 no no only 
ANA 
none 
Legend: AU: arbitrary units; AZA: Azathioprine; CP: classical pathway; CTX: Cyclophosphamide; f: 
female; HCQ: Hydroxychloroquine; LN: lupus nephritis; m: male; MMF: Mycophenolate mofetile; MTX: 
Methotrexate; Pred: Prednisone; R: remission; RIT: Rituximab; y: years 
1 Information at time point of blood sampling 
2 Classification of lupus nephritis according to WHO classification  
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All SLE patients fulfilled at least 4/11 criteria of the American College of Rheumatology (212, 
213). Collection and use of serum samples were approved by the local Ethics Committee 
(EKZ-No.: 110/04; 130/05). 
Isolation and differentiation of HMDMs  
HMDMs were derived from CD14-positive monocytes isolated from fresh buffy coat’s (Blood 
Transfusion Centre, Basel, Switzerland). Peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll gradient centrifugation (Histopaque 1077, Sigma-Aldrich, MO, USA). CD14-
positive monocytes were isolated from PBMCs using CD14 Microbeads (MACS, Bergisch 
Gladbach, Miltenyi Biotec, Germany) according to the manufacturer’s instructions (the 
average purity of the CD14-positive monocyte fraction was always >95-98% as assessed by 
flow cytometry). HMDMs were generated from CD14-positive monocytes by culture in 
Dulbecco modified essential medium supplemented with 1% penicillin/streptomycin (DMEM+; 
both obtained from GIBCO, Invitrogen, UK) and 10% NHS (pooled from 40 healthy donors). 
The culture was maintained in 5% CO2 at 37°C for 7 days and the media were exchanged 
every 2-3 days. 
SLE patient-derived macrophages 
15ml of heparinized venous blood was obtained from SLE patients (Table 9) after written 
consent according to the local Ethics committee (EKZ-No.: 2014/125).  
 
Table 9: Characterization of SLE patients from whom CD14-positive monocytes were isolated1. 
Pat ID  
(sex (f/m)) 
Age 
(y) 
Disease 
duration 
(y) 
Anti-C1q levels 
(cut-off: 98AU) 
C1q levels 
[µg/ml] 
Disease state Medication 
SLE(A) (f) 66 0 342 49.7 flare  
(stroke; LN) 
Pred 
SLE(B) (f) 31 12 203 40.0 R 
(LN (class IV)) 
AZA, Pred, 
Rit 
SLE(C) (m) 30 7 92 152 R HCQ 
SLE(D) (f) 48 20 51 108.3 R 
(LN (class IV)) 
MMF, Pred 
SLE(E) (f) 34 0.5 1’080 0 R 
(no LN)  
MMF 
SLE(F) (m) 40 14 73 94.0 R Pred 
Legend: AU: arbitrary units; AZA: Azathioprine; f: female; HCQ: Hydroxychloroquine; LN: lupus 
nephritis; m: male; MMF: Mycophenolate mofetile; Pred: Prednisone; R: remission; Rit: Rituximab; y: 
years; 
1 Information at time point of blood sampling 
 
All SLE patients fulfilled at least 4/11 criteria of the American College of Rheumatology (212, 
213). CD14-positive monocytes were isolated and differentiated as described above with one 
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exception. Adherent monocytes were differentiated into macrophages in DMEM+ 
supplemented with 10% autologous serum for 7days. For the analysis of LPS-induced 
cytokine release, the patient’s differentiated macrophages were stimulated as described 
below. For the stimulation, the patient’s own anti-C1q were also included in the experimental 
setting. 
In vitro model used for the stimulation of HMDMs 
After 7 days, HMDMs were harvested using ice-cold PBS (GIBCO, Invitrogen, UK), 
resuspended in DMEM+ supplemented with 0.1% human serum albumin (HSA; HSA-DMEM; 
Sigma-Aldrich, MO, USA) at 0.5x106cells/ml, and used for stimulation experiments. Therefore, 
96well plates (MaxiSorp, Nalge Nunc International, Denmark) were coated with purified C1q 
(immobilized C1q (imC1q); Complement Technology, TX, USA) or HSA at 5µg/ml in coating 
buffer (0.1M sodium carbonate buffer, pH 9.6) overnight at 4°C. The plates were washed twice 
with PBS and C1q-coated wells were incubated with 100µg/ml purified total IgG (purified by 
ProteinG affinity columns) from SLE patients or healthy donors diluted in high-salt buffer 
(PBS/1M NaCl) for 1h at 37°C. Before use, each IgG preparation was centrifuged at 14’000xg 
for 30min at 4°C. After washing the plates 4times with PBS, HMDMs (100µl of 0.5x106cells/ml: 
50’000cells/well) were added to the wells, cells were allowed to adhere for 60min at 37°C, and 
where indicated 10ng/ml lipopolysaccharide (LPS; E. coli: O127:B8; Sigma-Aldrich, MO, USA) 
or DMEM-HSA was added, and cells were incubated for 18h.  
For FcγR-blocking experiments, FcγRII were blocked by incubating HMDMs with 8µg/ml anti-
FcγRII (anti-human CD32 F(ab’)2, clone: 7.3; Ancell Corporation, MN, USA) for 30min at 4°C 
in DMEM-HSA before proceeding with stimulation experiments as described above. 
Morphology of HMDMs 
The morphology of HMDMs was assessed using the above described in vitro model and an 
Olympus IX50 inverted phase contrast microscope (Olympus, Hamburg, Germany) with 
magnifications of 10x and 20x. The size of cell aggregations was quantified using ImageJ 
software (ImageJ software 1.47, USA). Data are expressed relative to the cell size formed by 
HMDMs incubated on imC1q alone which was set to 1. 
Quantification of LPS-induced cytokine release  
After the stimulation of HMDMs on different coatings for 18h, supernatants (SN) were 
collected, centrifuged to remove cellular debris, and kept at -80°C until analysis. The 
concentrations of IL-1β, IL-6, TNFα, and IL-10 were measured using Opt ELISA kits (BD 
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Biosciences, CA, USA) according to the manufacturer’s instructions. All samples were 
analyzed in duplicates.   
Expression of surface markers 
After stimulating HMDMs on different coatings for 18h using the in vitro model described 
above, cells were collected and washed twice with ice-cold FACS buffer (PBS/1% BSA 
(Sigma-Aldrich, MO, USA)/1mM sodium azide). Cells were resuspended in FACS buffer at 
1x106cells/100µl. Non-specific binding to FcγRs was blocked by incubating cells with 2mg/ml 
human IgG/1x106 cells for 45min at 4°C. For FACS analysis of surface markers, the following 
mouse mABs conjugated with FITC were used: CD14 (Immunotools, Friesoythe, Germany), 
CD80 and CD86 (both obtained from BD Biosciences, CA, USA), CD206 (Biolegend, Fell, 
Germany), and MHC class II (Immunotools, Friesoythe, Germany), mouse mABs conjugated 
with PE: CD273 and CD274 (both obtained from Biolegend, Fell, Germany), and Mer tyrosine 
kinase (MerTK; R&D systems, MN, USA), or mouse mAB conjugated with APC: CD163 
(Biolegend, Fell, Germany). In each experiment, parallel stainings with appropriate isotype-
matched controls IgG1-FITC, IgG2a-FITC, IgG1-APC (all obtained from Immunotools, 
Friesoythe, Germany), or IgG2b-PE (Biolegend, Fell, Germany) were performed. For 
stainings, cells were resuspended at 5x105cells/100µl in FACS buffer and stained with FITC-, 
PE-, or APC-conjugated antibodies or their matched isotype-control for 45min at 4°C. Cells 
were washed twice with FACS buffer and resuspended in FACS buffer. For each dataset, 
10’000 events in the viable cell gate (Propidium iodide (PI; Sigma-Aldrich, MO, USA) 
exclusion of dead cells) were acquired using a FACSAccuri (BD Biosciences, CA, USA) and 
analyzed using Flowjow software (Tree Star Inc., OR, USA). The final geometric mean 
fluorescence intensities (gMFI) were calculated by subtracting the gMFI of the corresponding 
isotype control from the gMFI of the sample. 
Phagocytosis assays 
Endocytic activity of stimulated HMDMs 
The endocytic activity of stimulated HMDMs was measured by analyzing the uptake of FITC-
conjugated dextran (molecular mass: 40’000kDa; Sigma-Aldrich, MO, USA). 5x105cells/100µl 
stimulated HMDMs were incubated with 0.5mg/ml FITC-conjugated dextran in media for 0, 30, 
or 60min at 37°C or 4°C to measure specific uptake versus non-specific binding, respectively. 
HMDMs were washed 3times with FACS buffer and the uptake of FITC-conjugated dextran 
was analyzed by flow cytometry using a FACSAccuri. 
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Phagocytosis of apoptotic cells by stimulated HMDMs 
Jurkat T cells (Jurkats) were cultured in RPMI 1640 supplemented with 1% 
penicillin/streptomycin, 1% L-glutamine, 26mM Hepes, and 10% FCS (complete RPMI; all 
reagents obtained from GIBCO, Invitrogen, UK). Apoptosis was induced by UV-light treatment 
(Stratalinker 1800, Stratagene) at 254nm for 1 min at a cell concentration of 2x106cells/ml. 
Irradiated Jurkats were further cultured for 16h in complete RPMI to obtain early apoptotic 
cells or in FCS free complete RPMI to obtain late apoptotic cells. Prior to apoptosis induction, 
Jurkats were fluorescently labeled with 5µM CFSE (Invitrogen, Molecular Probes, UK) 
according to the manufacturer’s instructions. Apoptotic cells were characterized by double-
staining for AnnexinV (AnV; Immunotools, Friesoythe, Germany) and PI. For phagocytosis 
assays, HMDMs were primed for 18h as described above, harvested, and washed twice with 
DMEM+. CFSE-labeled apoptotic Jurkats were coincubated with differently primed HMDMs 
(105 cells) at a 1:1 ration for 0 or 30min at 37°C or 4°C in a total volume of 200µl phagocytosis 
buffer (DMEM+/26mM Hepes/5mM MgCl2). Phagocytosis was stopped by adding cold FACS 
buffer, and unphagocytosed Jurkats were washed away. HMDMs were further stained with an 
APC-conjugated mAB against CD14 (Immunotools, Friesoythe, Germany) and the uptake of 
apoptotic Jurkats was analyzed by flow cytometry. The percentage of CD14+CFSE+ double-
positive cells was used to assess the percentage of HMDMs that phagocytosed (incubated at 
37°C) and/or bound (incubated at 4°C) apoptotic Jurkats. The uptake of apoptotic Jurkats by 
HMDMs was expressed as percent phagocytosis (phagocytosis [%]) defined as CD14+CFSE+ 
double-positive cells divided by the total of CD14+-positive cells multiplied by 100. 
Statistical analysis 
Data are expressed as mean ± SEM if not stated otherwise. Statistical analyses were 
performed using the Wilcoxon-matched pair test or the Mann-Whitney U test to compare 2 
groups. To compare more than 2 groups, one-way ANOVA followed by Bonferroni’s post-test 
was used as indicated. Data were analyzed using GraphPad Prism software (GraphPad 
Prism, CA, USA). A p<0.05 was considered statistically significant. 
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Results 
ImC1q and anti-C1q bound to imC1q modify the morphology of HMDMs 
CD14-positive monocytes were cultured for 7 days to obtain HMDMs. Cells were then 
harvested and reseeded on wells with different coatings. The cell morphology on these 
coatings was assessed using phase contrast microscopy. 
HMDMs stimulated for 18h on HSA or imC1q showed different morphologies (Figure 11A). 
Cells on imC1q exhibited a circular cell shape as compared to those plated on HSA, which 
had a more elongated and spindle-like cell shape. This observation is consistent with previous 
findings on changes in the morphology of monocytes plated on imC1q as compared to those 
on HSA (135). 
Intriguingly, when HMDMs were plated on anti-C1q bound to imC1q (imC1q+SLEIgG) the 
cells still had a circular cell shape, but additionally formed cell aggregates (Figure 11A). This 
effect was anti-C1q specific, since HMDMs plated on bound anti-C1q derived from anti-C1q 
positive healthy donors also resulted in aggregations (data not shown). However, no cell 
aggregations could be observed when using ICs (BSA-human IgG anti-BSA) (Figure 11A). 
Furthermore, HMDMs plated on coated purified IgG also did not lead to cell aggregates, 
neither on SLEIgG nor on NHIgG (Figure 11A). The formation of cell aggregates was not due 
to increased cell death since double-staining for both, AnV and PI, did not show any 
significant difference between the different priming conditions (data not shown). 
Comparing total IgG derived from 4 different SLE patients to IgG from 4 healthy donors 
confirmed that the formation of cell aggregates by HMDMs on SLE patient’s anti-C1q can be 
observed in several patient’s anti-C1q but not in anti-C1q negative healthy donors 
(imC1q+NHIgG) (Figure 11B). 
Next, we studied the effects of anti-C1q from a whole cohort of SLE patients with variable anti-
C1q titers and healthy donors (Figure 11C). The average size of cell aggregates formed by 
HMDMs on bound anti-C1q was 1.8-fold increased as compared to the one of HMDMs plated 
on imC1q alone or on imC1q+NHIgG (imC1q+SLEIgG: 1.79±0.0.150 vs imC1q+NHIgG: 
1.17±0.082; p=0.0037**).  
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Figure 11: ImC1q and anti-C1q bound to imC1q affect the morphology of HMDMs. 
HMDMs were incubated on different coatings (as indicated in the figure) for 18h and their morphology 
was analyzed using an Olympus phase contrast microscope (original magnification, x10/x20). HMDMs 
were incubated on HSA (5µg/ml) or imC1q (5µg/ml), coated purified total IgG (50µg/ml) obtained from 
an anti-C1q positive SLE patient (SLEIgG(1)) or from a healthy donor (NHIgG(1)), on ICs (BSA–human 
anti-BSA IgG) or BSA only (A). HMDMs were incubated on imC1q+SLEIgG from 4 different SLE 
patients (all anti-C1q positive) or on imC1q+NHIgG from 4 healthy control donors (all anti-C1q negative) 
(B). Shown are the results of one donor used to obtain HMDMs representative for 5 independent 
experiments. HMDMs were incubated on IgG derived from a cohort of anti-C1q positive and negative 
SLE patients (n=17) and healthy donors (n=15) (C). The size of cell aggregates formed by HMDMs was 
analyzed using ImageJ software. Data are expressed relative to the cell size formed by HMDMs 
incubated on imC1q only (grey line; relative size=1). Each data point represents pooled mean values of 
5 different experiments. Data points above the dashed lines indicate anti-C1q positive SLE patients and 
healthy donors. Mann-Whitney U test, p<0.005**. 
 
Anti-C1q induce a proinflammatory cytokine response in HMDMs 
Beyond complement activation, C1q has been described to act as an anti-inflammatory 
regulator in immune cell processes. For example, C1q induces a less inflammatory response 
in phagocytes in combination with a proinflammatory stimulus such as LPS regarding cytokine 
secretion and cytokine mRNA levels (25, 120). 
Therefore, we next assessed whether anti-C1q bound to imC1q change the LPS-induced 
cytokine profile secreted by HMDMs as compared to imC1q or HSA alone. For this purpose, 
HMDMs were incubated on HSA, imC1q, or imC1q with different anti-C1q positive SLEIgG or 
anti-C1q negative NHIgG in the presence or absence of the TLR4-ligand LPS for 18h (Figure 
12).  
HMDMs mostly did not produce detectable cytokine levels in the absence of LPS independent 
of the coatings (data not shown).  
However, in accordance with previous reports (25, 120), imC1q significantly downregulated 
LPS-induced secretion of proinflammatory cytokines, such as IL-1β, IL-6, and TNFα, as 
compared to HSA alone (IL-1β/IL-6: p=0.031*; TNFα: p=0.0435*) (Figure 12A-C; first 
horizontal panel). The suppressive effect of imC1q alone was reversed by SLE patient-derived 
anti-C1q bound to imC1q as evident by a significant upregulation of proinflammatory cytokine 
levels as compared to imC1q+NHIgG (IL-1β/TNFα: p=0.0001***; IL-6: p=0.0003***) (Figure 
12A-C; second horizontal panel). Induction of a proinflammatory cytokine response could also 
be observed when NHIgG from anti-C1q positive healthy donors were used (Figure 12A-C; 
second horizontal panel, indicated by black arrows).   
In contrast, imC1q upregulated the LPS-induced level of the anti-inflammatory cytokine IL-10 
as compared to HSA-coating (IL-10: p=0.02*) (Figure 12D; first horizontal panel). Interestingly, 
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SLE patient-derived anti-C1q significantly attenuated LPS-induced IL-10 production as 
compared to imC1q+NHIgG (IL-10: p=0.0354*) (Figure 12D; second horizontal panel). Again, 
healthy donor-derived anti-C1q induced a similar effect as anti-C1q from SLE patients did 
(Figure 12D; second horizontal panel, indicated by black arrows).   
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Figure 12: Anti-C1q bound to imC1q shift LPS-induced cytokine secretion by HMDMs towards a 
proinflammatory response. 
After stimulation of HMDMs for 18h on different coatings, LPS-induced concentrations of secreted 
cytokines (IL-1β (A), IL-6 (B), TNFα (C), and IL-10 (D)) in SN were measured by ELISA. Data sets on 
the first horizontal panel show secreted LPS-induced cytokine levels of HMDMs incubated on HSA (□) 
or imC1q (■). Data represent cytokine release levels of 6 unrelated healthy donors used to obtain 
HMDMs. Wilcoxon-matched pair test, p<0.05*. Data sets on the second horizontal panel display LPS-
induced cytokine levels released by HMDMs when adhered to imC1q+SLEIgG or imC1q+NHIgG (n=10 
different IgG preparations each). Each data point represents pooled cytokine levels (mean) of 6 
independent experiments. Grey lines represent mean cytokine levels secreted by HMDMs incubated on 
imC1q alone. Black arrows indicate anti-C1q positive healthy donors. Mann-Whitney U test, p<0.05*, 
p<0.005**, p<0.0005***. 
 
When SLEIgG of anti-C1q negative patients were incubated on imC1q, no differences to 
NHIgG were detectable for any of the tested cytokines (data not shown). In addition, we found 
that IgG anti-C1q levels of SLE patients correlated with the LPS-induced secretion of all 
cytokines tested (data not shown). 
Taken together, imC1q-bound autoantibodies shifted the LPS-induced cytokine levels towards 
an inflammatory response, as evident by an upregulation of IL-1β, IL-6, and TNFα secretion, 
and accompanied by a slight downregulation of IL-10 secretion as compared to imC1q with 
control NHIgG.  
Anti-C1q-triggered proinflammatory cytokine response is mediated by a FcγRII-
dependent pathway 
Several reports suggest that FcγR-engagement by deposited ICs in kidneys is crucial for the 
development of lupus nephritis (10, 230). Given the close correlation of lupus nephritis and 
anti-C1q, we hypothesized that FcγR are of crucial importance for the proinflammatory effects 
of anti-C1q as described before. Since IgG2 is the predominant anti-C1q class and can trigger 
CD32 (FcγRII) (167, 181), we preincubated HMDMs in the presence or absence of a CD32-
blocking antibody. Next, HMDMs were incubated as outlined above and LPS-induced cytokine 
levels were analyzed (Figure 13). Blocking of FcγRII led to a decreased secretion of all 
proinflammatory cytokines tested down to levels as observed in the absence of anti-C1q (IL-
1β: 84.3±13.5%, p=0.021**; IL-6: 63.1±9.8%, p=0.0003***; TNFα: 86.0±5.3%, p=0.0011**) 
(Figure 13A-C). In contrast, IL-10 secretion was not significantly altered by CD32-blocking (IL-
10: -22.2±7.482.0%, p=0.075, ns) (Figure 13D).  
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Figure 13: LPS-induced secretion of proinflammatory cytokines by anti-C1q is FcγRII-mediated. 
HMDMs were preincubated in the absence or presence of CD32-blocking AB (8µg/ml) and further 
incubated on imC1q+SLEIgG (n=10). After 18h of stimulation, LPS-induced IL-1β (A), IL-6 (B), TNFα 
(C), and IL-10 (D) levels were measured. Each data point represents a mean value of 6 independent 
experiments using 6 different HMDMs preparations. Grey lines show mean cytokine levels secreted by 
HMDMs incubated on imC1q alone. Mann-Whitney U test, p<0.05*, p<0.005**, p<0.0001***. 
 
Anti-C1q induce a mixed phenotype in HMDMs 
Since the effect of anti-C1q can be found in the induction of a proinflammatory and activating 
response as evident by both, morphological changes and LPS-induced cytokine secretion 
levels, we next assessed whether anti-C1q also have an effect on surface markers expressed 
by HMDMs. For this, we evaluated the expression of several surface markers including CD14, 
co-stimulatory receptors (CD80, CD86, CD273, CD274), mannose receptor (CD206), 
scavenger receptor (CD163), and MHC class II (Figure 14).  
Fully differentiated HMDMs were primed as described before and then stained for surface 
markers. As control for M2 macrophages untreated HMDMs and for M1 macrophages 
HMDMs stimulated with LPS were used. 
HMDMs incubated on imC1q significantly upregulated CD14 and CD163 as compared to 
untreated control cells (CD14: p=0.011**; CD163: p=0.048*), whereas CD86 and CD274 were 
downregulated (CD86: p=0.0036**; CD274: p=0.048*). HMDMs primed on anti-C1q bound to 
imC1q showed a trend to upregulate MHC class II as compared to imC1q alone (MHC class II: 
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p=0.0625, ns). On the contrary, expression of CD163 was reversed by HMDMs stimulated on 
bound anti-C1q as compared to imC1q alone (CD163: p=0.030*) (Figure 14A-F, first/third 
vertical panel). No expression of CD80 and no differences in the expression levels of CD206 
and CD273 could be detected independent of the priming conditions that were used (data not 
shown). 
To mimic the inflammatory environment to which macrophages might be exposed in the tissue 
of SLE patients, an inflammatory signal was provided to the cells by adding LPS.  
In response to LPS priming, HMDMs altered their phenotype by upregulating CD14, CD80, 
and CD274 (CD14: p=0.031*; CD80: p=0.0049**; CD274: p=0.013*). Furthermore, TLR4-
triggering by LPS led to a downregulation of CD86 and CD163 (CD86: p=0.031*; CD163: 
p=0.040*). The expression of CD206 was unaffected by LPS (Figure 14A-F; second/fourth 
vertical panel).  
HMDMs, which were incubated on imC1q in the presence of LPS, showed a trend to express 
higher levels of CD80 as compared to cells primed with LPS alone (CD80: p=0.063, ns). In 
contrast, combination of imC1q and LPS led to a decreased expression of CD163, CD274, 
and MHC class II (CD163: p=0.06, ns; CD274: p=0.05*; MHC class II: p=0.031*). Anti-C1q 
bound to imC1q in addition to TLR4-triggering by LPS increased the expression of CD80, 
CD274, and MHC class II as compared to imC1q and LPS (CD80: p=0.024*; CD274: 
p=0.016*; MHC class II: p=0.015*). Neither the expression of CD206 nor of CD273 was 
affected by bound anti-C1q as compared to imC1q in combination with LPS (Figure 14A-F; 
second/fourth vertical panel). 
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Figure 14: Phenotypic characterization of HMDMs primed on imC1q and bound anti-C1q. 
Untreated HMDMs or HMDMs primed on imC1q alone or imC1q+SLEIgG(1) with or without 10ng/ml 
LPS for 18h were analyzed for their expression of surface markers by flow cytometry using conjugated 
antibodies (FITC-/PE-/APC-labeled antibodies) against CD14 (A), CD80 (B), CD86 (C), CD163 (D), 
CD274 (E), and MHC class II (F). The results of FACS analyses are expressed as gMFI (n=5). Grey 
lines represent mean gMFI values of untreated control cells. One-way ANOVA and Bonferroni’s post-
test, p<0.05*, p<0.005**, p<0.0005***. 
 
Using anti-C1q from 2 additional SLE patients, i.e., SLEIgG(2) and SLEIgG(3), led to similar 
results (data not shown). In general, we could not observe a difference in the expression of 
surface markers by HMDMs primed on C1q-coated wells incubated with NHIgG as compared 
to those cells incubated on imC1q alone (data not shown).  
Independent of the stimulation condition used, HMDMs exhibited macrophage characteristics 
such as the expression of CD14 and CD163, but no expression of DC-related markers, for 
example, no CD83 neo-expression upon LPS stimulation, could be detected. 
**
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*
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In summary, HMDMs incubated on imC1q exhibited a CD14high, CD86low, CD163high, CD274low 
phenotype being consistent with a M2-like phenotype. In the presence of LPS, imC1q priming 
led to a phenotype characterized by CD14intermediate(int), CD80int, CD274low, MHC class IIlow 
expression comparable with traits of both M1 as well as M2. Furthermore, imC1q-bound anti-
C1q priming resulted in a CD14high, CD86low, CD163low, MHC class IIhigh phenotype consistent 
with a more M1-like phenotype. Combination of anti-C1q with TLR4-stimulation by LPS 
induced a CD14high, CD80high, CD274high, MHC class IIhigh phenotype in HMDMs also 
consistent with a more M1-like phenotype. 
Anti-C1q downregulate the endocytosis and phagocytosis rates of HMDMs  
It is well known that C1q bound to apoptotic cells facilitates their uptake by phagocytes (23, 
120). C1q might be concentrated in tissues due to local production by DCs and macrophages. 
Consequently, C1q might be present either in fluid-phase or deposited on cell surfaces in 
tissues (so-called tissue deposited C1q). Deposited C1q might have unique functions in 
serving as a priming agent for HMDMs or as a target for anti-C1q, thus influencing the ability 
of HMDMs to phagocyte dying cells (231).  
Endocytosis is downregulated by anti-C1q 
To investigate whether C1q and anti-C1q bound to imC1q affect the endocytic capacity of 
macrophages, primed HMDMs were incubated with conjugated FITC-dextran for 30 (Figure 
15A) and 60min (Figure 15B). As expected, HMDMs primed with LPS alone slightly 
downregulated their ability to endocytose FITC-dextran as compared to untreated cells 
(30min: p=0.061, ns; 60min: p<0.05*). In contrast, imC1q priming alone slightly increased the 
endocytic activity of HMDMs as compared to untreated control cells (30min: p=0.2305, ns; 
60min: p=0.0793, ns). Interestingly, HMDMs plated on bound anti-C1q derived from 2 different 
SLE patients reduced the endocytosis of FITC-dextran to the level observed in LPS-primed 
HMDMs (untreated vs imC1q+SLEIgG(1/2): 30min/60min: p<0.05*; imC1q vs 
imC1q+SLEIgG(1/2): 30min/60min: p<0.001**).   
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Figure 15: Endocytic activity of HMDMs is modulated by bound anti-C1q and imC1q. 
After priming of HMDMs on imC1q, imC1q+SLEIgG(1/2), imC1q+NHIgG(1) or medium alone for 18h, 
cells were harvested, washed, and incubated with 0.5mg/ml FITC-dextran at 37°C (or 4°C) for 30 (A) or 
60 (B) min. The uptake of FITC-dextran was analyzed by flow cytometry. The results are expressed as 
relative gMFI ± SEM of 3 independent experiments according to the following equation: relative 
gMFI=(gMFI(37°C)–gMFI(4°C))/gMFI(untreated HMDMs). Grey line shows mean gMFI values of 
untreated control cells. One-way ANOVA and Bonferroni’s post-test, p<0.05*, p<0.005**. 
 
Phagocytosis of apoptotic cells is differently modulated by imC1q and bound anti-C1q 
Next, we investigated whether priming of HMDMs on imC1q as compared to cells being 
primed on bound anti-C1q has an effect on their phagocytosis rate. For this purpose, Jurkats 
were CFSE-labeled prior to UV-treatment to induce apoptosis. Early or late apoptotic Jurkats 
were then incubated with primed HMDMs (Figure 16). Early apoptotic cells were characterized 
by positivity for AnV and negativity for PI (Figure 16A; left side). Routinely, about 50-70% of 
early apoptotic cells were obtained. In contrast, late apoptotic cells were defined to be both 
AnV and PI positive (Figure 16A; right side). 
In general, untreated HMDMs phagocytosed only low numbers of apoptotic Jurkats (early: 
16.5%±4.3%; late: 13.4%±2.4%) (Figure 16B+C). In addition, we could not detect a significant 
difference when comparing the uptake of early to late apoptotic cells by any priming condition 
used. However, HMDMs primed with LPS downregulated their phagocytic ability as compared 
to untreated HMDMs (data not shown). Additional exposure to imC1q, on the other hand, led 
to an increased phagocytosis of both early and late apoptotic cells as compared to untreated 
control cells (early: 34.5%±7.3%, p=0.029*; late: 28%±1.3%, p=0.0057**). Furthermore, 
HMDMs incubated on anti-C1q bound to imC1q displayed a significantly lower phagocytosis 
rate of apoptotic cells as compared to imC1q-primed cells (early: 21.1%±4.3%, p=0.048*; late: 
18.7%±2.2%, p=0.017*).   
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Figure 16: Phagocytosis rate of early and late apoptotic cells is downregulated by bound anti-
C1q. 
Apoptosis of Jurkats was induced by UV-treatment. Characterization of early and late apoptotic cells 
was performed by AnV- and PI-staining (A). CFSE-labeled early or late apoptotic cells were 
coincubated with differently stimulated HMDMs at a 1:1 ratio for 30min at 37°C. Unphagocytosed 
apoptotic cells were washed away and HMDMs were stained with an APC-conjugated mAB against 
CD14 (B). FACS dot-plots of one experiment being representative of 3 independent experiments are 
shown. Quantification of the uptake/adherence of apoptotic Jurkats was calculated as phagocytosis 
[%]=((CFSE+CD14+)/CFSE-CD14+)x100) (C). Results are shown as mean ± SEM of 3 independent 
experiments. One-way ANOVA and Bonferroni’s post-test, p<0.05*, p<0.005**. 
 
The downregulated phagocytosis rate of HMDMs incubated on imC1q-bound anti-C1q further 
underlines that anti-C1q might have a direct effect on HMDMs altering the clearance of 
apoptotic cells.  
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Anti-C1q downregulate MerTK expression 
Because HMDMs primed on bound anti-C1q exhibited a lower phagocytosis rate as compared 
to cells stimulated on imC1q, we further analyzed MerTK expression by differently primed 
HMDMs (Figure 17). C1q can trigger an upregulation of MerTK in murine macrophages which 
was accompanied by an increased phagocytosis rate of apoptotic cells by macrophages 
(121). Additionally, it has been demonstrated that an efficient uptake of apoptotic cells by 
HMDMs is MerTK-dependent (232). 
HMDMs incubated on imC1q upregulated MerTK as compared to untreated control cells 
(p=0.017*), whereas anti-C1q bound to imC1q suppressed MerTK expression as compared to 
imC1q (p=0.0048**) (Figure 17A). HMDMs stimulated with LPS also downregulated their 
MerTK expression as compared to control cells (p=0.012*) (Figure 17B). Again, in the 
presence of a proinflammatory stimulus imC1q slightly upregulated MerTK levels of HMDMs, 
whereas the combination of anti-C1q and TLR4-triggering by LPS slightly suppressed MerTK 
expression.  
 
 
Figure 17: Anti-C1q suppress MerTK expression by HMDMs. 
Untreated HMDMs or HMDMs primed on imC1q alone or on imC1q+SLEIgG(1) in the absence (A) or 
presence (B) of 10ng/ml LPS were analyzed for their expression of MerTK by flow cytometry. The 
results of FACS analyses are expressed as gMFI (n=5). Grey lines represent mean gMFI values of 
untreated control cells. One-way ANOVA and Bonferroni’s post-test, p<0.05*, p<0.005**. 
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SLE patient-derived HMDMs exhibit a similar cytokine secretion profile as compared to 
HMDMs from healthy donors 
So far, all experiments were performed using healthy donor-derived cells. We next studied 
cells derived from SLE patients at different stages of disease (Table 9), since cells of the 
monocyte-macrophage linage of SLE patients are known to exhibit functional defects (17, 18). 
The morphology of SLE patient-derived HMDMs incubated on different coatings followed a 
similar pattern as observed for healthy donor-derived HMDMs (data not shown). 
Similar to healthy donor-derived HMDMs, HMDMs obtained from SLE patients secreted lower 
LPS-induced levels of proinflammatory cytokines (IL-1β, IL-6, TNFα) when these cells were 
incubated on imC1q as compared to those stimulated on HSA (IL-1β: p=0.016*; IL-6/TNFα: 
p=0.031*) (Figure 18A-C; first horizontal panel). The anti-inflammatory effect of imC1q alone 
was abolished when SLE-derived HMDMs were incubated on anti-C1q bound to imC1q as 
evident by a significant upregulation of all proinflammatory cytokines tested as compared to 
imC1q+NHIgG (IL-1β/IL-6/TNFα: p=0.029*) (Figure 18A-C; second horizontal panel). Thus, 
these results were in accordance with the LPS-induced cytokines profiles of healthy donor-
derived HMDMs (Figure 12A-C). 
In addition, secretion of the anti-inflammatory cytokine IL-10 was also increased by cells being 
stimulated on imC1q as compared to those being incubated on HSA (IL-10: p=0.031*) (Figure 
18D; first horizontal panel). However, when SLE patient-derived HMDMs were stimulated on 
anti-C1q bound to imC1q the cells significantly enhanced their LPS-induced IL-10 secretion as 
compared to imC1q+NHIgG (IL-10: p=0.029*) (Figure 18D; second horizontal panel). 
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Figure 18: SLE patient-derived HMDMs show a similar cytokine secretion response as compared 
to HMDMs from healthy donors. 
CD14-positive monocytes were isolated from SLE patients and differentiated into HMDMs. SLE 
HMDMs were incubated on different coatings for 18h and LPS-induced cytokine concentrations (IL-1β 
(A), IL-6 (B), TNFα (C), and IL-10 (D)) in SN were quantified. Data sets on the first horizontal panel 
show secreted LPS-induced cytokine levels of SLE HMDMs incubated on HSA (□) and imC1q (■). Data 
show cytokine release levels of 6 unrelated SLE patients. Wilcoxon-matched pair test, p<0.05*. Data 
sets on the second horizontal panel display LPS-induced cytokine levels secreted by SLE HMDMs 
adhered to imC1q+SLEIgG (n=4) or imC1q+NHIgG (n=2). Each data point represents pooled cytokine 
levels (mean) of 6 independent experiments. Grey lines represent mean cytokine levels secreted by 
SLE HMDMs incubated on imC1q alone. Mann-Whitney U test, p<0.05*, p<0.005**.  
 
Interestingly, SLE macrophages also strongly reacted to the combination of self-anti-C1q 
bound to imC1q (data not shown). This phenomenon could be observed in the majority of 
patients and was dependent on anti-C1q levels measured in the serum of patients (Table 9). 
Taken together, these results demonstrate that anti-C1q-triggered secretion of 
proinflammatory cytokines was similar between SLE- and healthy donor-derived HMDMs in 
the same experimental settings. However, LPS-induced IL-10 secretion was slightly increased 
in SLE-derived HMDMs when incubated on bound anti-C1q as compared to healthy donor 
control cells.   
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Discussion 
Anti-C1q are believed to be pathogenic in SLE, in particular with regard to lupus nephritis. 
Anti-C1q have been found to deposit in glomeruli of patients with lupus nephritis and are 
believed to contribute to renal inflammation (7-10, 223, 225). Nevertheless, their biological 
and pathogenic properties in this inflammatory disease are not well defined. In this context, 
limited information was available about the effect of imC1q-bound anti-C1q on HMDMs. Here, 
we can now demonstrate that SLE patient-derived anti-C1q bound to imC1q induce a 
proinflammatory cytokine response as evident by an increased LPS-induced production of IL-
1β, IL-6, and TNFα, as well as by a suppressed IL-10 secretion, thereby reversing the effect of 
imC1q alone. Additionally, bound autoantibodies induced a downregulation of CD163 and an 
upregulation of the LPS-induced expression of CD80, CD274, and MHC class II. In addition, 
HMDMs primed on anti-C1q bound to imC1q displayed a significantly lower phagocytosis rate 
of apoptotic cells accompanied by a reduced MerTK expression as compared to imC1q-
primed HMDMs. Thus, bound anti-C1q altered the C1q-dependent suppression of 
macrophage-mediated inflammation by inducing a proinflammatory phenotype.  
In analogy to the Th nomenclature, macrophage subsets have been classified as M1 and M2 
subsets which are associated with different functions (184, 188, 189). However, translation of 
these macrophage phenotypes into disease models might be over simplified. In vivo, 
macrophages are constantly encountering various signals. Therefore, it might be possible that 
macrophages exhibit a phenotype showing both M1 and M2 characteristics and that multiple 
phenotypes coexist. Additionally, polarization of macrophages is thought to be partially 
reversible and in response to their microenvironment macrophages can express constantly 
changing phenotypes, also termed plasticity (184, 188). In fact, no characteristic macrophage 
phenotype could be defined in lupus nephritis. Different reports show that infiltrating 
macrophages/dendritic cells (DCs) in murine lupus nephritis are very heterogeneous (193, 
194). Nevertheless, mononuclear cells play a role in the pathogenesis of organ related 
diseases, such as lupus nephritis, and are associated with chronic tissue damage and injury 
(195).  
Infiltration of mononuclear cells plays a role in the progression of lupus nephritis and is 
associated with poor prognosis in SLE patients (233). Data from murine models of lupus 
nephritis suggest that macrophages and DCs infiltrating the kidneys display a heterogeneous 
group and are derived from circulating peripheral monocytes (193, 194). Sahu et al. found that 
the dominant macrophage subtype was neither M1 nor M2 and concluded that this phenotype 
might reflect an overall failure to resolve inflammation present in kidneys during flares (193). 
Additionally, the onset of proliferative glomerulonephritis in mice was associated with an 
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upregulation of chemokine and cytokine expression mediating further infiltration of activated 
DCs and monocytes into the kidneys. Macrophage subsets mainly secreted inflammatory 
cytokines (IL-1, IL-6, TNFα) and expressed CD11b, CD80, and CD86 confirming an activated 
macrophage phenotype. The authors suggested that the renal phenotype of macrophages 
resembles a M2b phenotype which are induced by FcγR ligation in addition to TLR-4 
triggering by LPS (194). Others concluded that mononuclear phagocytes infiltrating the 
kidneys have an aberrant activation profile which contributes to the damage of renal tissue by 
mediating local inflammation as well as excessive tissue remodeling (234). We found that 
imC1q-bound anti-C1q induced the production of proinflammatory cytokines (IL-1β, IL-6, 
TNFα) accompanied by a significant upregulation of LPS-induced CD14, CD80, CD274, and 
MHC class II resembling more a M1-like phenotype.  
Moreover, certain cytokines are implicated in the pathogenesis of SLE and lupus nephritis 
such as IL-6, IL-10, IL-17, type I interferons, and TNFα (235). In the context of a disease, 
cytokines are thought to play a role as mediators of inflammation and tissue damage. For 
example, in experimental IC glomerulonephritis, monocytes infiltrating the kidneys secret IL-1 
which can trigger TNFα secretion and consequently leading to tissue injury (236). Additionally, 
urinary levels of IL-6 and IL-8 were higher in patients suffering from lupus nephritis as 
compared to patients without renal involvement or healthy controls suggesting a local 
production of these particular cytokines (237). Furthermore, analysis of isolated cell 
populations from nephritic mouse kidneys during flares demonstrated increased expression 
levels of IL-1, IL-6, IL-10, and TNFα in gene expression arrays (194). In addition to the anti-
C1q-triggered increased production of IL-1β, IL-6, and TNFα, we found that LPS-triggered IL-
10 secretion was suppressed in healthy donor-derived HMDMs when incubated on bound 
anti-C1q. In contrast, SLE patient-derived HMDMs showed an enhanced anti-C1q-triggered 
IL-10 production. Interestingly, serum levels of IL-10 are also elevated and even correlate with 
disease activity in SLE patients (203, 204). In vitro, both monocytes and B cells from SLE 
patients spontaneously secrete high IL-10 levels (238, 239). Based on these observations, IL-
10 is considered to be involved in the pathogenesis of lupus (240). In the context of a 
chronically inflamed environment, it may be possible that IL-10’s anti-inflammatory properties 
are lost and high IL-10 levels itself become pathogenic. Thus, SLE patient-derived HMDMs 
seem not only to have a defect in their phagocytosis efficiency but also in their cytokine 
response and thereby in the regulation of inflammation.  
Beyond host defense, the complement system has an important function in the recognition 
and removal of apoptotic cell material. The efficient and fast clearance of dead cell material is 
crucial to avoid inflammatory and autoimmune processes (48, 226, 241). Moreover, C1q is an 
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essential molecule in the clearance of apoptotic cells by bridging apoptotic cells and 
phagocytes (22, 23, 120). In this context, it has been hypothesized that the binding of anti-C1q 
to C1q might interfere in the phagocytosis process. We can now demonstrate that bound anti-
C1q suppress the C1q-dependent increased phagocytosis of apoptotic cell material by 
HMDMs. The downregulated phagocytosis rate of HMDMs incubated on imC1q-bound anti-
C1q supports the hypothesis that anti-C1q have a direct effect on HMDMs by altering the 
clearance of apoptotic cells either by direct binding of C1q bound to apoptotic cells or by 
interfering indirectly with the uptake of apoptotic cells by binding to imC1q (e.g., deposited in 
tissues) and suppressing the clearance of apoptotic cells by inducing a less efficient 
phagocytic macrophage phenotype. It is well known that not all macrophage subsets display 
the same phagocytic efficiency. IL-10 producing macrophages, reflecting a M2-like phenotype, 
were found to preferentially clear early apoptotic cells and were more efficient in phagocytosis 
as compared to other subsets (242). We found that healthy donor-derived HMDMs being 
primed on imC1q were superior in clearing apoptotic cells and produced higher levels of IL-10 
as compared to anti-C1q- and unprimed control cells.  
C1q has a non-hepatic origin and is mainly produced by DCs and macrophages (26). In 
tissues, C1q might be accumulated during inflammatory processes due to local production by 
infiltrating DCs and macrophages (27, 28). The local synthesis and availability of this freshly 
synthesized C1q might exert different implications for local cells and their effector functions. It 
might even be possible that the release of C1q during the phagocytosis of apoptotic cells is 
upregulated which then in turn could increase, for example, MerTK expression itself and thus 
facilitate the clearance of apoptotic cells. Moreover, efficient uptake of apoptotic cells by 
HMDMs has been demonstrated to be MerTK-dependent (232). Additionally, 2 recent studies 
by Galvan et al. showed that imC1q can trigger an upregulation of MerTK expression and its 
ligand grow-arrest specific 6 in murine macrophages (121, 243). In this context, upregulation 
of MerTK expression was accompanied by an increased phagocytosis rate of apoptotic cells 
by macrophages (121). In analogy, we found that imC1q increased MerTK expression in 
HMDMs which correlated with an increased ability to phagocytose apoptotic cells. In contrast, 
bound-anti-C1q reduced MerTK expression which was accompanied by a lower phagocytosis 
rate. The reduced MerTK expression induced by anti-C1q might indicate an indirect 
mechanism by which these autoantibodies interfere in the uptake of apoptotic cell material by 
macrophages resulting in an increased apoptotic cell load. This indirect effect might even 
potentiate the direct effects on C1q. In fact, impaired and inefficient clearance of apoptotic 
material has been proposed as a mechanism underlying SLE pathogenesis causing an 
accumulation of dead cell material (20, 21).
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An important limitation of our study is its in vitro character that not necessarily is reflecting the 
human in vivo situation. However, our experiments were performed using patient-derived 
high-affinity antibodies as described to correlate with disease activity (219) as well as patient-
derived macrophages. In addition, our report on anti-C1q is in line with other studies 
demonstrating that autoantibodies from SLE patients can modify the response of phagocytes 
(154, 244, 245). 
In conclusion, we can show that imC1q as well as bound anti-C1q skew the polarization of 
HMDMs into different phenotypes and that anti-C1q play a critical role as polarizing agent of 
HMDMs by inducing a proinflammatory phenotype and reversing the anti-inflammatory 
properties of imC1q alone. In addition, anti-C1q seem to directly and indirectly affect the 
phagocytic capacity of macrophages. Our results provide new insights into the pathogenic 
mechanisms of anti-C1q and their possible role in SLE. 
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Part 3  
Anti-C1q autoantibodies from systemic lupus erythematosus patients induce 
C1q production by macrophages 
Abstract 
Antibodies against C1q (anti-C1q) are frequently found in patients with systemic lupus 
erythematosus (SLE). They strongly correlate with the occurrence of lupus nephritis and low 
circulating C1q levels. Previous studies demonstrated that myeloid cells, i.e., dendritic cells 
and macrophages, are a major source of C1q. However, a direct effect of anti-C1q on C1q 
secretion by macrophages has not yet been established. In the present study, we investigated 
the C1q secretion profile of human monocyte-derived macrophages (HMDMs) obtained from 
healthy donors and SLE patients in vitro. The effect of SLE patient-derived anti-C1q bound to 
immobilized C1q (imC1q) and imC1q alone on HMDMs was investigated by C1q secretion 
levels, the expression of membrane-bound and intracellular C1q using flow cytometry and 
ImageStreamX technology, and testing the ability of secreted C1q to activate the classical 
pathway (CP) of complement. Bound anti-C1q induced significantly higher C1q secretion 
levels as compared to imC1q alone or healthy donor IgG. The extent of C1q secretion by 
HMDMs correlated with IgG anti-C1q levels of SLE patients but not of healthy controls. 
Furthermore, bound autoantibodies and imC1q induced continuous and de novo C1q 
synthesis as evident by the intracellular C1q content, which correlated with C1q secretion 
levels.  Finally, secreted C1q was able to activate the CP as reflected by C4b deposition. 
Interestingly, anti-C1q-dependent C1q secretion could also be observed in SLE patient-
derived cells. In conclusion, our data indicate that imC1q-bound anti-C1q strongly stimulate 
the C1q production by HMDMs. Anti-C1q-induced C1q secretion might be an important 
immune-modulatory factor in SLE. 
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Introduction 
Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity, production of a 
variety of autoantibodies directed against self-antigens including intra-cellular components 
and plasma proteins, formation of immune complexes (ICs), and ongoing complement 
activation and deposition resulting in inflammation and hypocomplementemia (44, 45).  
Independently, homozygous deficiency of the complement protein C1q is the strongest known 
disease susceptibility gene for the development of SLE in humans, underlining that C1q plays 
a major role in the pathogenesis of SLE (3, 74). However, most SLE patients do not suffer 
from primary C1q deficiency, but aberrant complement activation is accounted for secondary 
hypocomplementemia. Low or undetectable C1q levels are frequently observed in SLE 
patients and are often associated with autoantibodies directed against C1q (anti-C1q). Anti-
C1q are present in 20-50% of SLE patients and their occurrence correlates with both low 
complement levels as well as lupus nephritis (7-9). Even though, anti-C1q are clearly 
associated with active renal disease, the link between anti-C1q and low C1q antigen levels 
remains to be elucidated. In principle, anti-C1q could have an impact on complement 
activation as well as on C1q production. 
C1q is mainly of a non-hepatic origin as opposed to most complement proteins which are 
produced as acute phase proteins in the liver (88). So far, different cell types have been 
described to produce and secret C1q, including epithelial cells and fibroblasts (96, 97). 
Nevertheless, it is believed that C1q is predominantly produced by myeloid cells (26, 68-70). 
This hypothesis is based on the fact that C1q-deficient mice, being devoid of any detectable 
serum C1q levels, were able to restore normal C1q serum levels upon receiving a bone 
marrow transplant from wild type mice, and vice versa (116). In addition, a patient suffering 
from homozygous C1q deficiency restored normal C1q serum levels after receiving a 
hematopoietic stem cell transplantation (246). Interestingly, monocytes fail to secrete C1q, 
even though, some cells have been tested positive for C1q mRNA (98). However, monocytes 
gain the ability to produce C1q during their differentiation into macrophages or dendritic cells 
(DCs) (26, 69). In particular, immature DCs (iDCs) are an important source of C1q, but upon 
maturation they downregulate this capability (26). In the circulation of healthy individuals C1q 
is mostly associated with its proteases C1s and C1r to form the C1 complex, the starter 
molecule of the classical pathway (CP) of complement (65, 66), whereas free C1q is mostly 
limited to the tissue. However, beyond complement activation, C1q has a dominant role in 
regulating inflammatory processes including autoimmunity. C1q has a major role in the 
clearance of apoptotic cell material (49). Different reports demonstrated that upon binding of 
C1q to apoptotic cells (76, 78), C1q facilitates the engulfment and clearance of apoptotic cells 
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(22, 23, 120), thereby limiting inflammation and autoimmunity during the phagocytosis of dead 
cell material. In this context, local synthesis of C1q in tissues by myeloid cells is believed to 
play an important role in the clearance of apoptotic cell material and in the recruitment of 
immune cells to sites of inflammation or injury in situ. Indeed, upregulated C1q production has 
been demonstrated in the brains of mice suffering from infections or Alzheimer’s disease (130, 
131), underlining the importance of local C1q production in the regulation of tissue 
homeostasis during inflammation. 
We and others reported that immobilized (imC1q) induce an anti-inflammatory phenotype in 
macrophages (120, 247), whereas, on the other hand, anti-C1q bound to imC1q shifted the 
phenotype to a pro-inflammatory macrophage phenotype (247). So far, in vitro studies 
demonstrated that macrophages are also able to secrete C1q (26, 68-70). In addition, pro-
inflammatory murine macrophages were demonstrated to produce more C1q as compared to 
their anti-inflammatory (resident) counterparts (27, 103, 248). Therefore, the aim of this study 
was to determine how SLE patient-derived high-affinity anti-C1q modulate the secretion of 
C1q by human monocyte-derived macrophages (HMDMs) and thus elucidate the association 
between anti-C1q and low serum C1q levels. 
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Patients and methods 
Anti-C1q source/IgG source 
A cohort of 30 SLE patients (Table 10) and 25 healthy control donors was investigated in this 
study.  
 
Table 10: Characterization of SLE patients used as a source for anti-C1q. 
Sex (females/males) 24/6 
Age (years; median (range)) 44 (29-77) 
Hypocomplementemia (low C3 and/or C4) (yes/no) 1 18/12 
Lupus nephritis (yes/no) 1 19/11 
Positive for anti-C1q1 22 
Negative for anti-C1q1 8 
1 Information at time point of blood sampling 
 
All SLE patients fulfilled at least 4/11 criteria of the American College of Rheumatology (212, 
213). Collection and use of serum samples were approved by the local Ethics Committee 
(EKZ-No.: 110/04; 130/05). IgG anti-C1q levels in SLE patients and healthy donors were 
measured and the O.D. values standardized and expressed as arbitrary units (AU) as 
described previously (249). 
Isolation and differentiation of HMDMs 
HMDMs were isolated and differentiated as described previously (S. Thanei et al. 
(submitted)). Briefly, monocytes were purified by positive selection with CD14 Microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) from peripheral blood mononuclear cells 
isolated by Ficoll-Paque (Histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA)) density 
gradient centrifugation (consistent purities of >95% of CD14-positive monocytes). CD14-
positive monocytes were then cultured in Dulbecco modified essential medium supplemented 
with 1% penicillin/streptomycin (DMEM+; both from Life Technologies, Invitrogen, Carlsbad, 
CA, USA) and 10% normal human sera (pooled from 40 healthy donors). The culture was 
maintained in 5% CO2 at 37°C for 7 days and the media were exchanged every 2-3 days. 
Macrophages obtained from SLE patients 
15ml of heparinized venous blood was obtained from SLE patients (Table 11) (EKZ-No.: 
2014/125).  
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Table 11: Characterization of SLE patients from whom CD14-positive monocytes were isolated1. 
Pat ID  
(sex (f/m)) 
Age 
(y) 
Disease 
duration (y) 
Anti-C1q levels 
(cut-off: 98AU) 
Disease state Medication 
SLE(A) (f) 66 0 342AU flare (stroke; LN) Pred 
SLE(B) (f) 31 12 203AU R (LN (class IV)) AZA, Pred, RIT 
SLE(C) (m) 30 7 92AU R HCQ 
SLE(D) (f) 48 20 51AU R (LN (class IV)) MMF, Pred 
SLE(E) (f) 34 0.5 1'080AU R (no LN)  MMF 
SLE(F) (m) 40 14 73AU R Pred 
Legend: AU: arbitrary units; AZA: Azathioprine; f: female; HCQ: Hydroxychloroquine; LN: lupus 
nephritis; m: male; MMF: Mycophenolate mofetile; pat: patient; Pred: Prednisone; R: remission; RIT: 
Rituximab; y: years; 
1 Information at time point of blood sampling 
 
All these patients fulfilled at least 4/11 criteria of the American College of Rheumatology (212, 
213). CD14-positive monocytes were isolated and differentiated as described above with one 
exception. Adherent monocytes were differentiated into macrophages in DMEM+ 
supplemented with 10% autologous serum for 7days. For the analysis of secreted C1q levels, 
the patient’s differentiated macrophages were stimulated as described below. For the 
stimulation, the patient’s own anti-C1q were included in the experimental setting too. 
In vitro stimulation model for HMDMs 
After 7 days, HMDMs were harvested using ice-cold PBS (Life Technologies), resuspended in 
DMEM+ supplemented with 0.1% human serum albumin (HSA; HSA-DMEM; Sigma-Aldrich) 
at 0.5x106cells/ml, and used for stimulation experiments. Therefore, 96well plates (MaxiSorp, 
NalgeNunc International, Rosklide, Denmark) were coated with C1q (immobilized C1q 
(imC1q); Complement Technology, Tyler, TX, USA) or HSA at 5µg/ml in coating buffer (0.1M 
sodium carbonate buffer, pH 9.6) overnight at 4°C. Plates were washed twice with PBS and 
C1q-coated wells were incubated with 100µg/ml purified total IgG (purified by ProteinG affinity 
columns) from SLE patients or healthy donors diluted in high-salt buffer (PBS containing 1M 
NaCl) for 1h at 37°C. Before use, each IgG preparation was centrifuged for 30min at 14’000xg 
at 4°C. After washing plates 4times with PBS, HMDMs (100µl/well of 0.5x106cells/ml 
suspension) were added to the wells, cells were allowed to adhere for 60min at 37°C, and 
10ng/ml lipopolysaccharide (LPS; Escherichia coli: O127:B8; Sigma-Aldrich) or DMEM-HSA 
only were added. 
For reseeding experiments, cells were stimulated as described above, harvested after 22h, 
washed intensively with PBS, and reseeded into 96-well plates at 0.5x106cells/ml 
(50’000cells/200µl). Supernatants (SN) were collected as indicated. 
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Quantification of secreted C1q in SN by ELISA 
After stimulation of HMDMs on different coatings for 22h, SN were collected, centrifuged, and 
kept at -80°C until analysis. The concentrations of C1q were measured using a sandwich 
ELISA as described below. All samples were analyzed in duplicates.    
Description of the ELISA 
A specific sandwich ELISA was developed for the detection of secreted C1q in SN. As 
capturing antibody a mouse monoclonal C1q-specific antibody (mAB: clone 34A4: (153)) was 
coated over night at 4°C in coating buffer. Plates were blocked using PBS containing 3% BSA 
(assay diluent (AD)) for 1h at room temperature (RT). To generate a standard curve, purified 
C1q was used in a range of 0-25ng/ml diluted in AD. After adding samples and standards, and 
incubating for 2h at RT, a goat anti-human C1q (Quidel, San Diego, CA, USA) was used 
followed by a HRP-labeled anti-goat IgG (Sigma-Aldrich). Both antibodies were diluted in AD 
and were incubated for 1h at RT. After every incubation step, plates were washed 3times with 
washing buffer (PBS-T; PBS containing 0.05% Tween). Enzyme activity was assessed by 
addition of TMB substrate (BD Biosciences, San Diego, CA, USA) according to the 
manufacturer’s instructions. Absorbance was read at 450nm using a microplate-biokinetics 
reader (BioTek Instruments, Winooski, VT, USA). The detection limit of the ELISA was 
0.01ng/ml. 
The specificity of the ELISA for C1q was confirmed by measuring C1q in sera of 5 different 
healthy donors (range: 42-118µg/ml C1q). Additionally, C1q-depleted sera (C1qDS) and C1q-
deficient sera emitted no signal. To exclude unspecific C1q binding to coated mouse IgG, we 
used 2 control mABs (namely clone 24C4 and 36A10; showing no binding to C1q) as capture 
antibodies. No detectable signal could be measured when these coated mABs were incubated 
with different concentrations of purified C1q and compared to the C1q-specific mAB (clone 
34A4), generally used as capture AB. Levels of C1q were undetectable in identical C1q-
coated control wells that did not contain phagocytic cells, suggesting that the detected C1q 
was not the result of contaminating coating protein. Furthermore, to exclude degradation of 
imC1q by HMDMs, biotinylated C1q (biot-C1q) was coated and HMDMs were stimulated as 
described above. SN were then tested for biot-C1q using the sandwich ELISA described 
above with a minor modification. The ELISA was developed for captured biot-C1q with 
Streptavidin conjugated-HRP. No signal was obtained from this construct, suggesting that C1q 
was not detached from plates. Also, CD14-positive monocytes incubated on imC1q did not 
lead to detectable levels of secreted C1q (data not shown). 
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Detection of membrane-bound C1q and intracellular C1q by flow cytometry and 
ImageStreamX flow cytometry 
Flow cytometry 
After stimulation of HMDMs on different coatings for 22h using the in vitro model described 
above, cells were collected and washed twice with FACS buffer (PBS containing 1% BSA and 
1mM sodium azide). Finally, cells were resuspended in FACS buffer at 1x106cells/100µl. Non-
specific binding to Fcgamma receptors (FcγRs) was blocked by incubating cells with 2mg/ml 
human IgG in 100µl FACS buffer/1x106 cells for 45min at 4°C. For FACS analysis of 
membrane-bound C1q (mC1q), cells were resuspended at 5x105cells/100µl in FACS buffer 
and stained using a rabbit anti-C1q conjugated with FITC (Dako, Baar, Switzerland) or its 
isotype-control, a rabbit IgG conjugated with FITC (Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA), for 45min at 4°C. For intracellular C1q (iC1q) staining, cells were first 
fixed using PBS containing 4% paraformaldehyde for 20min on ice, washed, and 
permeabilized with FACS buffer containing 0.01% saponin (permeabilization buffer) on ice for 
10min. Cells were then incubated with either a FITC-labeled anti-C1q or its matched isotype 
control for 45min at 4°C. Both antibodies were diluted in permeabilization buffer. After washing 
cells twice, 10’000 events were acquired for each dataset using a FACSAccuri (BD 
Biosciences) and analyzed using Flowjow software (Tree Star Inc., Ashland, OR, USA). The 
final geometric mean fluorescence intensities (gMFI) were calculated by subtracting the gMFI 
of the corresponding isotype control from the gMFI of the sample. 
ImageStreamX flow cytometry 
For iC1q detection, primed HMDMs were stained as described above. Stained cells were 
analyzed using an ImageStreamX flow cytometer and IDEAS image analysis software package 
(both developed by Amnis, Seattle, WA, USA). 5’000 single cell images per sample were 
collected and single-color compensation controls (each 500 cells) were used to generate a 
compensation matrix that was applied to the image data to correct for spectral overlap as 
suggested by the manufacturer. The data file of each stimulation condition was then 
processed through a single template using a consistent gating strategy first gating on single 
cells (by area aspect ratio) and then on focused cells (by gradient root mean square of the 
brightfield image). The stored content of iC1q was quantified using the spot count feature. 
Data are expressed according to the following method: iC1q expression [%] (=number of 
spots/cell) were defined as low (0-15 spots/cell), as intermediate (15-30 spots/cell), or as high 
C1q expression (>30 spots/cell), respectively. There was no significant colocalization between 
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the intensity of iC1q with neither the cell nucleus (DAPI) nor the cell membrane (Dao far red) 
within HMDMs independent of the priming condition used (data not shown). 
Functional analysis of C1q produced by HMDMs 
Procedure for C1q-containing SN 
SN from HMDMs (stimulation experiments) were collected and pooled from 6 different donors 
in order to obtain sufficient amounts of C1q for functional tests. These SN were further 
processed as following: First, SN were concentrated by ammonium sulfate precipitation at a 
saturation of 40% on ice with stirring for 4h. The precipitate was collected by centrifugation at 
25’000xg for 60min at 4°C. The pellet was dissolved in dialysis buffer (10mM Hepes and 0.3M 
NaCl, pH 7.2) and dialyzed 3times against the same buffer overnight at 4°C (modified 
according to (100)). 
Activation of the CP using an IgM-coated plate 
Functional activity of secreted C1q in the activation of the CP was analyzed by ELISA using 
IgM as the ligand. ELISA plates were coated with human IgM (2µg/ml; Sigma-Aldrich) in 
coating buffer overnight at 4°C. After each incubation step, plates were washed 3times with 
PBS-T. Residual binding sites were blocked with BSA-PBS for 1 hour at RT. Then, the plates 
were incubated with C1qDS only or C1qDS reconstituted with either purified C1q 
(concentration corresponding to the concentration measured in purified SN) or with C1q 
obtained from concentrated SN. All samples were serially diluted 1:1-1:8 in 10% C1qDS 
diluted in veronal buffered saline (VBS: 5mM barbituric acid, 0.5mM MgCl2, 2mM CaCl2, 
140mM NaCl, and 0.05% Tween, pH 7.5) and incubated for 1 hour at 37°C. After washing, 
deposited C4b was detected by a goat-anti C4b (Complement Technology). As a secondary 
antibody a HRP-labeled anti-goat IgG was used. After a final washing step, the enzyme 
activity of HRP was detected as described above. 
Statistical analysis 
Data are expressed as mean ± SEM if not stated otherwise. Statistical analyses were 
performed using Mann-Whitney U test to compare 2 groups. To compare more than 2 groups, 
one-way or two-way ANOVA followed by Bonferroni’s post-test were used as indicated. 
Correlations were calculated using Spearman’s rank correlation coefficient (R). Data were 
analyzed using GraphPad Prism software (GraphPad Prism, CA, USA). A p value <0.05 was 
considered statistically significant. 
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Results 
Anti-C1q bound to imC1q induce C1q secretion by HMDMs 
Most complement proteins have a hepatic origin, except C1q which is predominantly produced 
by myeloid cells (26, 68-70). In vitro, its production can be modulated by different agents, 
including LPS, steroids, cytokines, and ICs (27, 104, 119).  
In order to study if anti-C1q bound to imC1q influence C1q secretion by HMDMs, we first 
incubated HMDMs on different coatings, including HSA, ICs (consisting of human anti-BSA 
IgG-BSA), purified total IgG from a healthy donor (NHIgG(1)) and from an anti-C1q positive 
SLE patient (SLEIgG(1)), as well as mannose-binding lectin (MBL), C1 complex, denatured 
C1q (denat. C1q; C1q stock-solution denatured at 56°C for 30min), and imC1q (Figure 19A). 
Most of these coated proteins did not induce C1q secretion or only to a low degree. However, 
imC1q itself increased C1q secretion by HMDMs (for example, imC1q vs HSA: p<0.05*). To 
induce a mild pro-inflammatory environment to which macrophages might be exposed in the 
tissue of SLE patients, an additional inflammatory stimulus was provided to HMDMs by adding 
LPS. This led to an increased C1q secretion as compared to imC1q-coating alone (imC1q vs 
imC1q+LPS: p<0.05*).  
Next, we assessed whether anti-C1q bound to imC1q (imC1q+SLEIgG) influence C1q 
secretion levels of HMDMs as compared to imC1q alone (Figure 19B). Interestingly, 
imC1q+SLEIgG upregulated C1q secretion levels as compared to imC1q alone or C1q-coated 
wells incubated with control IgG (imC1q+NHIgG) (imC1q+SLEIgG vs imC1q: p<0.005**; vs 
imC1q+NHIgG: p<0.001***). 
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Figure 19: Modulation of C1q secretion by HMDMs incubated on imC1q and anti-C1q bound to 
imC1q.  
HMDMs were incubated on different coatings for 22h: left untreated (MØ) or incubated on HSA, ICs 
(BSA–human anti-BSA IgG) or BSA only, coated purified total IgG (50µg/ml) obtained from a healthy 
donor (NHIgG(1)) or from an anti-C1q positive SLE patient (SLEIgG(1)), or MBL, C1 complex, denat. 
C1q, or on imC1q alone with or without LPS (all proteins were coated at 5µg/ml if not stated otherwise) 
(A). Data show the mean ± SEM of 5 different donors. One-way ANOVA including Bonferroni’s post-
test, p<0.05*. HMDMs were incubated on imC1+SLEIgG (n=30 different IgG preparations) or as a 
control on imC1q+NHIgG (n=25 different IgG preparations) for 22h (B). Each data point represents 
pooled C1q secretion levels (mean) of 5 independent experiments. Grey line represents mean C1q 
secretion levels secreted by HMDMs incubated on imC1q alone. Mann-Whitney U test, p<0.005**, 
p<0.001***. 
 
Furthermore, the C1q levels secreted by HMDMs correlated with IgG anti-C1q levels of SLE 
patients (n=30; R=0.5595; p=0.0013**) (Figure 20A). No such correlation was observed in 
healthy donors (n=25; R=0.3123; p=0.1285; ns) (Figure 20B).  
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Figure 20: Correlation of IgG anti-C1q levels with C1q secretion by HMDMs in SLE patients and 
healthy donors. 
IgG anti-C1q levels of SLE patients and healthy donors were plotted against C1q secretion levels of 
HMDMs obtained from healthy donors. The extent of C1q secretion induced in HMDMs correlated with 
IgG anti-C1q levels of SLE patients (A) but not of healthy donors (B). Anti-C1q levels are expressed 
relative to a standard serum as described in patients and methods. Vertical lines indicate the cut-off 
values for positive IgG anti-C1q levels. Spearman’s rank correlation coefficient (R); p<0.005**. 
 
In contrast, 2 anti-C1q control mABs (clones 34A4 and 12F10 (153)) bound to imC1q did not 
induce a significant upregulation of C1q secretion as compared to imC1q alone (data not 
shown), and a polyclonal goat anti-C1q bound to imC1q completely abolished C1q secretion 
(data not shown). However, it needs to be considered that both antibodies were not of human 
origin (as indicated).  
In contrast to imC1q alone, the addition of LPS to HMDMs incubated on imC1q-bound anti-
C1q derived from different SLE patients did not significantly alter C1q secretion (data not 
shown).   
To exclude the possibility that a potential LPS contamination in the HSA, C1q, or SLEIgG 
preparations could be responsible for the stimulation of HMDMs inducing the secretion of C1q, 
we used Polymixin B to block LPS. However, the C1q secretion profile was unaffected by the 
presence of Polymixin B indicating that a LPS contamination is unlikely (data not shown). 
Even though, we obtained consistent C1q secretion profiles, secreted C1q levels varied 
between HMDMs derived from different healthy donors which seems to be in line with the fact 
that C1q serum levels also vary in healthy individuals (range: 70-250µg/ml (67)).  
Taken together, these data indicate that SLE patient-derived bound anti-C1q can induce C1q 
secretion by HMDMs. 
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Anti-C1q induce continuous and cumulative synthesis of C1q by HMDMs  
C1q has been shown to be continuously and cumulatively secreted by macrophages when 
kept in cultures for several days (69). To evaluate the kinetics of C1q secretion by differently 
stimulated HMDMs, cells were incubated on HSA, imC1q, imC1q+SLEIgG(1), or 
imC1q+NHIgG(1). SN were collected every 24h and analyzed for secreted C1q levels. 
Analyzing C1q secretion over 6 days, we observed that C1q is continuously secreted by 
HMDMs (Figure 21/ Table 12).  
 
Table 12: Summary of the kinetics of C1q secretion by HMDMs. 
Stimulation 
conditions 
C1q secretion [pg/ml] during stimulation time [days] 
1day 2days 6days 
HSA 132.7±229.8 198.2±245.6 1’019±643.5 
imC1q 1’203±677.5 2’088±878.5 5’332±2’727 
imC1q+SLEIgG(1) 2’230±1’052 3’822±1’617 7’295±2’651 
imC1q+NHIgG(1) 1’586±892.7 2’643±500.7 6’003±1’072 
Shown are mean values ± SEM of 3 independent donors. 
 
In addition, we detected a linear kinetic of C1q secretion by HMDMs independent of the 
stimulation condition used. HMDMs adherent to HSA continuously secreted low levels of C1q, 
whereas, in general, HMDMs incubated on imC1q produced continuously higher C1q levels. 
We did not observe a significant difference in the kinetics of C1q secretion by HMDMs 
incubated on imC1q as compared to imC1q+NHIgG(1). However, when HMDMs were 
incubated on imC1q+SLEIgG(1), the cells secreted significantly higher C1q levels within the 
first 24h of culture and throughout the whole incubation time of 6 days as compared to all 
other stimulation conditions used. Interestingly, cells incubated on both, imC1q as well as 
bound-anti-C1q, reached a plateau in their C1q production on day 5. This plateau of C1q 
secretion was not due to increased cell death since double-staining for AnnexinV and 
Propidium iodide did not show any significant difference between the different priming 
conditions (data not shown). 
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Figure 21: Kinetics of C1q secretion by 
HMDMs incubated on different coatings. 
HMDMs were incubated on HSA, imC1q, or 
imC1q+SLEIgG/NHIgG for up to 6days. SN were 
collected at different time points as indicated in 
the figure and secreted C1q levels were 
measured by ELISA. Shown are the results of one 
donor used to obtain HMDMs being 
representative of 3 independent experiments. 
Two-way ANOVA including Bonferroni’s post-test 
(vs imC1q+SLEIgG(1)), p<0.05*, p<0.01**. 
  
 
Thus, independent of the stimulation condition used, HMDMs continuously secreted C1q. 
These data suggest that bound anti-C1q can induce continuously high C1q production levels 
in macrophage-riche tissues where anti-C1q are deposited. 
Prolonged effect of C1q secretion by HMDMs stimulated on imC1q and anti-C1q bound 
to imC1q  
Next, we assessed whether the increased C1q secretion by imC1q and imC1q-bound anti-
C1q is sustained in HMDMs after withdrawal of the initial stimulus. After stimulation on 
different coatings, SN were collected and cells were washed and reseeded into fresh 
uncoated culture plates (Figure 22).  
In accordance with previously described data (Figure 19), untreated HMDMs secreted 
consistently low C1q levels, whereas cells being incubated on imC1q+SLEIgG(1) secreted 
significantly more C1q as compared to imC1q-primed HMDMs (data not shown).   
24h after reseeding, C1q secretion levels decreased to low or undetectable levels dependent 
on the coating condition used before (Figure 22). However, 3days after reseeding, cells being 
initially primed on imC1q+SLEIgG(1) secreted significantly higher levels of C1q as compared 
to the other priming conditions (imC1q+SLEIgG vs untreated: p<0.01**; vs imC1q: p<0.05*). 
Strikingly, 5days after reseeding, HMDMs primed on imC1q secreted significantly higher C1q 
levels as compared to untreated control cells (p<0.001***). Nevertheless, the highest C1q 
levels were produced by HMDMs primed on bound anti-C1q before being reseeded and kept 
in culture for 5days (imC1q+SLEIgG vs untreated: p<0.001***; vs imC1q: p<0.01**). 
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Figure 22: Prolonged effect of C1q secretion in stimulated HMDMs. 
HMDMs were incubated either on HSA, imC1q, imC1q+SLEIgG, or imC1q+NHIgG. After 22h, SN and 
cells were collected. Cells were washed, resuspended in fresh medium, reseeded, and further 
incubated for indicated time points. Results are shown of C1q secretion levels by HMDMs after being 
reseeded into new culture dish (without the initial coating) for 1, 3, or 5 days. Data represent pooled 
C1q secretion levels (mean) ± SEM of 5 unrelated healthy donors used to obtain HMDMs. One-way 
ANOVA including Bonferroni’s post-test, p<0.05*, p<0.01**, p<0.001***. 
 
Anti-C1q bound to imC1q induce high iC1q storage and de novo C1q synthesis 
Since we observed that both imC1q as well as imC1q-bound anti-C1q induced an increased 
C1q secretion by HMDMs, we sought to determine if differently primed HMDMs express 
different levels of membrane-bound C1q (mC1q) or intracellular C1q (iC1q). Furthermore, we 
analyzed the stored content of iC1q by ImageStreamX flow cytometry.   
mC1q has been described as a feature of macrophages and earlier reports demonstrated that 
both HMDMs and DCs exhibit low expression of mC1q (250, 251). In contrast, Bensa et al. 
could not detect mC1q on unstimulated macrophages (69). 
Independent of the stimulation conditions used, we observed only minor expression of mC1q 
on the surface of HMDMs derived from 3 out of 5 different healthy donors (Figure 23A). The 
low expression levels of mC1q were not due to the detecting antibody that was verified to be 
able to detect surface-bound C1q (data not shown). In addition, expression of mC1q did not 
increase during extended observations as outlined in the paragraph before. 
To evaluate whether differently primed HMDMs express different iC1q levels, we used flow 
cytometry and ImageStreamX flow cytometry technologies. 
HMDMs incubated on imC1q significantly upregulated their iC1q expression as compared to 
untreated control cells which expressed low levels of iC1q (p<0.05*) (Figure 23B). In addition, 
we observed a slightly increased iC1q expression by HMDMs being incubated on bound anti-
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C1q derived from one SLE patient when compared to cells stimulated on imC1q alone 
(p=0.063; ns). HMDMs stimulated with the TLR4-ligand LPS displayed higher expression of 
iC1q as compared to untreated cells (data not shown). The findings of the stored iC1q content 
are consistent with C1q levels being secreted by HMDMs from the same donor (Figure 23C).  
 
 
Figure 23: Expression of mC1q and iC1q by differently primed HMDMs detected by flow 
cytometry. 
HMDMs were left untreated or stimulated on imC1q alone or imC1q+SLEIgG(1). After 22h of stimulation 
on different coatings, SN and cells were collected. Cells were washed and stained for mC1q (A) or iC1q 
(B) as described in patients and methods. The results of FACS analyses are expressed as gMFI (n=5). 
C1q secretion levels in SN (C) from the same HMDM donors were analyzed in parallel. Results are 
shown as mean ± SEM of 5 independent experiments. Lines between data points indicate that the cells 
were derived from the same donor. One-way ANOVA including Bonferroni’s post-test, p<0.05*, 
p<0.005**. 
 
Using anti-C1q from 2 additional SLE patients, i.e., SLEIgG(2) and SLEIgG(3), led to similar 
iC1q expression levels (data not shown). Furthermore, we could not observe a difference in 
iC1q expression by HMDMs primed on C1q-coated wells incubated with NHIgG as compared 
to those cells incubated on imC1q alone (data not shown).  
Using ImageStreamX flow cytometry, we next evaluated whether C1q is freshly synthesized or 
released from intracellular storage pools.  
Untreated HMDMs had only a small amount of iC1q stored intracellularly. Moreover, not all 
cells stained positive for iC1q (Figure 24A; first 2 horizontal panels; Figure 24B; upper 
histogram) confirming findings reported previously (99). Nevertheless, we observed brighter 
storage pools in HMDMs being incubated on imC1q and even more in cells stimulated on 
imC1q+SLEIgG(1) (Figure 24A; third-sixth horizontal panels; Figure 24; middle/lower 
histograms). When quantifying iC1q in HMDMs primed on different coatings (Figure 24C), 
untreated HMDMs had mostly low expression levels of iC1q and only a low percentage of 
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cells had intermediate or high iC1q expression levels. HMDMs primed on imC1q had mostly 
intermediate iC1q expression levels, whereas HMDMs primed on bound anti-C1q displayed 
mostly high iC1q expression levels.  
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Figure 24: Intracellular content of C1q correlates with C1q secretion levels. 
HMDMs were stimulated and stained as described in patients and methods. Stained cells were 
analyzed using an Amnis ImageStreamX instrument and cell images were processed using IDEAS 
software. Representative images of differently stimulated HMDMs captured by the Amnis 
ImageStreamX system and stained with C1q (green) and DAPI (blue) are shown (A). Shown are 6 
single cell images per priming condition from one experiment being representative for 5 independent 
experiments. Histograms show iC1q intensities (blue) and isotype controls (grey) for each priming 
condition (B). Mean gMFI values ± SEM are indicated for each priming condition in the corresponding 
histogram. Shown is one histogram per priming condition from one experiment being representative for 
5 independent experiments. Different levels of iC1q were calculated using a template provided by the 
IDEAS software package and as described in patients and methods (C). One-way ANOVA including 
Bonferroni’s post-test, p<0.05*, p<0.01**, p<0.001***. 
 
These data indicate that high C1q secretion levels are associated with an accumulation of 
iC1q, indicating that anti-C1q and imC1q upregulate both, the secretion as well as the 
secretion of C1q. 
C1q secreted by HMDMs is functional 
C1q produced by macrophages and iDCs is able to activate the CP of complement (26, 70). In 
order to verify that secreted C1q is functional, we analyzed its complement-activating potential 
in a CP-activation assay using IgM-coated ELISA plates.  
Serial dilutions of concentrated culture SN of stimulated HMDMs diluted in C1qDS/VBS and 
incubated on IgM-coated plates resulted in the activation of the CP as assessed by C4b 
deposition (Figure 25), indicating that HMDMs secret functional and intact C1q. In accordance 
with the observed C1q secretion profile of differently primed HMDMs, SN of untreated HMDMs 
displayed the lowest CP-activating potential. The highest CP-activating capacity was observed 
testing C1q secreted by HMDMs incubated on imC1q+SLEIgG(1) as evident at every SN 
dilution. C1q secreted by cells exposed to imC1q alone exerted a CP-activating potential 
which was in general lower as compared to anti-C1q-primed HMDMs but higher as compared 
to untreated cells. The CP-activating potential of C1q produced by HMDMs was in general 
lower than that of purified serum-derived C1q, being in line with previous reports on 
macrophages and iDCs (26, 70). 
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Figure 25: Activation of the CP by secreted C1q using 
an IgM-coated plate. 
The ability of secreted C1q in activating the CP was 
investigated using an IgM-coated ELISA plate. HMDMs 
were left untreated or stimulated on imC1q or 
imC1q+SLEIgG(1) for 22h. SN of 6 different donors used 
to obtain HMDMs were pooled and processed as 
described in patients and methods. Serial dilutions of 
concentrated C1q-containing SN were diluted in 10% 
C1qDS/VBS and added to IgM-coated plates. The 
activation of the CP was assessed by detecting C4b 
deposition. Dashed grey line represents IgM-coated 
plates incubated with 10% C1qDS/VBS only. O.D. values 
were normalized to the corresponding O.D. values 
obtained when purified C1q was diluted in C1qDS/VBS at 
the same C1q concentration as measured in processed 
SN set to 100%. Data are shown as the mean ± SEM of 4 
independent experiments using pooled SN of 6 different 
HMDMs donors. 
 
Macrophages obtained from SLE patients also secrete C1q 
So far, all experiments were performed using HMDMs obtained from healthy donors. 
Therefore, we next studied HMDMs derived from SLE patients at different stages of disease 
(Table 11) to assess whether differentiated macrophages of SLE patients show a similar C1q 
secretion profile as compared to healthy donor-derived cells. 
Similar to healthy donor-derived cells, HMDMs obtained from SLE patients secreted higher 
C1q levels when these cells were incubated on imC1q as compared to those stimulated on 
HSA alone (p<0.05*) (Figure 26A). Providing a mild inflammatory stimulus by adding LPS to 
SLE HMDMs incubated on imC1q or HSA further increased C1q secretion levels (imC1q+LPS 
vs imC1q/HSA+LPS: p<0.05*). Importantly, SLE patient-derived HMDMs also strongly reacted 
to the combination of self-anti-C1q bound to imC1q (data not shown). This phenomenon could 
be observed in the majority of SLE patients and was dependent on anti-C1q serum levels 
(Table 11). 
However, when SLE patient-derived HMDMs were incubated on anti-C1q bound to imC1q, the 
cells significantly enhanced their C1q secretion as compared to imC1q+NHIgG-incubated cells 
(p<0.05*) (Figure 26B). 
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Figure 26: Macrophages of SLE patients show a similar C1q secretion profile. 
CD14-positive monocytes obtained from SLE patients (n=6) or as control from healthy donors (n=5) 
were differentiated into macrophages and incubated on different coatings. After 22h, SN were collected 
and analyzed for secreted C1q levels. SLE patient-derived macrophages (black bars) and healthy 
donor-derived macrophages (white bars) were incubated on HSA or imC1q with or without LPS (A). 
Shown are secreted C1q levels of at least 5 different donors used to isolate cells. One-way ANOVA 
including Bonferroni’s post-test, p<0.05*. SLE patient-derived macrophages (●) or healthy donor-
derived macrophages (○) were incubated on imC1q+SLEIgG of unrelated anti-C1q positive SLE 
patients (n=5 different IgG preparations) or on imC1q+NHIgG (n=3 different IgG preparations) (B). Grey 
line represents mean C1q secretion levels of HMDMs incubated on imC1q alone. Each data point 
represents pooled C1q secretion levels (mean) of at least 5 independent experiments. Mann-Whitney U 
test, p<0.05*. 
 
In general, when comparing C1q secretion levels of healthy donor-derived HMDMs (Figure 
19) to SLE patient-derived HMDMs (Figure 26), we observed a trend towards an elevated C1q 
secretion capacity in SLE patient-derived cells for all stimulation conditions used, however, 
differences did not reach significance (Table 13).  
 
Table 13: Comparison of C1q secretion levels of HMDMs obtained from healthy donors or SLE 
patients. 
Stimulation 
condition 
C1q [pg/ml] by healthy 
donor-derived HMDMs (n=5) 
C1q [pg/ml] by SLE-
derived HMDMs (n=6) 
p values 
(Mann-Whitney U test) 
HSA 60±39 390±265  p=0.09 
HSA+LPS 82±59 384±213 p=0.31 
imC1q 662±552 1’603±695 p=0.94 
imC1q+LPS 1’278±180 2’524±1’304 p=0.94 
imC1q+SLEIgG(1) 3’591±1’341 5’985±2’851 p=0.95 
imC1q+NHIgG(1) 1’830±72 2’284±371 p=0.23 
Shown are means ± SEM of 5 or 6 different donors. 
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In conclusion, SLE patient-derived HMDMs have a similar C1q secretion profile as compared 
to healthy donor-derived cells. 
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Discussion 
Anti-C1q are believed to be pathogenic in lupus nephritis. This hypothesis is based on the 
presence of both, C1q and anti-C1q, in glomeruli of patients with proliferative lupus nephritis 
(11, 12) and anti-C1q were found to strongly correlate with the occurrence of lupus nephritis 
(7-10). However, their biological and pathogenic properties in this inflammatory kidney 
disease are not well defined. In parallel, anti-C1q seem to influence C1q levels, as anti-C1q 
negatively correlate with C1q serum levels (29, 183). This might be due to enhanced 
complement activation as demonstrated recently (183). However, anti-C1q might also be able 
to directly alter C1q secretion by HMDMs. In this study, we can now demonstrate that imC1q 
and to a higher extent anti-C1q bound to imC1q stimulate C1q synthesis and secretion by 
HMDMs. In addition, this secreted C1q is functional, i.e., able to activate the CP of 
complement. Thus, bound anti-C1q can induce a potent C1q-producing phenotype in 
macrophages. This enhanced C1q secretion might potentiate anti-C1q induced complement 
activation and the binding of additional anti-C1q molecules leading to a local vicious circle. 
As opposed to most other complement proteins, C1q has a non-hepatic origin and is 
predominantly produced by myeloid cells, such as DCs and macrophages (26, 68-70). 
Therefore, free C1q is limited to the tissue due to local synthesis by these cells, whereas in 
the circulation C1q is mostly associated with its proteases C1s and C1r to form the C1 
complex in the circulation (65, 66). In vitro, C1q synthesis can be influenced by different 
agents, including LPS, steroids, cytokines, and ICs (27, 69, 104, 119). Interestingly, in a 
previous report, imC1q triggered its own production by DCs but not by HMDMs (120). In 
contrast, Galvan et al. reported that imC1q upregulates C1q mRNA in murine macrophages 
(121). We found that both imC1q and even more imC1q-bound anti-C1q induce C1q secretion 
by HMDMs.  
The additional effect of anti-C1q cannot be explained by the recruitment of FcγRs alone as 
using ICs or IgG-coating alone only induced low levels of secreted C1q. Therefore, we 
hypothesize that a double trigger of macrophages by imC1q via C1q receptors and bound 
anti-C1q via FcγRs is required for the observed C1q secretion profile. The pathway, however, 
leading to upregulated C1q synthesis and the regulation of the genes encoding C1q is not well 
understood. In general, it is believed that locally secreted C1q may act in an auto-/paracrine 
manner maintaining tissue homeostasis by suppressing cell-mediated inflammation. We 
observed that HMDMs on imC1q and bound-anti-C1q continuously secreted high C1q levels 
and produced an accumulation of iC1q suggesting continued de novo C1q synthesis, 
indicating that high levels of secreted C1q are unlikely to act as a negative feedback 
mechanism. Our data is in accordance with findings published by Zhou et al. who found that 
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murine macrophages continuously secreted C1q triggered by LPS, ICs, or C3b-opsonized 
zymosan (27). In contrast, C1q secretion by HMDMs remained unaffected when cells were 
incubated with IgG-coated sheep erythrocytes, yeast, or latex beads (69). Furthermore, 
addition of exogenous C1q to murine macrophages led to an increase in C1q mRNA levels 
(28). Taken together, these reports suggest that C1q secretion might act as a positive 
feedback, i.e., reflecting a temporal requirement of an increased amount of C1q in inflamed 
tissue (130, 131) and underlining the importance of local C1q production in the regulation of 
tissue homeostasis during inflammation.  
To evaluate changes in the C1q secretion profile by macrophages at the site of inflammation, 
macrophages have been stimulated with different agents: Cytokines and different drugs have 
been tested in their properties to modulate C1q secretion. Whereas IL-1β and IFNγ decreased 
C1q biosynthesis over time, IL-6 acted as a potent stimulus for C1q secretion (119). Recently, 
we found that bound anti-C1q induce a pro-inflammatory phenotype in HMDMs (247). We 
observed that imC1q alone and bound anti-C1q induce C1q secretion by HMDMs. As it has 
been demonstrated that pro-inflammatory macrophages secrete considerably more C1q as 
compared to resident peritoneal macrophages (103, 248), our observation supports the view 
that C1q secretion is, in general, enhanced under inflammatory conditions.  
A recent report indicated that infiltrating mononuclear cells play a role in the progression of 
lupus nephritis and are associated with poor prognosis in SLE patients (233). In addition, data 
from murine models suggest that macrophages and DCs infiltrating nephritic kidneys display 
an activated and heterogeneous phenotype and contribute to renal damage (193, 194). In 
kidney biopsies of lupus nephritis patients, immunoglobulins (IgG, IgA, IgM) are deposited 
close to complement proteins (C1q, MBL, C4, C3) (11, 12). Furthermore, concentrations of 
deposited anti-C1q in the glomeruli are up to 50times above those found in the sera of 
patients (223) leading to the conclusion that anti-C1q deposition and consecutive activation of 
infiltrating mononuclear cells occur in kidneys and contribute to the pathogenesis of lupus 
nephritis. Based on the fact that myeloid cells are a rich source for C1q, a common hypothesis 
is that macrophages and DCs contribute to high local C1q concentrations and consequently 
deposition in inflamed tissues. Indeed, it has been reported that C1q mRNA expression in 
kidneys was strongly upregulated in vivo in MRL/lpr mice suffering from severe lupus 
nephritis. Using this lupus-prone mouse model, infiltration of myeloid cells and local C1q 
production was associated with disease progression (252). Finally, MRL/lpr mice have 
elevated levels of anti-C1q present in serum as well as deposited in the kidneys which 
negatively correlate with low serum C1q levels (253).  
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Many SLE patients display hypocomplementemia during flares characterized by low or even 
undetectable C1q serum levels which negatively correlate with anti-C1q titers (7-9). Notably, 
Tan et al. did not find an association of C1q serum levels with glomerular C1q deposition in 
SLE patients. The authors concluded that serum C1q might contribute only little to C1q 
deposition in nephritic kidneys, whereas local C1q production by DCs and macrophages might 
be the main source of deposited C1q (254). At sites of local inflammation accompanied by 
increased apoptotic cell load, it is thought that locally secreted C1q has a major impact in the 
clearance of dying cells and has immune-regulatory functions in cell-mediated inflammation. 
Beyond complement activation, C1q plays a critical role in the clearance of apoptotic cells by 
bridging apoptotic cells and phagocytes thereby facilitating the uptake of apoptotic cells (22, 
23, 120). Furthermore, during the phagocytosis of apoptotic cells, the production of C1q might 
be elevated due to an increased temporal requirement of C1q and consequently, facilitate the 
clearance of dying cells. Indeed, C3b-opsonized zymosan (resembling the surface of an 
apoptotic cell) increased C1q production by murine macrophages mainly through C3b 
receptor triggering (27). In addition, Galvan et al. reported that adhesion to C1q is followed by 
an upregulation of genes encoding C1q (121). Thus, enhanced C1q production might lead to 
an improved clearance of apoptotic cell material. However, this mechanism seems to be 
contradictory to the observation that anti-C1q decrease the phagocytic capacity of HMDMs 
and THP-1 cells (154, 247). 
The defective clearance of apoptotic material by macrophages has been proposed as a 
mechanism underlying SLE pathogenesis causing an accumulation of dead cell material (20). 
It is well established that SLE patient-derived macrophages exhibit a defect in the clearance of 
apoptotic cell material correlating with low complement levels (17, 18). This impaired 
phagocytosis might be due to functional C1q deficiency induced by a high consumption rate of 
C1q or an insufficient production of C1q by myeloid cells. Our data now provide evidence that 
anti-C1q rather enhance C1q production by HMDMs, indicating that freshly available C1q is 
quickly consumed in affected tissues. This effect might be beneficial in the context of the 
removal of apoptotic cell debris, but it still might have disadvantage effects. Notably, elevated 
C1q secretion by HMDMs triggered by im-C1q bound anti-C1q might result in more available 
C1q which then can bind to tissue-deposited ICs and consequently lead to the activation of 
complement. Deposition of further C1q might serve as an additional target for anti-C1q leading 
to a local vicious cycle including complement activation and inflammation. 
In conclusion, we can show that imC1q-bound anti-C1q induce a potent C1q-producing 
phenotype in HMDMs. This anti-C1q-induced C1q secretion by HMDMs might be an important 
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disease exacerbating factor in SLE patients. This observation provides new insights into 
pathogenic mechanisms of anti-C1q and their role in SLE.    
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Conclusions, ongoing projects, and outlook 
Conclusions 
In my thesis, I developed an in vitro model to study the pathogenic effects of systemic lupus 
erythematosus (SLE) patient-derived high-affinity autoantibodies directed against C1q (anti-
C1q) on the activation of the complement system and their down-stream effects on 
macrophages. In conclusion, I can demonstrate that anti-C1q have proinflammatory effects 
that could be pathogenic (Figure 27). First, these autoantibodies amplify complement 
activation via both the classical and lectin pathways but not via the alternative pathway (see 
part 1, p. 29, (249)). Second, anti-C1q alter the phenotype of human monocyte-derived 
macrophages (HMDMs) by cross-linking of Fcgamma receptors (FcγRs) and activate HMDMs 
(S. Thanei et al. (submitted); see part 2, p. 46). These autoantibodies induce a 
proinflammatory cytokine response by upregulating IL-1β, IL-6, and TNFα secretion, 
downregulating the phagocytosis rate of apoptotic cells and Mer tyrosine kinase (MerTK) 
expression, and upregulating lipopolysaccharide (LPS)-induced CD80, CD274, and MHC 
class II expression. Third, immobilized C1q (imC1q)-bound anti-C1q induced C1q secretion by 
HMDMs (S. Thanei et al. (submitted); see part 3, p. 73).  
 
 
Figure 27: Overview of the functional consequences of the binding of SLE patient-derived high-
affinity anti-C1q to imC1q. 
The proposed effects of imC1q alone, as occurring in healthy individuals, and imC1q-bound anti-C1q, 
as occurring in SLE patients, are summarized.  
Legend: C1qR: C1q receptor; M1: proinflammatory macrophages; M2: anti-inflammatory macrophages 
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Thus, anti-C1q have an effect on 2 major effector mechanisms of the immune system used by 
antibodies, the complement system as well as FcγRs. These interactions might play a critical 
role in lupus nephritis by the amplification of local inflammatory immune responses and 
consecutive tissue damage resulting in a local vicious cycle. 
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Ongoing projects and future perspectives 
Ongoing projects and future perspectives are not included in the printed or online versions of 
this thesis. 
 
 
  References  
100 
References 
1. Walport, M. J. 2001. Complement. First of two parts. N Engl J Med 344: 1058-1066. 
2. Sjöberg, A. P., L. A. Trouw, and A. M. Blom. 2009. Complement activation and 
inhibition: a delicate balance. Trends Immunol 30: 83-90. 
3. Pickering, M. C., and M. J. Walport. 2000. Links between complement abnormalities 
and systemic lupus erythematosus. Rheumatology (Oxford) 39: 133-141. 
4. Aringer, M., C. Günther, and M. A. Lee-Kirsch. 2013. Innate immune processes in 
lupus erythematosus. Clin Immunol 147: 216-222. 
5. Botto, M., C. Dell'Agnola, A. E. Bygrave, E. M. Thompson, H. T. Cook, F. Petry, M. 
Loos, P. P. Pandolfi, and M. J. Walport. 1998. Homozygous C1q deficiency causes 
glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56-59. 
6. Agnello, V. 1978. Association of systemic lupus erythematosus and SLE-like 
syndromes with hereditary and acquired complement deficiency states. Arthritis 
Rheum 21: S146-152. 
7. Bigler, C., H. Hopfer, D. Danner, M. Schaller, M. J. Mihatsch, and M. Trendelenburg. 
2011. Anti-C1q autoantibodies do not correlate with the occurrence or severity of 
experimental lupus nephritis. Nephrol Dial Transplant 26: 1220-1228. 
8. Marto, N., M. L. Bertolaccini, E. Calabuig, G. R. Hughes, and M. A. Khamashta. 2005. 
Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity 
and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64: 
444-448. 
9. Coremans, I. E., P. E. Spronk, H. Bootsma, M. R. Daha, E. A. van der Voort, L. Kater, 
F. C. Breedveld, and C. G. Kallenberg. 1995. Changes in antibodies to C1q predict 
renal relapses in systemic lupus erythematosus. Am J Kidney Dis 26: 595-601. 
10. Trouw, L. A., T. W. Groeneveld, M. A. Seelen, J. M. Duijs, I. M. Bajema, F. A. Prins, U. 
Kishore, D. J. Salant, J. S. Verbeek, C. van Kooten, and M. R. Daha. 2004. Anti-C1q 
autoantibodies deposit in glomeruli but are only pathogenic in combination with 
glomerular C1q-containing immune complexes. J Clin Invest 114: 679-688. 
11. Nisihara, R. M., F. Magrini, V. Mocelin, and I. J. Messias-Reason. 2013. Deposition of 
the lectin pathway of complement in renal biopsies of lupus nephritis patients. Hum 
Immunol 74: 907-910. 
12. Kim, M. K., Y. I. Maeng, S. J. Lee, I. H. Lee, J. Bae, Y. N. Kang, B. T. Park, and K. K. 
Park. 2013. Pathogenesis and significance of glomerular C4d deposition in lupus 
nephritis: activation of classical and lectin pathways. Int J Clin Exp Pathol 6: 2157-
2167. 
13. Kościelska-Kasprzak, K., D. Bartoszek, M. Myszka, M. Zabińska, and M. Klinger. 
2014. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 
62: 47-57. 
  References  
101 
14. Siegert, C. E., M. R. Daha, C. Halma, E. A. van der Voort, and F. C. Breedveld. 1992. 
IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp 
Rheumatol 10: 19-23. 
15. Coremans, I. E., M. R. Daha, E. A. van der Voort, C. E. Siegert, and F. C. Breedveld. 
1995. Subclass distribution of IgA and IgG antibodies against Clq in patients with 
rheumatic diseases. Scand J Immunol 41: 391-397. 
16. Pfueller, B., K. Wolbart, A. Bruns, G. R. Burmester, and F. Hiepe. 2001. Successful 
treatment of patients with systemic lupus erythematosus by immunoadsorption with a 
C1q column: a pilot study. Arthritis Rheum 44: 1962-1963. 
17. Herrmann, M., R. E. Voll, O. M. Zoller, M. Hagenhofer, B. B. Ponner, and J. R. Kalden. 
1998. Impaired phagocytosis of apoptotic cell material by monocyte-derived 
macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41: 
1241-1250. 
18. Bijl, M., E. Reefman, G. Horst, P. C. Limburg, and C. G. Kallenberg. 2006. Reduced 
uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates 
with decreased serum levels of complement. Ann Rheum Dis 65: 57-63. 
19. Sule, S., A. Rosen, M. Petri, E. Akhter, and F. Andrade. 2011. Abnormal production of 
pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic 
cells. PLoS One 6: e17495. 
20. Shao, W. H., and P. L. Cohen. 2011. Disturbances of apoptotic cell clearance in 
systemic lupus erythematosus. Arthritis Res Ther 13: 202. 
21. Gaipl, U. S., L. E. Munoz, G. Grossmayer, K. Lauber, S. Franz, K. Sarter, R. E. Voll, T. 
Winkler, A. Kuhn, J. Kalden, P. Kern, and M. Herrmann. 2007. Clearance deficiency 
and systemic lupus erythematosus (SLE). J Autoimmun 28: 114-121. 
22. Ogden, C. A., A. deCathelineau, P. R. Hoffmann, D. Bratton, B. Ghebrehiwet, V. A. 
Fadok, and P. M. Henson. 2001. C1q and mannose binding lectin engagement of cell 
surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. 
J Exp Med 194: 781-795. 
23. Nauta, A. J., G. Castellano, W. Xu, A. M. Woltman, M. C. Borrias, M. R. Daha, C. van 
Kooten, and A. Roos. 2004. Opsonization with C1q and mannose-binding lectin targets 
apoptotic cells to dendritic cells. J Immunol 173: 3044-3050. 
24. Fraser, D. A., A. K. Laust, E. L. Nelson, and A. J. Tenner. 2009. C1q differentially 
modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by 
human monocytes, macrophages, and dendritic cells. J Immunol 183: 6175-6185. 
25. Benoit, M. E., E. V. Clarke, P. Morgado, D. A. Fraser, and A. J. Tenner. 2012. 
Complement protein C1q directs macrophage polarization and limits inflammasome 
activity during the uptake of apoptotic cells. J Immunol 188: 5682-5693. 
26. Castellano, G., A. M. Woltman, A. J. Nauta, A. Roos, L. A. Trouw, M. A. Seelen, F. P. 
Schena, M. R. Daha, and C. van Kooten. 2004. Maturation of dendritic cells abrogates 
C1q production in vivo and in vitro. Blood 103: 3813-3820. 
  References  
102 
27. Zhou, A. Q., M. J. Herriott, and R. W. Leu. 1991. Kinetics of the biosynthesis of 
complement subcomponent C1q by murine macrophages: LPS, immune complexes, 
and zymosan alone and in combination with interferon-gamma. J Leukoc Biol 50: 453-
463. 
28. Kolosov, M., I. Kolosova, A. Zhou, and R. W. Leu. 1996. Autocrine induction of 
macrophage synthesis of complement subcomponent C1q by endogenous interferon-
alpha/beta. J Interferon Cytokine Res 16: 209-215. 
29. Trendelenburg, M., M. Lopez-Trascasa, E. Potlukova, S. Moll, S. Regenass, V. 
Frémeaux-Bacchi, J. Martinez-Ara, E. Jancova, M. L. Picazo, E. Honsova, V. Tesar, S. 
Sadallah, and J. Schifferli. 2006. High prevalence of anti-C1q antibodies in biopsy-
proven active lupus nephritis. Nephrol Dial Transplant 21: 3115-3121. 
30. Frémeaux-Bacchi, V., L. Weiss, C. Demouchy, J. Blouin, and M. D. Kazatchkine. 1996. 
Autoantibodies to the collagen-like region of C1q are strongly associated with classical 
pathway-mediated hypocomplementemia in systemic lupus erythematosus. Lupus 5: 
216-220. 
31. Walport, M. J. 2001. Complement. Second of two parts. N Engl J Med 344: 1140-1144. 
32. Józsi, M. l. 2011. Anti-complement autoantibodies in membranoproliferative 
glomerulonephritis and dense deposit disease. In An update on glomerulopathies - 
etiology and pathogenesis. S. Prabhakar, ed. In Tech, Croatia. 
33. Merle, N. S., S. E. Church, V. Fremeaux-Bacchi, and L. T. Roumenina. 2015. 
Complement System Part I - Molecular Mechanisms of Activation and Regulation. 
Front Immunol 6: 262. 
34. Parham, P. 2009. The immune system. Garland Science. 
35. Tegla, C. A., C. Cudrici, S. Patel, R. Trippe, V. Rus, F. Niculescu, and H. Rus. 2011. 
Membrane attack by complement: the assembly and biology of terminal complement 
complexes. Immunol Res 51: 45-60. 
36. Reid, K. B. 1986. Activation and control of the complement system. Essays Biochem 
22: 27-68. 
37. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The 
role of the anaphylatoxins in health and disease. Mol Immunol 46: 2753-2766. 
38. Holers, V. M. 2014. Complement and its receptors: new insights into human disease. 
Annu Rev Immunol 32: 433-459. 
39. Kang, Y. H., L. A. Tan, M. V. Carroll, M. E. Gentle, and R. B. Sim. 2009. Target pattern 
recognition by complement proteins of the classical and alternative pathways. Adv Exp 
Med Biol 653: 117-128. 
40. Mills, J. A. 1994. Systemic lupus erythematosus. N Engl J Med 330: 1871-1879. 
41. D'Cruz, D. P., M. A. Khamashta, and G. R. Hughes. 2007. Systemic lupus 
erythematosus. Lancet 369: 587-596. 
  References  
103 
42. Rahman, A., and D. A. Isenberg. 2008. Systemic lupus erythematosus. N Engl J Med 
358: 929-939. 
43. Tsao, B. P. 2003. The genetics of human systemic lupus erythematosus. Trends 
Immunol 24: 595-602. 
44. Mok, C. C., and C. S. Lau. 2003. Pathogenesis of systemic lupus erythematosus. J 
Clin Pathol 56: 481-490. 
45. Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell 
hyperactivity. Nat Immunol 2: 764-766. 
46. Roumenina, L. T., D. Sène, M. Radanova, J. Blouin, L. Halbwachs-Mecarelli, M. A. 
Dragon-Durey, W. H. Fridman, and V. Fremeaux-Bacchi. 2011. Functional 
complement C1q abnormality leads to impaired immune complexes and apoptotic cell 
clearance. J Immunol 187: 4369-4373. 
47. Manderson, A. P., M. Botto, and M. J. Walport. 2004. The role of complement in the 
development of systemic lupus erythematosus. Annu Rev Immunol 22: 431-456. 
48. Trouw, L. A., A. M. Blom, and P. Gasque. 2008. Role of complement and complement 
regulators in the removal of apoptotic cells. Mol Immunol 45: 1199-1207. 
49. Taylor, P. R., A. Carugati, V. A. Fadok, H. T. Cook, M. Andrews, M. C. Carroll, J. S. 
Savill, P. M. Henson, M. Botto, and M. J. Walport. 2000. A hierarchical role for 
classical pathway complement proteins in the clearance of apoptotic cells in vivo. J 
Exp Med 192: 359-366. 
50. Botto, M., and M. J. Walport. 2002. C1q, autoimmunity and apoptosis. Immunobiology 
205: 395-406. 
51. Huggins, M. L., I. Todd, M. A. Cavers, S. R. Pavuluri, P. J. Tighe, and R. J. Powell. 
1999. Antibodies from systemic lupus erythematosus (SLE) sera define differential 
release of autoantigens from cell lines undergoing apoptosis. Clin Exp Immunol 118: 
322-328. 
52. Casciola-Rosen, L., A. Rosen, M. Petri, and M. Schlissel. 1996. Surface blebs on 
apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation 
events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S 
A 93: 1624-1629. 
53. Cohen, P. L., R. Caricchio, V. Abraham, T. D. Camenisch, J. C. Jennette, R. A. 
Roubey, H. S. Earp, G. Matsushima, and E. A. Reap. 2002. Delayed apoptotic cell 
clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine 
kinase. J Exp Med 196: 135-140. 
54. Potter, P. K., J. Cortes-Hernandez, P. Quartier, M. Botto, and M. J. Walport. 2003. 
Lupus-prone mice have an abnormal response to thioglycolate and an impaired 
clearance of apoptotic cells. J Immunol 170: 3223-3232. 
55. Mevorach, D., J. L. Zhou, X. Song, and K. B. Elkon. 1998. Systemic exposure to 
irradiated apoptotic cells induces autoantibody production. J Exp Med 188: 387-392. 
  References  
104 
56. Casciola-Rosen, L. A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted in 
systemic lupus erythematosus are clustered in two populations of surface structures 
on apoptotic keratinocytes. J Exp Med 179: 1317-1330. 
57. Savill, J., and V. Fadok. 2000. Corpse clearance defines the meaning of cell death. 
Nature 407: 784-788. 
58. Henson, P. M., D. L. Bratton, and V. A. Fadok. 2001. Apoptotic cell removal. Curr Biol 
11: R795-805. 
59. Carroll, M. C. 2004. A protective role for innate immunity in systemic lupus 
erythematosus. Nat Rev Immunol 4: 825-831. 
60. Walport, M. J. 2000. Lupus, DNase and defective disposal of cellular debris. Nat Genet 
25: 135-136. 
61. Reid, K. B. 1989. Chemistry and molecular genetics of C1q. Behring Inst Mitt: 8-19. 
62. Reid, K. B. 1983. Proteins involved in the activation and control of the two pathways of 
human complement. Biochem Soc Trans 11: 1-12. 
63. Kishore, U., and K. B. Reid. 2000. C1q: structure, function, and receptors. 
Immunopharmacology 49: 159-170. 
64. Ghebrehiwet, B., K. K. Hosszu, A. Valentino, and E. I. Peerschke. 2012. The C1q 
family of proteins: insights into the emerging non-traditional functions. Front Immunol 
3. 
65. Kilchherr, E., H. Fuchs, J. Tschopp, and J. Engel. 1982. Dissociation of C1 and 
concentration dependence of its activation kinetics. Mol Immunol 19: 683-691. 
66. Ziccardi, R. J., and J. Tschopp. 1982. The dissociation properties of native C1. 
Biochem Biophys Res Commun 107: 618-623. 
67. Dillon, S. P., A. D'Souza, B. T. Kurien, and R. H. Scofield. 2009. Systemic lupus 
erythematosus and C1q: A quantitative ELISA for determining C1q levels in serum. 
Biotechnol J 4: 1210-1214. 
68. Rabs, U., H. Martin, T. Hitschold, M. D. Golan, H. P. Heinz, and M. Loos. 1986. 
Isolation and characterization of macrophage-derived C1q and its similarities to serum 
C1q. Eur J Immunol 16: 1183-1186. 
69. Bensa, J. C., A. Reboul, and M. G. Colomb. 1983. Biosynthesis in vitro of complement 
subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human 
monocytes. Biochem J 216: 385-392. 
70. Tenner, A. J., and D. B. Volkin. 1986. Complement subcomponent C1q secreted by 
cultured human monocytes has subunit structure identical with that of serum C1q. 
Biochem J 233: 451-458. 
71. Nayak, A., J. Ferluga, A. G. Tsolaki, and U. Kishore. 2010. The non-classical functions 
of the classical complement pathway recognition subcomponent C1q. Immunol Lett 
131: 139-150. 
  References  
105 
72. Singh, J., A. Ahmed, and G. Girardi. 2011. Role of complement component C1q in the 
onset of preeclampsia in mice. Hypertension 58: 716-724. 
73. Hong, Q., C. I. Sze, S. R. Lin, M. H. Lee, R. Y. He, L. Schultz, J. Y. Chang, S. J. Chen, 
R. J. Boackle, L. J. Hsu, and N. S. Chang. 2009. Complement C1q activates tumor 
suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One 4: e5755. 
74. Walport, M. J., K. A. Davies, and M. Botto. 1998. C1q and systemic lupus 
erythematosus. Immunobiology 199: 265-285. 
75. Arlaud, G. J., A. Biro, and W. L. Ling. 2011. Enzymatically modified low-density 
lipoprotein is recognized by c1q and activates the classical complement pathway. J 
Lipids 2011: 376092. 
76. Korb, L. C., and J. M. Ahearn. 1997. C1q binds directly and specifically to surface 
blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus 
erythematosus revisited. J Immunol 158: 4525-4528. 
77. Nauta, A. J., L. A. Trouw, M. R. Daha, O. Tijsma, R. Nieuwland, W. J. Schwaeble, A. 
R. Gingras, A. Mantovani, E. C. Hack, and A. Roos. 2002. Direct binding of C1q to 
apoptotic cells and cell blebs induces complement activation. Eur J Immunol 32: 1726-
1736. 
78. Navratil, J. S., S. C. Watkins, J. J. Wisnieski, and J. M. Ahearn. 2001. The globular 
heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial 
cells. J Immunol 166: 3231-3239. 
79. Roumenina, L. T., K. T. Popov, S. V. Bureeva, M. Kojouharova, M. Gadjeva, S. 
Rabheru, R. Thakrar, A. Kaplun, and U. Kishore. 2008. Interaction of the globular 
domain of human C1q with Salmonella typhimurium lipopolysaccharide. Biochim 
Biophys Acta 1784: 1271-1276. 
80. Martin, M., J. Leffler, and A. M. Blom. 2012. Annexin A2 and A5 serve as new ligands 
for C1q on apoptotic cells. J Biol Chem 287: 33733-33744. 
81. Païdassi, H., P. Tacnet-Delorme, M. Verneret, C. Gaboriaud, G. Houen, K. Duus, W. 
L. Ling, G. J. Arlaud, and P. Frachet. 2011. Investigations on the C1q-calreticulin-
phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol 
Biol 408: 277-290. 
82. Lu, J. H., B. K. Teh, L. Wang, Y. N. Wang, Y. S. Tan, M. C. Lai, and K. B. Reid. 2008. 
The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol 
Immunol 5: 9-21. 
83. Lu, J., X. Wu, and B. K. Teh. 2007. The regulatory roles of C1q. Immunobiology 212: 
245-252. 
84. Vogel, D. Y., P. D. Heijnen, M. Breur, H. E. de Vries, A. T. Tool, S. Amor, and C. D. 
Dijkstra. 2014. Macrophages migrate in an activation-dependent manner to 
chemokines involved in neuroinflammation. J Neuroinflammation 11: 23. 
  References  
106 
85. Vegh, Z., R. R. Kew, B. L. Gruber, and B. Ghebrehiwet. 2006. Chemotaxis of human 
monocyte-derived dendritic cells to complement component C1q is mediated by the 
receptors gC1qR and cC1qR. Mol Immunol 43: 1402-1407. 
86. Csomor, E., Z. Bajtay, N. Sándor, K. Kristóf, G. J. Arlaud, S. Thiel, and A. Erdei. 2007. 
Complement protein C1q induces maturation of human dendritic cells. Mol Immunol 
44: 3389-3397. 
87. Son, M., F. Santiago-Schwarz, Y. Al-Abed, and B. Diamond. 2012. C1q limits dendritic 
cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U S A 109: 
E3160-3167. 
88. Morgan, B. P., and P. Gasque. 1997. Extrahepatic complement biosynthesis: where, 
when and why? Clin Exp Immunol 107: 1-7. 
89. Laufer, J., Y. Katz, and J. H. Passwell. 2001. Extrahepatic synthesis of complement 
proteins in inflammation. Mol Immunol 38: 221-229. 
90. Reis, E. S., J. A. Barbuto, and L. Isaac. 2006. Human monocyte-derived dendritic cells 
are a source of several complement proteins. Inflamm Res 55: 179-184. 
91. Granucci, F., C. Vizzardelli, E. Virzi, M. Rescigno, and P. Ricciardi-Castagnoli. 2001. 
Transcriptional reprogramming of dendritic cells by differentiation stimuli. Eur J 
Immunol 31: 2539-2546. 
92. Le Naour, F., L. Hohenkirk, A. Grolleau, D. E. Misek, P. Lescure, J. D. Geiger, S. 
Hanash, and L. Beretta. 2001. Profiling changes in gene expression during 
differentiation and maturation of monocyte-derived dendritic cells using both 
oligonucleotide microarrays and proteomics. J Biol Chem 276: 17920-17931. 
93. Ramadori, G., H. P. Heinz, H. Martin, K. H. Meyer zum Büschenfelde, and M. Loos. 
1986. Biosynthesis of the subcomponents C1q, C1r and C1s of the first component of 
complement (C1) by guinea pig hepatocyte primary cultures. Eur J Immunol 16: 1137-
1141. 
94. Armbrust, T., B. Nordmann, M. Kreissig, and G. Ramadori. 1997. C1Q synthesis by 
tissue mononuclear phagocytes from normal and from damaged rat liver: up-regulation 
by dexamethasone, down-regulation by interferon gamma, and lipopolysaccharide. 
Hepatology 26: 98-106. 
95. Petry, F., K. B. Reid, and M. Loos. 1991. Gene expression of the A- and B-chain of 
mouse C1q in different tissues and the characterization of the recombinant A-chain. J 
Immunol 147: 3988-3993. 
96. Al-Adnani, M., and J. McGee. 1976. C1q production by fibroblasts. Nature. 145-146. 
97. Morris, K. M., H. R. Colten, and D. H. Bing. 1978. The first component of complement. 
A quantitative comparison of its biosynthesis in culture by human epithelial and 
mesenchymal cells. J Exp Med 148: 1007-1019. 
98. Kaul, M., and M. Loos. 2001. Expression of membrane C1q in human monocyte-
derived macrophages is developmentally regulated and enhanced by interferon-
gamma. FEBS Lett 500: 91-98. 
  References  
107 
99. Moosig, F., F. Damm, A. Knorr-Spahr, M. Ritgen, R. A. Zeuner, M. Kneba, M. Ernst, 
and J. O. Schröder. 2006. Reduced expression of C1q-mRNA in monocytes from 
patients with systemic lupus erythematosus. Clin Exp Immunol 146: 409-416. 
100. Vegh, Z., E. C. Goyarts, K. Rozengarten, A. Mazumder, and B. Ghebrehiwet. 2003. 
Maturation-dependent expression of C1q-binding proteins on the cell surface of human 
monocyte-derived dendritic cells. Int Immunopharmacol 3: 345-357. 
101. Castellano, G., A. M. Woltman, F. P. Schena, A. Roos, M. R. Daha, and C. van 
Kooten. 2004. Dendritic cells and complement: at the cross road of innate and 
adaptive immunity. Mol Immunol 41: 133-140. 
102. Liu, S., J. Wu, T. Zhang, B. Qian, P. Wu, L. Li, Y. Yu, and X. Cao. 2008. Complement 
C1q chemoattracts human dendritic cells and enhances migration of mature dendritic 
cells to CCL19 via activation of AKT and MAPK pathways. Mol Immunol 46: 242-249. 
103. Müller, W., H. Hanauske-Abel, and M. Loos. 1978. Biosynthesis of the first component 
of complement by human and guinea pig peritoneal macrophages: evidence for an 
independent production of the C1 subunits. J Immunol 121: 1578-1584. 
104. Faust, D., B. Akoglu, D. Zgouras, E. H. Scheuermann, V. Milovic, and J. Stein. 2002. 
Anti-inflammatory drugs modulate C1q secretion in human peritoneal macrophages in 
vitro. Biochem Pharmacol 64: 457-462. 
105. Teo, B. H., Y. V. Bobryshev, B. K. Teh, S. H. Wong, and J. Lu. 2012. Complement C1q 
production by osteoclasts and its regulation of osteoclast development. Biochem J 
447: 229-237. 
106. Reid, K. B., and E. Solomon. 1977. Biosynthesis of the first component of complement 
by human fibroblasts. Biochem J 167: 647-660. 
107. Skok, J., E. Solomon, K. B. Reid, and R. A. Thompson. 1981. Distinct genes for 
fibroblast and serum C1q. Nature 292: 549-551. 
108. Gulati, P., C. Lemercier, D. Guc, D. Lappin, and K. Whaley. 1993. Regulation of the 
synthesis of C1 subcomponents and C1-inhibitor. Behring Inst Mitt: 196-203. 
109. Bulla, R., C. Agostinis, F. Bossi, L. Rizzi, A. Debeus, C. Tripodo, O. Radillo, F. De 
Seta, B. Ghebrehiwet, and F. Tedesco. 2008. Decidual endothelial cells express 
surface-bound C1q as a molecular bridge between endovascular trophoblast and 
decidual endothelium. Mol Immunol 45: 2629-2640. 
110. Lynch, N. J., C. L. Willis, C. C. Nolan, S. Roscher, M. J. Fowler, E. Weihe, D. E. Ray, 
and W. J. Schwaeble. 2004. Microglial activation and increased synthesis of 
complement component C1q precedes blood-brain barrier dysfunction in rats. Mol 
Immunol 40: 709-716. 
111. Färber, K., G. Cheung, D. Mitchell, R. Wallis, E. Weihe, W. Schwaeble, and H. 
Kettenmann. 2009. C1q, the recognition subcomponent of the classical pathway of 
complement, drives microglial activation. J Neurosci Res 87: 644-652. 
112. Agostinis, C., R. Bulla, C. Tripodo, A. Gismondi, H. Stabile, F. Bossi, C. Guarnotta, C. 
Garlanda, F. De Seta, P. Spessotto, A. Santoni, B. Ghebrehiwet, G. Girardi, and F. 
  References  
108 
Tedesco. 2010. An alternative role of C1q in cell migration and tissue remodeling: 
contribution to trophoblast invasion and placental development. J Immunol 185: 4420-
4429. 
113. Tripodo, C., R. Porcasi, C. Guarnotta, S. Ingrao, V. Campisi, A. M. Florena, and V. 
Franco. 2007. C1q production by bone marrow stromal cells. Scand J Immunol 65: 
308-309. 
114. Kolosov, M., I. Kolosova, and R. W. leu. 1996. Stimulation of macrophage synthesis of 
complement C1q by interferon-gamma mediated by endogenous interferon-alpha/beta. 
J Interferon Cytokine Res 16: 245-249. 
115. Schwaeble, W., M. K. Schäfer, F. Petry, T. Fink, D. Knebel, E. Weihe, and M. Loos. 
1995. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-
macrophage lineage are the C1q-producing sources in the spleen. Identification of 
specific cell types by in situ hybridization and immunohistochemical analysis. J 
Immunol 155: 4971-4978. 
116. Petry, F., M. Botto, R. Holtappels, M. J. Walport, and M. Loos. 2001. Reconstitution of 
the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow 
cells. J Immunol 167: 4033-4037. 
117. Leu, R. W., D. Kriet, A. Zhou, M. J. Herriott, J. A. Rummage, and B. J. Shannon. 1989. 
Reconstitution of murine resident peritoneal macrophages for antibody-dependent 
cellular cytotoxicity by homologous serum Clq. Cell Immunol 122: 48-61. 
118. Trinder, P. K., D. Faust, F. Petry, and M. Loos. 1995. Modulation of mRNA expression 
and secretion of C1q in mouse macrophages by anti-inflammatory drugs and cAMP: 
evidence for the partial involvement of a pathway that includes cyclooxygenase, 
prostaglandin E2 and adenylate cyclase. Immunology 84: 638-644. 
119. Faust, D., and M. Loos. 2002. In vitro modulation of C1q mRNA expression and 
secretion by interleukin-1, interleukin-6, and interferon-gamma in resident and 
stimulated murine peritoneal macrophages. Immunobiology 206: 368-376. 
120. Fraser, D. A., A. K. Laust, E. L. Nelson, and A. J. Tenner. 2009. C1q differentially 
modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by 
human monocytes, macrophages, and dendritic cells. J Immunol 183: 6175-6185. 
121. Galvan, M. D., D. B. Foreman, E. Zeng, J. C. Tan, and S. S. Bohlson. 2012. 
Complement component C1q regulates macrophage expression of Mer tyrosine kinase 
to promote clearance of apoptotic cells. J Immunol 188: 3716-3723. 
122. Baruah, P., I. E. Dumitriu, G. Peri, V. Russo, A. Mantovani, A. A. Manfredi, and P. 
Rovere-Querini. 2006. The tissue pentraxin PTX3 limits C1q-mediated complement 
activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 80: 87-
95. 
123. Walker, D. G. 1998. Expression and regulation of complement C1q by human THP-1-
derived macrophages. Mol Chem Neuropathol 34: 197-218. 
124. Leu, R. W., A. Q. Zhou, J. Rummage, D. J. Fast, and B. J. Shannon. 1991. 
Reconstitution of a deficiency of AKR mouse macrophages for their response to lipid A 
  References  
109 
activation for tumor cytotoxicity by complement subcomponent C1q: role of IFN-
gamma. J Immunol 147: 1315-1321. 
125. Zhou, A. Q., M. J. Herriott, and R. W. Leu. 1991. Kinetics of the biosynthesis of 
complement subcomponent C1q by murine macrophages: effects of stimulation by 
interferon-gamma. J Interferon Res 11: 111-119. 
126. Depboylu, C., M. K. Schäfer, W. J. Schwaeble, T. A. Reinhart, H. Maeda, H. Mitsuya, 
R. Damadzic, D. M. Rausch, L. E. Eiden, and E. Weihe. 2005. Increase of C1q 
biosynthesis in brain microglia and macrophages during lentivirus infection in the 
rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2',3'-
dideoxyguanosine. Neurobiol Dis 20: 12-26. 
127. Biswas, S. K., L. Gangi, S. Paul, T. Schioppa, A. Saccani, M. Sironi, B. Bottazzi, A. 
Doni, B. Vincenzo, F. Pasqualini, L. Vago, M. Nebuloni, A. Mantovani, and A. Sica. 
2006. A distinct and unique transcriptional program expressed by tumor-associated 
macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 
107: 2112-2122. 
128. Ohmi, K., D. S. Greenberg, K. S. Rajavel, S. Ryazantsev, H. H. Li, and E. F. Neufeld. 
2003. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and 
IIIB. Proc Natl Acad Sci U S A 100: 1902-1907. 
129. Haga, S., T. Aizawa, T. Ishii, and K. Ikeda. 1996. Complement gene expression in 
mouse microglia and astrocytes in culture: comparisons with mouse peritoneal 
macrophages. Neurosci Lett 216: 191-194. 
130. Dietzschold, B., W. Schwaeble, M. K. Schäfer, D. C. Hooper, Y. M. Zehng, F. Petry, H. 
Sheng, T. Fink, M. Loos, H. Koprowski, and E. Weihe. 1995. Expression of C1q, a 
subcomponent of the rat complement system, is dramatically enhanced in brains of 
rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci 
130: 11-16. 
131. Goldsmith, S. K., P. Wals, I. Rozovsky, T. E. Morgan, and C. E. Finch. 1997. Kainic 
acid and decorticating lesions stimulate the synthesis of C1q protein in adult rat brain. 
J Neurochem 68: 2046-2052. 
132. Hoekzema, R., M. C. Brouwer, E. R. de Graeff-Meeder, H. P. van Helden, and C. E. 
Hack. 1989. Biosynthesis of normal and low-molecular-mass complement component 
C1q by cultured human monocytes and macrophages. Biochem J 257: 477-486. 
133. Hoekzema, R., A. J. Hannema, T. J. Swaak, J. Paardekooper, and C. E. Hack. 1985. 
Low molecular weight C1q in systemic lupus erythematosus. J Immunol 135: 265-271. 
134. Hoekzema, R., A. J. Swaak, M. C. Brouwer, A. van Rooijen, E. J. Nieuwenhuys, and 
C. E. Hack. 1990. Significance of low molecular weight C1q in systemic lupus 
erythematosus. Ann Rheum Dis 49: 698-704. 
135. Fraser, D. A., S. S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. 
Rochford, and A. J. Tenner. 2006. C1q and MBL, components of the innate immune 
system, influence monocyte cytokine expression. J Leukoc Biol 80: 107-116. 
  References  
110 
136. Yamada, M., K. Oritani, T. Kaisho, J. Ishikawa, H. Yoshida, I. Takahashi, S. 
Kawamoto, N. Ishida, H. Ujiie, H. Masaie, M. Botto, Y. Tomiyama, and Y. Matsuzawa. 
2004. Complement C1q regulates LPS-induced cytokine production in bone marrow-
derived dendritic cells. Eur J Immunol 34: 221-230. 
137. Clarke, E. V., B. M. Weist, C. M. Walsh, and A. J. Tenner. 2015. Complement protein 
C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-
mediated Th17 and Th1 T cell subset proliferation. J Leukoc Biol 97: 147-160. 
138. Bajtay, Z., M. Józsi, Z. Bánki, S. Thiel, N. Thielens, and A. Erdei. 2000. Mannan-
binding lectin and C1q bind to distinct structures and exert differential effects on 
macrophages. Eur J Immunol 30: 1706-1713. 
139. Son, M., and B. Diamond. 2014. C1q-mediated repression of human monocytes is 
regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1). Mol Med 20: 559-568. 
140. Castellano, G., A. M. Woltman, N. Schlagwein, W. Xu, F. P. Schena, M. R. Daha, and 
C. van Kooten. 2007. Immune modulation of human dendritic cells by complement. Eur 
J Immunol 37: 2803-2811. 
141. Chen, A., S. Gaddipati, Y. Hong, D. J. Volkman, E. I. Peerschke, and B. Ghebrehiwet. 
1994. Human T cells express specific binding sites for C1q. Role in T cell activation 
and proliferation. J Immunol 153: 1430-1440. 
142. Young, K. R., J. L. Ambrus, A. Malbran, A. S. Fauci, and A. J. Tenner. 1991. 
Complement subcomponent C1q stimulates Ig production by human B lymphocytes. J 
Immunol 146: 3356-3364. 
143. Leigh, L. E., B. Ghebrehiwet, T. P. Perera, I. N. Bird, P. Strong, U. Kishore, K. B. Reid, 
and P. Eggleton. 1998. C1q-mediated chemotaxis by human neutrophils: involvement 
of gClqR and G-protein signalling mechanisms. Biochem J 330 ( Pt 1): 247-254. 
144. Eggleton, P., B. Ghebrehiwet, J. P. Coburn, K. N. Sastry, K. S. Zaner, and A. I. 
Tauber. 1994. Characterization of the human neutrophil C1q receptor and functional 
effects of free ligand on activated neutrophils. Blood 84: 1640-1649. 
145. Bordin, S., and D. Whitfield. 2003. Cutting edge: proliferating fibroblasts respond to 
collagenous C1q with phosphorylation of p38 mitogen-activated protein kinase and 
apoptotic features. J Immunol 170: 667-671. 
146. Oiki, S., and Y. Okada. 1988. C1q induces chemotaxis and K+ conductance activation 
coupled to increased cytosolic Ca2+ in mouse fibroblasts. J Immunol 141: 3177-3185. 
147. Tenner, A. J., S. L. Robinson, J. Borchelt, and J. R. Wright. 1989. Human pulmonary 
surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- 
and CR1-mediated phagocytosis. J Biol Chem 264: 13923-13928. 
148. Goodman, E. B., and A. J. Tenner. 1992. Signal transduction mechanisms of C1q-
mediated superoxide production. Evidence for the involvement of temporally distinct 
staurosporine-insensitive and sensitive pathways. J Immunol 148: 3920-3928. 
149. Tyagi, S., A. Nicholson-Weller, S. F. Barbashov, S. W. Tas, and L. B. Klickstein. 2000. 
Intercellular adhesion molecule 1 and beta2 integrins in C1q-stimulated superoxide 
  References  
111 
production by human neutrophils: an example of a general regulatory mechanism 
governing acute inflammation. Arthritis Rheum 43: 2248-2259. 
150. Otabor, I., S. Tyagi, F. J. Beurskens, I. Ghiran, P. Schwab, A. Nicholson-Weller, and L. 
B. Klickstein. 2004. A role for lipid rafts in C1q-triggered O2- generation by human 
neutrophils. Mol Immunol 41: 185-190. 
151. Jehle, A. W., S. J. Gardai, S. Li, P. Linsel-Nitschke, K. Morimoto, W. J. Janssen, R. W. 
Vandivier, N. Wang, S. Greenberg, B. M. Dale, C. Qin, P. M. Henson, and A. R. Tall. 
2006. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells 
and associated ERK signaling in macrophages. J Cell Biol 174: 547-556. 
152. Gershov, D., S. Kim, N. Brot, and K. B. Elkon. 2000. C-Reactive protein binds to 
apoptotic cells, protects the cells from assembly of the terminal complement 
components, and sustains an antiinflammatory innate immune response: implications 
for systemic autoimmunity. J Exp Med 192: 1353-1364. 
153. Bigler, C., M. Schaller, I. Perahud, M. Osthoff, and M. Trendelenburg. 2009. 
Autoantibodies against complement C1q specifically target C1q bound on early 
apoptotic cells. J Immunol 183: 3512-3521. 
154. Pang, Y., X. W. Yang, Y. Song, F. Yu, and M. H. Zhao. 2014. Anti-C1q autoantibodies 
from active lupus nephritis patients could inhibit the clearance of apoptotic cells and 
complement classical pathway activation mediated by C1q in vitro. Immunobiology 
219: 980-989. 
155. Fraser, D. A., and A. J. Tenner. 2010. Innate immune proteins C1q and mannan-
binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and 
macrophages. J Immunol 185: 3932-3939. 
156. Farrera, C., and B. Fadeel. 2013. Macrophage clearance of neutrophil extracellular 
traps is a silent process. J Immunol 191: 2647-2656. 
157. Santer, D. M., A. E. Wiedeman, T. H. Teal, P. Ghosh, and K. B. Elkon. 2012. 
Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene 
induction by lupus immune complexes. J Immunol 188: 902-915. 
158. Santer, D. M., B. E. Hall, T. C. George, S. Tangsombatvisit, C. L. Liu, P. D. Arkwright, 
and K. B. Elkon. 2010. C1q deficiency leads to the defective suppression of IFN-alpha 
in response to nucleoprotein containing immune complexes. J Immunol 185: 4738-
4749. 
159. Jiang, K., Y. Chen, C. S. Xu, and J. N. Jarvis. 2003. T cell activation by soluble C1q-
bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis. 
Clin Exp Immunol 131: 61-67. 
160. Agnello, V., D. Koffler, J. W. Eisenberg, R. J. Winchester, and H. G. Kundel. 1971. 
C1g precipitins in the sera of patients with systemic lupus erythematosus and other 
hypocomplementemic states: characterization of high and low molecular weight types. 
J Exp Med 134: 228s-241s. 
  References  
112 
161. Antes, U., H. P. Heinz, and M. Loos. 1988. Evidence for the presence of 
autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. 
Arthritis Rheum 31: 457-464. 
162. Uwatoko, S., and M. Mannik. 1988. Low-molecular weight C1q-binding 
immunoglobulin G in patients with systemic lupus erythematosus consists of 
autoantibodies to the collagen-like region of C1q. J Clin Invest 82: 816-824. 
163. Sinico, R. A., A. Radice, M. Ikehata, G. Giammarresi, C. Corace, G. Arrigo, B. Bollini, 
and M. Li Vecchi. 2005. Anti-C1q autoantibodies in lupus nephritis: prevalence and 
clinical significance. Ann N Y Acad Sci 1050: 193-200. 
164. Saadoun, D., S. Sadallah, M. Trendelenburg, N. Limal, D. Sene, J. C. Piette, J. A. 
Schifferli, and P. Cacoub. 2006. Anti-C1q antibodies in hepatitis C virus infection. Clin 
Exp Immunol 145: 308-312. 
165. Siegert, C. E., M. R. Daha, A. J. Swaak, E. A. van der Voort, and F. C. Breedveld. 
1993. The relationship between serum titers of autoantibodies to C1q and age in the 
general population and in patients with systemic lupus erythematosus. Clin Immunol 
Immunopathol 67: 204-209. 
166. Wisnieski, J. J., and S. M. Jones. 1992. IgG autoantibody to the collagen-like region of 
Clq in hypocomplementemic urticarial vasculitis syndrome, systemic lupus 
erythematosus, and 6 other musculoskeletal or rheumatic diseases. J Rheumatol 19: 
884-888. 
167. Wisnieski, J. J., and S. M. Jones. 1992. Comparison of autoantibodies to the collagen-
like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic 
lupus erythematosus. J Immunol 148: 1396-1403. 
168. Trendelenburg, M., J. Marfurt, I. Gerber, A. Tyndall, and J. A. Schifferli. 1999. Lack of 
occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. 
Arthritis Rheum 42: 187-188. 
169. Wener, M. H., S. Uwatoko, and M. Mannik. 1989. Antibodies to the collagen-like region 
of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum 32: 
544-551. 
170. Strife, C. F., A. E. Leahy, and C. D. West. 1989. Antibody to a cryptic, solid phase C1Q 
antigen in membranoproliferative nephritis. Kidney Int 35: 836-842. 
171. Gunnarsson, I., J. Rönnelid, I. Lundberg, and S. H. Jacobson. 1997. Occurrence of 
anti-C1q antibodies in IgA nephropathy. Nephrol Dial Transplant 12: 2263-2268. 
172. Prohászka, Z., M. R. Daha, C. Süsal, V. Daniel, J. Szlávik, D. Bánhegyi, K. Nagy, V. 
Várkonyi, A. Horváth, E. Ujhelyi, F. D. Tóth, K. Uray, F. Hudecz, and G. Füst. 1999. 
C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies 
against 60-kDa heat-shock proteins. Clin Immunol 90: 247-255. 
173. Schaller, M., C. Bigler, D. Danner, H. J. Ditzel, and M. Trendelenburg. 2009. 
Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven. J 
Immunol 183: 8225-8231. 
  References  
113 
174. Uwatoko, S., S. Aotsuka, M. Okawa, Y. Egusa, R. Yokohari, C. Aizawa, and K. Suzuki. 
1987. C1q solid-phase radioimmunoassay: evidence for detection of antibody directed 
against the collagen-like region of C1q in sera from patients with systemic lupus 
erythematosus. Clin Exp Immunol 69: 98-106. 
175. Golan, M. D., R. Burger, and M. Loos. 1982. Conformational changes in C1q after 
binding to immune complexes: detection of neoantigens with monoclonal antibodies. J 
Immunol 129: 445-447. 
176. Gaboriaud, C., N. M. Thielens, L. A. Gregory, V. Rossi, J. C. Fontecilla-Camps, and G. 
J. Arlaud. 2004. Structure and activation of the C1 complex of complement: unraveling 
the puzzle. Trends Immunol 25: 368-373. 
177. Vanhecke, D., L. T. Roumenina, H. Wan, M. Osthoff, M. Schaller, and M. 
Trendelenburg. 2012. Identification of a major linear C1q epitope allows detection of 
systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based 
enzyme-linked immunosorbent assay. Arthritis Rheum 64: 3706-3714. 
178. Mårtensson, U., S. Thiel, J. C. Jensenius, and A. G. Sjöholm. 1996. Human 
autoantibodies against Clq: lack of cross reactivity with the collectins mannan-binding 
protein, lung surfactant protein A and bovine conglutinin. Scand J Immunol 43: 314-
320. 
179. Sjoholm, A. G., U. Martensson, and G. Sturfelt. 1997. Serial analysis of autoantibody 
responses to the collagen-like region of Clq, collagen type II, and double stranded 
DNA in patients with systemic lupus erythematosus. J Rheumatol 24: 871-878. 
180. Uwatoko, S., and M. Mannik. 1989. IgG subclasses of antibodies to the collagen-like 
region of C1q in patients with systemic lupus erythematosus. Arthritis Rheum 32: 
1601-1603. 
181. Prada, A. E., and C. F. Strife. 1992. IgG subclass restriction of autoantibody to solid-
phase C1q in membranoproliferative and lupus glomerulonephritis. Clin Immunol 
Immunopathol 63: 84-88. 
182. Haseley, L. A., J. J. Wisnieski, M. R. Denburg, A. R. Michael-Grossman, E. M. Ginzler, 
M. F. Gourley, J. H. Hoffman, R. P. Kimberly, and J. E. Salmon. 1997. Antibodies to 
C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA 
alleles. Kidney Int 52: 1375-1380. 
183. Thanei, S., D. Vanhecke, and M. Trendelenburg. 2015. Anti-C1q autoantibodies from 
systemic lupus erythematosus patients activate the complement system via both the 
classical and lectin pathways. Clin Immunol. 
184. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The 
chemokine system in diverse forms of macrophage activation and polarization. Trends 
Immunol 25: 677-686. 
185. Gordon, S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3: 23-35. 
186. Ambarus, C. A., S. Krausz, M. van Eijk, J. Hamann, T. R. Radstake, K. A. Reedquist, 
P. P. Tak, and D. L. Baeten. 2012. Systematic validation of specific phenotypic 
markers for in vitro polarized human macrophages. J Immunol Methods 375: 196-206. 
  References  
114 
187. Gordon, S., and P. R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat 
Rev Immunol 5: 953-964. 
188. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized M2 
mononuclear phagocytes. Trends Immunol 23: 549-555. 
189. Duffield, J. S. 2003. The inflammatory macrophage: a story of Jekyll and Hyde. Clin 
Sci (Lond) 104: 27-38. 
190. Martinez, F. O., and S. Gordon. 2014. The M1 and M2 paradigm of macrophage 
activation: time for reassessment. F1000Prime Rep 6: 13. 
191. Mosser, D. M. 2003. The many faces of macrophage activation. J Leukoc Biol 73: 209-
212. 
192. Xu, W., X. Zhao, M. R. Daha, and C. van Kooten. 2013. Reversible differentiation of 
pro- and anti-inflammatory macrophages. Mol Immunol 53: 179-186. 
193. Sahu, R., R. Bethunaickan, S. Singh, and A. Davidson. 2014. Structure and function of 
renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol 66: 
1596-1607. 
194. Schiffer, L., R. Bethunaickan, M. Ramanujam, W. Huang, M. Schiffer, H. Tao, M. P. 
Madaio, M. M. Madaio, E. P. Bottinger, and A. Davidson. 2008. Activated renal 
macrophages are markers of disease onset and disease remission in lupus nephritis. J 
Immunol 180: 1938-1947. 
195. Nikolic-Paterson, D. J., and R. C. Atkins. 2001. The role of macrophages in 
glomerulonephritis. Nephrol Dial Transplant 16 Suppl 5: 3-7. 
196. Ren, Y., J. Tang, M. Y. Mok, A. W. Chan, A. Wu, and C. S. Lau. 2003. Increased 
apoptotic neutrophils and macrophages and impaired macrophage phagocytic 
clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 
48: 2888-2897. 
197. Steinbach, F., F. Henke, B. Krause, B. Thiele, G. R. Burmester, and F. Hiepe. 2000. 
Monocytes from systemic lupus erythematous patients are severely altered in 
phenotype and lineage flexibility. Ann Rheum Dis 59: 283-288. 
198. Ding, D., H. Mehta, W. J. McCune, and M. J. Kaplan. 2006. Aberrant phenotype and 
function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol 177: 
5878-5889. 
199. Li, Y., P. Y. Lee, E. S. Sobel, S. Narain, M. Satoh, M. S. Segal, W. H. Reeves, and H. 
B. Richards. 2009. Increased expression of FcgammaRI/CD64 on circulating 
monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Res Ther 11: 
R6. 
200. Katsiari, C. G., S. N. Liossis, V. L. Souliotis, A. M. Dimopoulos, M. N. Manoussakis, 
and P. P. Sfikakis. 2002. Aberrant expression of the costimulatory molecule CD40 
ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 
103: 54-62. 
  References  
115 
201. Laborde, E. A., S. Vanzulli, M. Beigier-Bompadre, M. A. Isturiz, R. A. Ruggiero, M. G. 
Fourcade, A. C. Catalan Pellet, S. Sozzani, and M. Vulcano. 2007. Immune complexes 
inhibit differentiation, maturation, and function of human monocyte-derived dendritic 
cells. J Immunol 179: 673-681. 
202. Gyimesi, E., M. Kavai, E. Kiss, I. Csipö, G. Szücs, and G. Szegedi. 1993. Triggering of 
respiratory burst by phagocytosis in monocytes of patients with systemic lupus 
erythematosus. Clin Exp Immunol 94: 140-144. 
203. Houssiau, F. A., C. Lefebvre, M. Vanden Berghe, M. Lambert, J. P. Devogelaer, and J. 
C. Renauld. 1995. Serum interleukin 10 titers in systemic lupus erythematosus reflect 
disease activity. Lupus 4: 393-395. 
204. Beebe, A. M., D. J. Cua, and R. de Waal Malefyt. 2002. The role of interleukin-10 in 
autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis 
(MS). Cytokine Growth Factor Rev 13: 403-412. 
205. Bethunaickan, R., R. Sahu, and A. Davidson. 2012. Analysis of renal mononuclear 
phagocytes in murine models of SLE. Methods Mol Biol 900: 207-232. 
206. Daha, N. A., N. K. Banda, A. Roos, F. J. Beurskens, J. M. Bakker, M. R. Daha, and L. 
A. Trouw. 2011. Complement activation by (auto-) antibodies. Mol Immunol 48: 1656-
1665. 
207. Trouw, L. A., E. M. Haisma, E. W. Levarht, D. van der Woude, A. Ioan-Facsinay, M. R. 
Daha, T. W. Huizinga, and R. E. Toes. 2009. Anti-cyclic citrullinated peptide antibodies 
from rheumatoid arthritis patients activate complement via both the classical and 
alternative pathways. Arthritis Rheum 60: 1923-1931. 
208. Xiao, H., A. Schreiber, P. Heeringa, R. J. Falk, and J. C. Jennette. 2007. Alternative 
complement pathway in the pathogenesis of disease mediated by anti-neutrophil 
cytoplasmic autoantibodies. Am J Pathol 170: 52-64. 
209. Banda, N. K., A. K. Wood, K. Takahashi, B. Levitt, P. M. Rudd, L. Royle, J. L. 
Abrahams, G. L. Stahl, V. M. Holers, and W. P. Arend. 2008. Initiation of the 
alternative pathway of murine complement by immune complexes is dependent on N-
glycans in IgG antibodies. Arthritis Rheum 58: 3081-3089. 
210. Girardi, G., J. Berman, P. Redecha, L. Spruce, J. M. Thurman, D. Kraus, T. J. 
Hollmann, P. Casali, M. C. Caroll, R. A. Wetsel, J. D. Lambris, V. M. Holers, and J. E. 
Salmon. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the 
antiphospholipid syndrome. J Clin Invest 112: 1644-1654. 
211. Trendelenburg, M. 2012. The complement system in cryoglobulinemia. In HCV 
Infection and Cryoglobulinemia. F. Dammacco, ed. Springer Verlag, Mailand, Italy. p. 
85-89. 
212. Hochberg, M. C. 1997. Updating the American College of Rheumatology revised 
criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 
1725. 
  References  
116 
213. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. 
Schaller, N. Talal, and R. J. Winchester. 1982. The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277. 
214. Roos, A., L. H. Bouwman, D. J. van Gijlswijk-Janssen, M. C. Faber-Krol, G. L. Stahl, 
and M. R. Daha. 2001. Human IgA activates the complement system via the mannan-
binding lectin pathway. J Immunol 167: 2861-2868. 
215. McMullen, M. E., M. L. Hart, M. C. Walsh, J. Buras, K. Takahashi, and G. L. Stahl. 
2006. Mannose-binding lectin binds IgM to activate the lectin complement pathway in 
vitro and in vivo. Immunobiology 211: 759-766. 
216. Siegert, C. E., M. R. Daha, S. Lobatto, E. A. van der Voort, and F. C. Breedveld. 1992. 
IgG autoantibodies to C1q do not detectably influence complement activation in vivo 
and in vitro in systemic lupus erythematosus. Immunol Res 11: 91-97. 
217. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway revisited. J 
Cell Mol Med 12: 1074-1084. 
218. Moura, C. G., I. Lima, L. Barbosa, D. Athanazio, E. Reis, M. Reis, R. W. Burlingame, 
and M. B. Santiago. 2009. Anti-C1q antibodies: association with nephritis and disease 
activity in systemic lupus erythematosus. J Clin Lab Anal 23: 19-23. 
219. Oelzner, P., B. Deliyska, R. Fünfstück, G. Hein, D. Herrmann, and G. Stein. 2003. 
Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus 
erythematosus - relationship with disease activity and renal involvement. Clin 
Rheumatol 22: 271-278. 
220. Cook, H. T., and M. Botto. 2006. Mechanisms of Disease: the complement system and 
the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2: 330-
337. 
221. Sato, N., I. Ohsawa, S. Nagamachi, M. Ishii, G. Kusaba, H. Inoshita, A. Toki, S. 
Horikoshi, H. Ohi, M. Matsushita, and Y. Tomino. 2011. Significance of glomerular 
activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus 20: 
1378-1386. 
222. Trouw, L. A., M. A. Seelen, J. M. Duijs, S. Wagner, M. Loos, I. M. Bajema, C. van 
Kooten, A. Roos, and M. R. Daha. 2005. Activation of the lectin pathway in murine 
lupus nephritis. Mol Immunol 42: 731-740. 
223. Mannik, M., and M. H. Wener. 1997. Deposition of antibodies to the collagen-like 
region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. 
Arthritis Rheum 40: 1504-1511. 
224. O'Flynn, J., R. Flierman, P. van der Pol, A. Rops, S. C. Satchell, P. W. Mathieson, C. 
van Kooten, J. van der Vlag, J. H. Berden, and M. R. Daha. 2011. Nucleosomes and 
C1q bound to glomerular endothelial cells serve as targets for autoantibodies and 
determine complement activation. Mol Immunol 49: 75-83. 
225. Uwatoko, S., V. J. Gauthier, and M. Mannik. 1991. Autoantibodies to the collagen-like 
region of C1Q deposit in glomeruli via C1Q in immune deposits. Clin Immunol 
Immunopathol 61: 268-273. 
  References  
117 
226. Taylor, P. R., A. Carugati, V. A. Fadok, H. T. Cook, M. Andrews, M. C. Carroll, J. S. 
Savill, P. M. Henson, M. Botto, and M. J. Walport. 2000. A hierarchical role for 
classical pathway complement proteins in the clearance of apoptotic cells in vivo. J 
Exp Med 192: 359-366. 
227. Mevorach, D., J. O. Mascarenhas, D. Gershov, and K. B. Elkon. 1998. Complement-
dependent clearance of apoptotic cells by human macrophages. J Exp Med 188: 2313-
2320. 
228. Kozyro, I., L. Korosteleva, D. Chernoshej, D. Danner, A. Sukalo, and M. 
Trendelenburg. 2008. Autoantibodies against complement C1q in acute post-
streptococcal glomerulonephritis. Clin Immunol 128: 409-414. 
229. Barilla-Labarca, M. L., K. Toder, and R. Furie. 2013. Targeting the complement system 
in systemic lupus erythematosus and other diseases. Clin Immunol 148: 313-321. 
230. Bergtold, A., A. Gavhane, V. D'Agati, M. Madaio, and R. Clynes. 2006. FcR-bearing 
myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 177: 
7287-7295. 
231. Bobak, D. A., T. A. Gaither, M. M. Frank, and A. J. Tenner. 1987. Modulation of FcR 
function by complement: subcomponent C1q enhances the phagocytosis of IgG-
opsonized targets by human monocytes and culture-derived macrophages. J Immunol 
138: 1150-1156. 
232. Zizzo, G., B. A. Hilliard, M. Monestier, and P. L. Cohen. 2012. Efficient clearance of 
early apoptotic cells by human macrophages requires M2c polarization and MerTK 
induction. J Immunol 189: 3508-3520. 
233. Hill, G. S., M. Delahousse, D. Nochy, P. Rémy, F. Mignon, J. P. Méry, and J. Bariéty. 
2001. Predictive power of the second renal biopsy in lupus nephritis: significance of 
macrophages. Kidney Int 59: 304-316. 
234. Bethunaickan, R., C. C. Berthier, M. Ramanujam, R. Sahu, W. Zhang, Y. Sun, E. P. 
Bottinger, L. Ivashkiv, M. Kretzler, and A. Davidson. 2011. A unique hybrid renal 
mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus 
nephritis. J Immunol 186: 4994-5003. 
235. Yap, D. Y., and K. N. Lai. 2010. Cytokines and their roles in the pathogenesis of 
systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 
2010: 365083. 
236. Timoshanko, J. R., A. R. Kitching, Y. Iwakura, S. R. Holdsworth, and P. G. Tipping. 
2004. Leukocyte-derived interleukin-1beta interacts with renal interleukin-1 receptor I 
to promote renal tumor necrosis factor and glomerular injury in murine crescentic 
glomerulonephritis. Am J Pathol 164: 1967-1977. 
237. Tsai, C. Y., T. H. Wu, C. L. Yu, J. Y. Lu, and Y. Y. Tsai. 2000. Increased excretions of 
beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall 
glycoprotein in urine of patients with active lupus nephritis. Nephron 85: 207-214. 
238. Llorente, L., Y. Richaud-Patin, J. Wijdenes, J. Alcocer-Varela, M. C. Maillot, I. Durand-
Gasselin, B. M. Fourrier, P. Galanaud, and D. Emilie. 1993. Spontaneous production 
  References  
118 
of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. 
Eur Cytokine Netw 4: 421-427. 
239. Yuan, W., S. J. DiMartino, P. B. Redecha, L. B. Ivashkiv, and J. E. Salmon. 2011. 
Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the 
presence of immune complexes. Arthritis Rheum 63: 212-218. 
240. Llorente, L., and Y. Richaud-Patin. 2003. The role of interleukin-10 in systemic lupus 
erythematosus. J Autoimmun 20: 287-289. 
241. Lleo, A., C. Selmi, P. Invernizzi, M. Podda, and M. E. Gershwin. 2008. The 
consequences of apoptosis in autoimmunity. J Autoimmun 31: 257-262. 
242. Xu, W., A. Roos, N. Schlagwein, A. M. Woltman, M. R. Daha, and C. van Kooten. 
2006. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 
107: 4930-4937. 
243. Galvan, M. D., H. Hulsebus, T. Heitker, E. Zeng, and S. S. Bohlson. 2014. 
Complement Protein C1q and Adiponectin Stimulate Mer Tyrosine Kinase-Dependent 
Engulfment of Apoptotic Cells through a Shared Pathway. J Innate Immun. 
244. Janko, C., S. Franz, L. E. Munoz, S. Siebig, S. Winkler, G. Schett, K. Lauber, A. 
Sheriff, J. van der Vlag, and M. Herrmann. 2011. CRP/anti-CRP antibodies assembly 
on the surfaces of cell remnants switches their phagocytic clearance toward 
inflammation. Front Immunol 2: 70. 
245. Reefman, E., G. Horst, M. T. Nijk, P. C. Limburg, C. G. Kallenberg, and M. Bijl. 2007. 
Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies 
inhibits their uptake via an Fcgamma receptor-dependent mechanism. Arthritis Rheum 
56: 3399-3411. 
246. Arkwright, P. D., P. Riley, S. M. Hughes, H. Alachkar, and R. F. Wynn. 2014. 
Successful cure of C1q deficiency in human subjects treated with hematopoietic stem 
cell transplantation. J Allergy Clin Immunol 133: 265-267. 
247. Thanei, S., and M. Trendelenburg. 2016. Anti-C1q Autoantibodies from Systemic 
Lupus Erythematosus Patients Induce a Proinflammatory Phenotype in Macrophages. 
J Immunol 196: 2063-2074. 
248. Leu, R. W., A. Q. Zhou, J. A. Rummage, M. J. Kennedy, and B. J. Shannon. 1989. 
Exogenous C1q reconstitutes resident but not inflammatory mouse peritoneal 
macrophages for Fc receptor-dependent cellular cytotoxicity and phagocytosis. 
Relationship to endogenous C1q availability. J Immunol 143: 3250-3257. 
249. Thanei, S., D. Vanhecke, and M. Trendelenburg. 2015. Anti-C1q autoantibodies from 
systemic lupus erythematosus patients activate the complement system via both the 
classical and lectin pathways. Clin Immunol 160: 180-187. 
250. Kaul, M., and M. Loos. 1995. Collagen-like complement component C1q is a 
membrane protein of human monocyte-derived macrophages that mediates 
endocytosis. J Immunol 155: 5795-5802. 
  References  
119 
251. Martin, H., H. P. Heinz, K. Reske, and M. Loos. 1987. Macrophage C1q: 
characterization of a membrane form of C1q and of multimers of C1q subunits. J 
Immunol 138: 3863-3867. 
252. Castellano, G., L. A. Trouw, N. Fiore, M. R. Daha, F. P. Schena, and C. van Kooten. 
2010. Infiltrating dendritic cells contribute to local synthesis of C1q in murine and 
human lupus nephritis. Mol Immunol 47: 2129-2137. 
253. Trouw, L. A., M. A. Seelen, R. Visseren, J. M. Duijs, H. Benediktsson, E. de Heer, A. 
Roos, C. van Kooten, and M. R. Daha. 2004. Anti-C1q autoantibodies in murine lupus 
nephritis. Clin Exp Immunol 135: 41-48. 
254. Tan, Y., D. Song, L. H. Wu, F. Yu, and M. H. Zhao. 2013. Serum levels and renal 
deposition of C1q complement component and its antibodies reflect disease activity of 
lupus nephritis. BMC Nephrol 14: 63. 
255. Vogelpoel, L. T., I. S. Hansen, M. W. Visser, S. Q. Nagelkerke, T. W. Kuijpers, M. L. 
Kapsenberg, E. C. de Jong, and J. den Dunnen. 2015. FcγRIIa cross-talk with TLRs, 
IL-1R, and IFNγR selectively modulates cytokine production in human myeloid cells. 
Immunobiology 220: 193-199. 
256. Vogelpoel, L. T., I. S. Hansen, T. Rispens, F. J. Muller, T. M. van Capel, M. C. Turina, 
J. B. Vos, D. L. Baeten, M. L. Kapsenberg, E. C. de Jong, and J. den Dunnen. 2014. 
Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by 
human M2 macrophages. Nat Commun 5: 5444. 
257. Teh, B. K., J. G. Yeo, L. M. Chern, and J. Lu. 2011. C1q regulation of dendritic cell 
development from monocytes with distinct cytokine production and T cell stimulation. 
Mol Immunol 48: 1128-1138. 
258. Tenner, A. J. 1998. C1q receptors: regulating specific functions of phagocytic cells. 
Immunobiology 199: 250-264. 
259. Ramirez-Ortiz, Z. G., W. F. Pendergraft, A. Prasad, M. H. Byrne, T. Iram, C. J. 
Blanchette, A. D. Luster, N. Hacohen, J. El Khoury, and T. K. Means. 2013. The 
scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents 
autoimmunity. Nat Immunol 14: 917-926. 
260. Verneret, M., P. Tacnet-Delorme, R. Osman, R. Awad, A. Grichine, J. P. Kleman, and 
P. Frachet. 2014. Relative contribution of c1q and apoptotic cell-surface calreticulin to 
macrophage phagocytosis. J Innate Immun 6: 426-434. 
261. Basu, S., R. J. Binder, T. Ramalingam, and P. K. Srivastava. 2001. CD91 is a common 
receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 
303-313. 
262. Steinø, A., C. S. Jørgensen, I. Laursen, and G. Houen. 2004. Interaction of C1q with 
the receptor calreticulin requires a conformational change in C1q. Scand J Immunol 
59: 485-495. 
263. Steinberger, P., A. Szekeres, S. Wille, J. Stöckl, N. Selenko, E. Prager, G. Staffler, O. 
Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the 
phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71: 133-140. 
  References  
120 
264. Klickstein, L. B., S. F. Barbashov, T. Liu, R. M. Jack, and A. Nicholson-Weller. 1997. 
Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 7: 345-355. 
265. van den Dobbelsteen, M. E., F. J. van der Woude, W. E. Schroeijers, N. Klar-
Mohamad, L. A. van Es, and M. R. Daha. 1993. C1Q, a subunit of the first component 
of complement, enhances the binding of aggregated IgG to rat renal mesangial cells. J 
Immunol 151: 4315-4324. 
266. Turk, V., V. Stoka, O. Vasiljeva, M. Renko, T. Sun, B. Turk, and D. Turk. 2012. 
Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim 
Biophys Acta 1824: 68-88. 
267. Gupta, S., R. K. Singh, S. Dastidar, and A. Ray. 2008. Cysteine cathepsin S as an 
immunomodulatory target: present and future trends. Expert Opinion on Therapeutic 
Targets 12: 291-299. 
268. Shi, G. P., J. A. Villadangos, G. Dranoff, C. Small, L. Gu, K. J. Haley, R. Riese, H. L. 
Ploegh, and H. A. Chapman. 1999. Cathepsin S required for normal MHC class II 
peptide loading and germinal center development. Immunity 10: 197-206. 
269. Driessen, C., R. A. Bryant, A. M. Lennon-Duménil, J. A. Villadangos, P. W. Bryant, G. 
P. Shi, H. A. Chapman, and H. L. Ploegh. 1999. Cathepsin S controls the trafficking 
and maturation of MHC class II molecules in dendritic cells. J Cell Biol 147: 775-790. 
270. Shen, L., L. J. Sigal, M. Boes, and K. L. Rock. 2004. Important role of cathepsin S in 
generating peptides for TAP-independent MHC class I crosspresentation in vivo. 
Immunity 21: 155-165. 
271. Neefjes, J., M. L. Jongsma, P. Paul, and O. Bakke. 2011. Towards a systems 
understanding of MHC class I and MHC class II antigen presentation. Nat Rev 
Immunol 11: 823-836. 
272. Riese, R. J., P. R. Wolf, D. Brömme, L. R. Natkin, J. A. Villadangos, H. L. Ploegh, and 
H. A. Chapman. 1996. Essential role for cathepsin S in MHC class II-associated 
invariant chain processing and peptide loading. Immunity 4: 357-366. 
273. Riese, R. J., R. N. Mitchell, J. A. Villadangos, G. P. Shi, J. T. Palmer, E. R. Karp, G. T. 
De Sanctis, H. L. Ploegh, and H. A. Chapman. 1998. Cathepsin S activity regulates 
antigen presentation and immunity. Journal of Clinical Investigation 101: 2351-2363. 
274. Blum, J. S., and P. Cresswell. 1988. Role for intracellular proteases in the processing 
and transport of class II HLA antigens. Proc Natl Acad Sci U S A 85: 3975-3979. 
275. Nakagawa, T. Y., W. H. Brissette, P. D. Lira, R. J. Griffiths, N. Petrushova, J. Stock, J. 
D. McNeish, S. E. Eastman, E. D. Howard, S. R. Clarke, E. F. Rosloniec, E. A. Elliott, 
and A. Y. Rudensky. 1999. Impaired invariant chain degradation and antigen 
presentation and diminished collagen-induced arthritis in cathepsin S null mice. 
Immunity 10: 207-217. 
276. Beers, C., K. Honey, S. Fink, K. Forbush, and A. Rudensky. 2003. Differential 
regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J 
Exp Med 197: 169-179. 
  References  
121 
277. Sjöberg, S., and G. P. Shi. 2011. Cysteine Protease Cathepsins in Atherosclerosis and 
Abdominal Aortic Aneurysm. Clin Rev Bone Miner Metab 9: 138-147. 
278. Rupanagudi, K. V., O. P. Kulkarni, J. Lichtnekert, M. N. Darisipudi, S. R. Mulay, B. 
Schott, S. Gruner, W. Haap, G. Hartmann, and H. J. Anders. 2015. Cathepsin S 
inhibition suppresses systemic lupus erythematosus and lupus nephritis because 
cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann 
Rheum Dis 74: 452-463. 
279. Kim, M., J. Jeon, J. Song, K. H. Suh, Y. H. Kim, K. H. Min, and K. O. Lee. 2013. 
Synthesis of proline analogues as potent and selective cathepsin S inhibitors. Bioorg 
Med Chem Lett 23: 3140-3144. 
280. Lee-Dutra, A., D. K. Wiener, and S. Sun. 2011. Cathepsin S inhibitors: 2004-2010. 
Expert Opin Ther Pat 21: 311-337. 
281. Liu, J., L. Ma, J. Yang, A. Ren, Z. Sun, G. Yan, J. Sun, H. Fu, W. Xu, C. Hu, and G. P. 
Shi. 2006. Increased serum cathepsin S in patients with atherosclerosis and diabetes. 
Atherosclerosis 186: 411-419. 
282. Naour, N., C. Rouault, S. Fellahi, M. E. Lavoie, C. Poitou, M. Keophiphath, D. Eberle, 
S. Shoelson, S. Rizkalla, J. P. Bastard, R. Rabasa-Lhoret, K. Clement, and M. Guerre-
Millo. 2010. Cathepsins in human obesity: changes in energy balance predominantly 
affect cathepsin s in adipose tissue and in circulation. J Clin Endocrinol Metab 95: 
1861-1868. 
283. Jobs, E., U. Riserus, E. Ingelsson, J. Helmersson, E. Nerpin, M. Jobs, J. Sundstrom, 
L. Lind, A. Larsson, S. Basu, and J. Arnlov. 2010. Serum cathepsin S is associated 
with serum C-reactive protein and interleukin-6 independently of obesity in elderly 
men. J Clin Endocrinol Metab 95: 4460-4464. 
284. Petanceska, S., P. Canoll, and L. A. Devi. 1996. Expression of rat cathepsin S in 
phagocytic cells. J Biol Chem 271: 4403-4409. 
285. Latchman, Y., C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. 
Iwai, A. J. Long, J. A. Brown, R. Nunes, E. A. Greenfield, K. Bourque, V. A. Boussiotis, 
L. L. Carter, B. M. Carreno, N. Malenkovich, H. Nishimura, T. Okazaki, T. Honjo, A. H. 
Sharpe, and G. J. Freeman. 2001. PD-L2 is a second ligand for PD-1 and inhibits T 
cell activation. Nat Immunol 2: 261-268. 
286. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, 
N. Malenkovich, T. Okazaki, M. C. Byrne, H. F. Horton, L. Fouser, L. Carter, V. Ling, 
M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, and T. Honjo. 2000. 
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member 
leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034. 
287. Tseng, S. Y., M. Otsuji, K. Gorski, X. Huang, J. E. Slansky, S. I. Pai, A. Shalabi, T. 
Shin, D. M. Pardoll, and H. Tsuchiya. 2001. B7-DC, a new dendritic cell molecule with 
potent costimulatory properties for T cells. J Exp Med 193: 839-846. 
288. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 
family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365-
1369. 
  References  
122 
289. Loke, P., and J. P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 
and Th2 cells. Proc Natl Acad Sci U S A 100: 5336-5341. 
  
  Curriculum vitae  
123 
Curriculum vitae 
Personal details 
Name:   Thanei 
First names:  Sophia Maria 
Date of birth:  12th August 1986 
Place of birth:  Zurich (ZH) 
Nationality:  Swiss 
E-mail:   sophia.thanei@unibas.ch 
 
Academic Education 
2012-present: Graduate (PhD) studies in Immunology, 
 Laboratory of Clinical Immunology, Department of Biomedicine 
Supervisor:  Prof. Dr. M. Trendelenburg 
Thesis title: Functional consequences of anti-C1q autoantibodies form 
systemic lupus erythematosus patients 
2011:   Swiss Federal Diploma for Pharmacists 
2009-2011:  Master of Science in Pharmacy, University of Basel 
2010: Undergraduate studies in Pharmacy (Pharmacokinetics),  
Department of Pharmacy, College of Pharmacy, Gainesville, FL, USA  
 Supervisor:  Prof. Dr. V. Butterweck  
Master thesis title: Pharmacokinetics of valerenic acid in rats after 
intravenous and oral administrations  
2005-2009:  Bachelor of Science in Pharmaceutical Sciences, University of Basel 
2002-2005:  High school diploma in Oberwil (BL)  
  
Working experience 
2012-present: PhD student at the Department of Biomedicine, Laboratory of Clinical 
Immunology, University Hospital Basel 
2011-present:  Part-time pharmacist at “Steinen Apotheke”, Basel 
2010-2011:  Trainee at “Steinen Apotheke”, Basel 
2010: Master student at the Department of Pharmacy, College of Pharmacy, 
Gainesville, FL, USA   
  Curriculum vitae  
124 
Laboratory skills 
• Cell culture: Isolation of monocytes and culture of HMDMs and DCs, cell isolation using 
magnetic-activated cell sorting (MACS); ELISA; ELISA development 
• Complement activation assays 
• IgG and protein purification methods: affinity chromatography (fast protein liquid 
chromatography (FPLC)); Protein G; ammonium sulfate precipitation method 
• Flow cytometry: CyanTM ADP Analyzer (Dako, CA, USA), Accuri and LSR Fortessa (both 
instruments manufactured by BD Biosciences, CA, USA); data analysis using FlowJo Software 
(Tree Star Inc., OR, USA)  
• ImageStreamX flow cytometry; data analysis using IDEAS software (Amnis, Seattle, WA) 
• Microscopy: phase contrast microscopy, fluorescence microscopy; data analysis using ImageJ 
software 
• Molecular biology and Biochemistry: gel electrophoresis; Western Blot 
 
Languages 
German (mother tongue); English (fluent); French (basic knowledge) 
 
Publications 
Sampath, C., Haug, K., Thanei, S., Hamburger, M., Derendorf, H., Frye, R., Butterweck, V.: 
Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations. Planta 
Med, 2012. 
 
Thanei, S., Vanhecke, D., Trendelenburg, M.: Anti-C1q autoantibodies from systemic lupus 
erythematosus patients activate the complement system via both the classical and lectin 
pathways. Clin Immunol, 2015. 
 
Thanei, S., Trendelenburg, M.: Anti-C1q autoantibodies from systemic lupus erythematosus 
patients induce a proinflammatory phenotype in macrophages. J Immunol, 2016. 
 
Thanei, S., Trendelenburg, M.: Anti-C1q autoantibodies from systemic lupus erythematosus 
patients induce C1q production by macrophages. Submitted, 2015. 
 
 
  Curriculum vitae  
125 
Oral presentations 
Thanei, S., Vanhecke, D., Trendelenburg, M.: Functional consequences of SLE autoantibody 
binding on macrophages. Immunomeeting, November 2013, Department of Biomedicine, 
University Hospital Basel, Basel. 
 
Thanei, S., Trendelenburg, M.: Anti-C1q autoantibodies from SLE patients induce a 
proinflammatory phenotype in macrophages. European Meeting on Complement in Health 
and Disease, August 2015, Uppsala, Sweden. 
 
Poster presentations 
Vanhecke, D., Thanei, S., Ploix, C., Trendelenburg, M.: Complement activation: functional 
consequences of circulating anti-C1q autoantibodies and structural prerequisites for 
complement fixation by IgG in solution. Roche Hub meeting, November 2012, Penzberg, 
Germany. 
 
Thanei, S., Vanhecke, D., Ploix, C., Trendelenburg, M.: Effect of anti-C1q antibodies from 
SLE patients on complement activation. European Meeting on Complement in Health and 
Disease, August 2013, Jena, Germany. 
 
Thanei, S., Vanhecke, D., Trendelenburg, M.: Anti-C1q autoantibodies from SLE patients 
activate the complement system via both the classical and lectin pathways. European Meeting 
on Complement in Health and Disease, June 2015, Uppsala, Sweden. 
 
 
 
